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scientific report series published by the
National Institute for Working Life. The
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publishes scientific original works, disser-
tations, criteria documents and literature
surveys.
Arbete och Hälsa has a broad target-
group and welcomes articles in different
areas. The language is most often English,
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Preface
The Criteria Group of the Swedish National Institute for Working Life (NIWL) has the
task of gathering and evaluating data which can be used as a scientific basis for the
proposal of occupational exposure limits given by the Swedish Work Environment
Authority (SWEA). In most cases a scientific basis is written on request from the SWEA.
The Criteria Group shall not propose a numerical occupational exposure limit value but,
as far as possible, give a dose-response/dose-effect relationship and the critical effect of
occupational exposure.
In searching of the literature several databases are used, such as RTECS, Toxline,
Medline, Cancerlit, Nioshtic and Riskline. Also information in existing criteria documents
is used, e.g. documents from WHO, EU, US NIOSH, the Dutch Expert Committee for
Occupational Standards (DECOS) and the Nordic Expert Group (NEG). In some cases
criteria documents are produced within the Criteria Group, often in collaboration with
DECOS or US NIOSH.
Evaluations are made of all relevant published original papers found in the searches. In
some cases information from handbooks and reports from e.g. US NIOSH and US EPA
is used. A draft consensus report is written by the secretariat or by a scientist appointed
by the secretariat. The author of the draft is indicated under Contents. A qualified
evaluation is made of the information in the references. In some cases the information can
be omitted if some criteria are not fulfilled. In some cases such information is included in
the report but with a comment why the data are not included in the evaluation. After
discussion in the Criteria Group the drafts are approved and accepted as a consensus
report from the group. They are sent to the SWEA.
This is the 25th volume that is published and it contains consensus reports approved by
the Criteria Group during the period July 2003 through June 2004. These and previously
published consensus reports are listed in the Appendix (p 117).
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1Consensus Report for Tin and Inorganic
Tin Compounds
October 22, 2003
This Consensus Report is based primarily on a criteria document compiled jointly
by the Nordic Expert Group and the Dutch Expert Committee (65).
Chemical and physical data
Name
  chemical formula
CAS No. Molecular
weight
Melting
point (°C)
Boiling point
(°C)
Solubility
in water
Tin
  Sn
7440-31-5 118.7  231.9 2602 insoluble
Potassium stannate
  K2Sn(OH)6
12125-03-0 298.9  - - soluble
Sodium stannate
  Na2Sn(OH)6
12209-98-2 266.7  140 - soluble
Tin(IV) bromide
  SnBr4
7789-67-5 438.3    31 205 soluble
Tin(II) chloride
  SnCl2
7772-99-8 189.6  247 623 soluble
Tin(IV) chloride
  SnCl4
7646-78-8 260.5   -33 114 soluble
Tin(IV) chloride iodide
  SnCl2I2
13940-16-4 443.4  - 297 soluble
Tin(II) fluoride
  SnF2
7783-47-3 156.7  213 850 soluble
Tin(II) iodide
  SnI2
10294-70-9 372.5  320 714 somewhat
soluble
Tin(IV) iodide
  SnI4
7790-47-8 626.3  143 364.5 soluble
Tin(II) oxide
  SnO
21651-19-4 134.7 1080 - insoluble
Tin(IV) oxide
  SnO2
18282-10-5 150.7 1630 1900 insoluble
Tin(II) pyrophosphate
  Sn2P2O7
15578-26-4 411.3 disintegrates
 at 400 °C
insoluble
Tin(II) sulfide
  SnS
12738-87-3 150.8  880 1210 insoluble
Tin(II) sulfate
  SnSO4
7488-55-3 214.8 disintegrates at
>378 °C (SO2)
- soluble
2At room temperature tin is a shiny, silver-white metal (white tin) that develops a
thin oxide layer on exposure to dry air or oxygen. Below 13.2 °C white tin slowly
crumbles to a gray powder (gray tin). At 200 °C white tin is transformed to brittle
tin. Tin reacts with strong acids and bases but is relatively resistant to neutral
solutions. Tin occurs naturally in ten stable isotopes. Tin in compounds has an
oxidation number of +II or +IV. The water solubility of tin compounds varies
(25, 35, 65). Simple inorganic tin salts are hydrolyzed and form acids (2). SnCl4
is hydrolyzed by water in a violent reaction producing hydrogen chloride and
quite a bit of heat (25).
Occurrence, use
Tin is mined primarily as the mineral cassiterite (tin stone), SnO2. Other ores
containing tin include stannite (Cu2FeSnS4) and teallite (PbZnSnS2) (25, 65).
Metallic tin is obtained from tin ore by smelting. The metal is widely used as a
corrosion-resistant plating on other metals (tin plating, tinning) such as sheet steel
for “tin” cans for the food industry. Tin is also used in alloys ranging from solder
to dental amalgam (2, 25, 65). Inorganic tin compounds are used in the production
of ceramics, porcelain, enamel, drill glass, textiles (to fix dyes), ink and tooth-
paste. SnCl2 is widely used as a reducing agent in production of ceramics, glass
and ink. SnCl4 occurs as a thickener in organic syntheses, as a stabilizer in plastics
and as a chemical intermediate in the production of other tin compounds. SnO2 is
used as an opacifier in ceramics and as a pigment. SnF2 is used in dentistry (6,
65).
Uptake, biotransformation, excretion
In general, uptake of inorganic tin via the digestive tract is low. Data indicate,
however, that uptake can be dose-dependent and also dependent on the anion. One
study with human subjects reports that when 0.11 mg Sn/day was ingested in food
about 50% of the dose was absorbed, whereas uptake was only 3% in subjects on
a diet containing a further 50 mg Sn/day (administered as SnCl2) (65). There are
no data on uptake via lungs or skin.
Human data and data from animal experiments indicate that very little inorganic
tin passes the blood-brain barrier. Inorganic tin accumulates primarily in bone, but
some accumulation has also been shown in human lungs, liver, kidneys, adrenals,
lymph nodes and testes. Some data also indicate that tin has a higher affinity for
thymus than for other organs. The biological half time for Sn(II) and Sn(IV) in the
bones of rats is reported to be 20 to 100 days, and the half time for Sn(II) in rat
liver and kidney 10 to 20 days (65). Differences between Sn(II) and Sn(IV) in
their relative affinity to kidney and liver suggest that tin is not rapidly oxidized
or reduced during absorption and systemic transport. Animal data on differences
between SnCl2 and SnCl4 with regard to effects on the immune system also
indicate valence stability in vivo (65).
3Absorbed tin is excreted primarily via the kidneys. In a study with rats, it is
reported that 35% of an injected (i.v.) dose of Sn(II) citrate and 40% of a dose of
Sn(IV) citrate were excreted in urine – most of it within 10 hours. Excretion in
feces amounted to 12% of the Sn(II) but only 3% of the Sn(IV), which indicates
that excretion in bile is more important for Sn(II) compounds than for Sn(IV)
compounds (23, 65).
Toxic effects
Human data
There are some reports that tin may be able to cause metal fume fever, but no
primary data supporting this assertion have been published (1, 5, 24, 39, 47, 60,
64).
An accumulation of tin in the lungs, visible on x-rays but with no effect on lung
function (stannosis, a form of pneumoconiosis), has been reported in workers
exposed to dust/fumes of SnO2 for 3 years or longer in tin foundries and scrap
metal recycling plants and around tin plating. These case reports usually contain
no information on exposure levels (65). In a study of 215 workers in a tin foundry,
x-ray changes indicating stannosis were observed in 121 of them. There were no
indications of fibrosis or clinically significant emphysema. Nor did any of the
workers have clinical symptoms that could be ascribed to the occurrence of
stannosis, and lung function tests (FEV and airway resistance) showed no indi-
cation of reduced lung function (50, 51, 52). These authors also report mortality
among 607 men who had been employed in the tin foundry for at least 3 years in
the 1921 – 1955 period. The population had lower mortality than predicted (51).
Dust levels up to 2.22 mg Sn/m3 were reported in the foundry, but no details
(analysis methods etc.) are given (51). Another study (Hlebnikova 1957, reviewed
in Reference 26) reports that workers developed stannosis after 6 to 8 years of
work at the smelting ovens. The workers were exposed to aerosols formed during
the smelting process and consisting primarily of SnO2 (<3% total silicon dioxide).
Total dust concentrations in air ranged from 3 to 70 mg/m3. The dust concen-
tration was reduced to 10 mg/m3, and no new cases were reported in the following
ten years.
A smaller study (questionnaire) reports elevated prevalence of wheezing, chest
pains, coughing and shortness of breath with physical exertion in workers who
were exposed for about 7 hours/day to fumes consisting mainly of SnCl4 and the
hydrogen chloride formed when the SnCl4 combined with moisture in the heated
air. According to the authors, the effects were probably due primarily to the
hydrogen chloride exposure, although smoking may have contributed to the
elevated frequencies of coughing and shortness of breath. Up to 0.18 mg SnCl4/m3
and up to 5 ppm hydrogen chloride were measured in the air. However, the air
concentrations were not monitored until after radical measures had been taken to
improve the work environment, and thus do not reflect the exposure situation at
the time of the questionnaire (34).
4A Belgian case-control study (n = 272) reports a significant increase in risk
for chronic kidney failure (odds ratio 3.72; 95% CI 1.22 – 11.3) in persons with
occupational exposure to tin (42).
Ingested tin can have an irritating effect on the digestive tract. There are many
reports of acute poisoning after intake of canned fruit or fruit juice. The most
common symptoms are nausea, vomiting, diarrhea and stomach cramps (65). In
one study with volunteers (3), nausea and diarrhea were reported after a single
glass of orange juice containing 1370 mg Sn/liter (intake of about 330 mg Sn, or
about 4.4 – 6.7 mg Sn/kg b.w.). No effects were observed after intake of a glass
of juice containing 540 mg Sn/l (about 130 mg Sn; 1.7 – 2.7 mg Sn/kg b.w.). In
another study, however, nausea, cramps and loose stools were reported after a
single dose of 100 mg Sn (as SnCl2) in Coca Cola. According to the authors, the
concentration of Sn in the test solution was about the same as that which produced
the symptoms described in Reference 3 (56).
Daily intake of fruit juice containing 50 mg Sn (as SnCl2) for 20 days (about
0.7 mg Sn/kg b.w./day) was found to increase excretion of zinc and selenium in
feces and reduce retention of zinc and excretion of zinc in urine. No significant
effects on excretion of calcium, copper, iron, manganese or magnesium were
observed (20, 28, 29). Inhibited zinc absorption, measured as retention of radio-
actively labeled zinc in the body after 7 to 10 days, is reported in another work
in which SnCl2 (36 mg Sn) in a ZnCl2 solution/diet containing zinc was given to
subjects on a single occasion (63). In the study in which volunteers were given
zinc in Coca Cola containing up to 100 mg Sn as SnCl2, however, there was no
clear reduction in uptake of zinc, measured as reduction of zinc in plasma after
1 to 4 hours (56).
Positive reactions in patch tests, regarded as expressions of an allergic reaction,
have been reported for metallic Sn or 1% or 2% SnCl2 in petrolatum. SnCl2, 5%
or 10% in petrolatum, is reported to be irritating to skin (13, 16, 38, 49). Contact
eczema was reported in one worker who had been exposed to dust from an alloy
containing 43% tin. The patient also had a positive result in a patch test with 1%
SnCl2 in petrolatum, and the case was judged to be an occupation-related allergic
contact dermatitis to tin (40). Considering that tin is a widely occurring substance
and that only a single case of allergic contact eczema has been definitely attrib-
uted to tin exposure, it must be concluded that tin and tin compounds very seldom
cause contact allergy.
Animal data
When rats were given a single intratracheal instillation of 50 mg tin dust from a
tin smelter (in saline), an accumulation of dust was observed in the lungs, but
there were no indications of changes in connective tissue during the year fol-
lowing the exposure (50). Greater susceptibility to lung infections was noted in
a study in which mice were given a single intratracheal instillation of 0.01 or
0.1 mg SnCl2 in saline (equivalent to about 0.25 or 2.5 mg Sn/kg b.w.) and then
exposed to a bacterial aerosol. Reported increases in mortality were 36% and 87%
5respectively (22). An older study reports that temporary irritation of eyes and
noses were the only observed effects on guinea pigs exposed by inhalation to
3000 mg/m3 SnCl4, 10 minutes per day “for months” (45).
The LD50 (24 hours) for oral administration to laboratory rodents is reported in
one study to be 146 – 396 mg Sn/kg b.w. for NaSn2F5, and 1197 – 1678 mg Sn/kg
b.w. for SnCl2. With intraperitoneal injection, the LD50 for rats (24 hours) was 43
– 50 mg Sn/kg b.w. for the former substance and 136 mg Sn/kg b.w. for the latter.
The toxic picture, characterized by a soporific effect on the central nervous system
and ataxia, was attributed to the Sn and (in the latter case) F. Both substances
resulted in pathological changes in kidneys (tubular necroses, regeneration) (11).
The effects of inorganic tin compounds given in oral doses vary with such
factors as the compound’s solubility in water (14). In one study, rats were given
feed containing 0.03, 0.1, 0.3 or 1% of various tin salts and tin oxides for 4 weeks
(SnCl2, Sn orthophosphate, Sn sulfate, SnS, SnO2, Sn oxalate, Sn tartrate, Sn
oleate) or 13 weeks (SnCl2, SnO). No noteworthy effects (growth, hematology,
histology, organ weights etc.) were reported at any dose level for SnS, SnO2, SnO
or Sn oleate. The 4-week exposures resulted in inhibited growth, histological
changes in livers (possibly an effect of partial starvation) and indications of
anemia in rats given 0.3 or 1% SnCl2, Sn orthophosphate, Sn sulfate, Sn oxalate
or Sn tartrate. Similar effects were observed in the 13-week experiment with
SnCl2. However, mortality at the highest dose level was high in this experiment,
and for this dose group the exposure was stopped before the scheduled time. The
NOEL for the ‘active’ tin salts in this study was estimated by the authors to be
0.1%, a level said to yield an intake of 22 – 33 mg Sn/kg b.w./day in a 90-day
study. It was suggested that with a diet containing less iron and copper the NOEL
might be lower (14, 65).
In another study in which SnCl2 was given to rats in feed for 4 weeks, observed
effects included lower body weights and reduction of hemoglobin at an average
intake of about 30 mg Sn/kg b.w./day (27). In a 30-day study in which rats were
given oral doses of 20, 100 or 175 mg NaSn2F5/kg b.w./day (about 13.4, 67, or
117 mg Sn/kg b.w./day), observed effects included dose-related growth inhibition,
degenerative changes in proximal renal tubuli (15 – 20% of the high-dose group)
and significant reduction of hemoglobin levels (males in the two highest dose
groups, day 15). According to the authors, effects on animals in the lowest dose
group were minimal (significantly lower body weights and serum glucose on one
occasion) (10).
No noteworthy histopathological observations of non-neoplastic nature are
reported in a long-term study (105 weeks) in which rats and mice were given
0.1 or 0.2% SnCl2 in feed. The intake in the low-dose group can be calculated to
be 20 – 50 mg Sn/kg b.w./day for the rats and 80 – 180 mg Sn/kg b.w./day for the
mice (41). In older literature, however, effects of long-term oral administration of
very low doses of tin have been reported to occur. In a study with rats, lifetime
exposure to SnCl2 in drinking water was reported to result in significant (p<0.001)
increase in fatty degeneration of the liver (both sexes) at an intake equivalent to
about 0.4 mg Sn/kg b.w./day (54). For moderate/severe fatty degeneration,
6however, the difference between the control group and the treated group was less
significant (p<0.05), and a larger proportion of controls than treated animals were
reported to have ‘degeneration and necrosis’ in the liver. A somewhat elevated
occurrence of tubular vacuolization in kidneys (p<0.05) was also reported in both
sexes. Further, significantly elevated serum glucose levels and somewhat short-
ened life spans were noted in females, and in males somewhat lower weight gain
(54). However, this study was not made according to modern praxis and the
observations can not be interpreted with the documentation provided. Lifelong
exposure to SnCl2 in drinking water at a dose level of 0.4 mg Sn/kg b.w./day
resulted in no noteworthy effects on mice (53).
Effects on iron, copper and zinc status have also been reported in some studies
in which low doses of SnCl2 were given orally to experimental animals (Table 1).
In a study (46) in which rats were given feed containing 0.5 – 226 mg Sn/kg (as
SnCl2) for 28 days, it is reported that tissue and plasma concentrations of iron,
copper and zinc were somewhat reduced at the dose level 1 mg Sn/kg b.w./day
(10 mg Sn/kg feed). Increasing tin content in feed was associated with a dose-
dependent reduction of iron in plasma (significantly lower than controls only at
the higher dose levels) and a generally dose-dependent reduction of iron in
kidneys, spleen and tibias. There was also a generally dose-dependent reduction
of copper concentration in plasma, liver, kidneys, spleen and tibias, and of zinc
concentration in plasma, kidneys and tibias. The hemoglobin concentration in
blood also decreased with increasing doses of tin, but was lower than controls
only at the highest dose. A percentual reduction of transferrin saturation with
increasing tin dose was also observed (significantly lower than in controls only
at higher doses). The statistical assessment was made using analysis of variance
and test for linear trend.
Reduced calcium in bones, inhibited collagen synthesis and lowered enzyme
activity, especially in bones, have also been demonstrated in studies in which
rodents were given low oral doses of SnCl2 (Table 1). In one study, rats were
given oral doses of 0.3, 1 or 3 mg Sn/kg b.w. (as SnCl2 in solution) twice daily for
90 days: there was a non-significant reduction of calcium in femurs at the lowest
dose level (0.6 mg Sn/kg b.w./day), and at the higher dose levels (2 and 6 mg
Sn/kg b.w./day) significant reductions of calcium in femurs as well as significant
reductions in enzyme activity. At the highest level significant reductions in serum
calcium and relative femur weight were also observed (66). These authors also
report reduced calcium content in bones of rats after 28 days, and reduced enzyme
activity in bones after only 3 days of oral administration of 1 mg Sn/kg b.w., twice
a day for up to 28 days. Inhibited collagen synthesis in femurs was also reported
(67, 68).
Tin cations have been shown to affect several different enzyme systems in
experimental animals. This may interfere with the oxidative function in the cells
and affect the detoxification of chemical substances (65). Reduced activity of the
enzyme δ-aminolevulinic acid dehydratase (ALAD) was observed in the blood of
rats after administration (oral, intraperitoneal, subcutaneous) of 2 doses of SnCl2
7(total 4 mg Sn/kg b.w.). Other studies report that ALAD is not inhibited by SnCl4
(65). Dose-dependent induction of hemoxygenase in kidneys and livers of rats
was reported after a single subcutaneous injection of SnCl2 (3 – 30 mg Sn/kg
b.w.). Significant inhibition of cytochrome P450-dependent liver enzymes and
reduced levels of cytochrome P450 in liver microsomes were observed in mice
after a single intravenous injection of 0.2 mg SnCl2 /kg b.w. (0.1 mg Sn/kg b.w.)
(7).
Patch tests on intact rabbit skin using 1% SnCl2 or 0.25% SnF2 in water
produced no indications of skin irritation (57). The highest concentrations of
SnCl2 or SnCl4 in alcohol that were non-irritating with a 1-minute application
were 5% for rat skin, and 3% (SnCl2) and 0.05% (SnCl4) for oral mucosa (33).
Neither substance caused sensitization when tested on rats (33).
Mutagenicity, genotoxicity
Tin compounds have been tested in several short-term in vitro tests, with
contradictory results. SnCl2 was reported to be negative in mutagenicity tests with
E.coli WP2 and several strains of Salmonella typhimurium. SnF2 was tested on the
same Salmonella strains, and with metabolic activation showed a weak mutagenic
effect on TA100 (19, 48). No DNA damage was indicated in two studies reporting
tests of SnCl2, SnCl4 and SnSO4 by the rec-assay system with Bacillus subtilis and
of SnCl4 by the SOS chromotest with E.coli, but SnCl2 and SnCl4 showed high
toxicity in the rec-assay (21, 32). However, DNA damage has been reported in
other in vitro studies in which SnCl2 was tested on strains of E.coli, and also
reduced survival of E.coli strains deficient in DNA repair (4, 44, 55). Experiments
with E.coli have shown that one mechanism behind SnCl2-induced damage
(genotoxicity, cell death) may be production of reactive oxygen species (12).
Dose-dependent increase of DNA damage was also observed when SnCl2 was
tested in vitro on mammalian cells and human white blood cells (36, 37). SnCl4,
however, did not cause DNA damage (36, 37), and in one of the experiments it
was shown that the tin(IV) compound was not taken up in the cells (36). In other
in vitro studies with human lymphocytes and SnCl4, however, significant
increases of chromosome aberrations, micronuclei and sister chromatid exchanges
have been reported (17, 18, 59).
There are few in vivo studies. SnCl2 was reported to be non-genotoxic in the
Drosophila wing spot test (62). In another mutation test with Drosophila, the Basc
test, it was concluded that SnF2 was not mutagenic (19). SnF2 was also negative in
tests for micronuclei (bone marrow cells). In these tests the SnCl2 was given to
mice in two intraperitoneal injections (2 x 9.8, 2 x 19.6 or 2 x 39.5 mg/kg b.w.)
(19).
Carcinogenicity
In a cancer study (41) feed containing 1000 or 2000 mg/kg SnCl2 was given to
rats and mice of both sexes for 105 weeks. A significantly elevated incidence of
8C-cell adenomas in thyroid was noted in male rats in the low-dose group (controls
2/50; low-dose group 9/49; high-dose group 5/50) and the incidence of male rats
with C-cell adenomas/carcinomas indicated a positive trend and significantly
higher proportions in both dose groups (controls 2/50; low-dose group 13/49;
high-dose group 8/50). However, the elevated incidence of C-cell tumors was not
accompanied by an increase of C-cell hyperplasias. A significant positive trend
for lung adenoma was also found in the male rats (controls 0/50; low-dose group
0/50; high-dose group 3/50). In the female mice there was a significant trend for
hepatic adenomas/carcinomas (controls 3/49; low-dose group 4/49; high-dose
group 8/49) and for a type of malignant lymphoma (controls 0/50; low-dose group
0/49; high-dose group 4/49). A comparison with historic controls (mice and rats)
from the laboratory indicates that the tumor incidence was significantly elevated
only for male rats in the low-dose group (C-cell tumors in thyroid). The intake in
this group was calculated to be about 20 – 40 mg Sn/kg b.w./day. In the judgment
of the authors, however, the increased incidence of thyroid tumors in this group
could not be definitely related to the exposure, and they concluded that SnCl2
was not carcinogenic to rats or mice.
No significant increase in the frequency of lung tumors was reported in a study
in which mice were given three intraperitoneal injections of SnCl2 per week (total
24 injections) and killed 30 weeks later. The total doses were 240 – 1200 mg/kg
b.w. (150 – 750 mg Sn/kg b.w.) (58). Nor have long-term studies in which mice
and rats were given small amounts of SnCl2 in drinking water (amounting to about
0.4 mg Sn/kg b.w./day) yielded evidence that tin is carcinogenic (65). No
evidence that tin is carcinogenic has been reported in several studies made with
implantation or injection of metallic tin in laboratory rodents. Abnormal growth
of glial tissue, however, was noted in a study in which metallic tin was implanted
inside the skulls of mice (65).
No cancer studies of persons exposed only to tin were found. An elevated risk
of lung cancer has been reported for miners in tin mines, but exposure to other
substances such as radon, arsenic and tobacco were considered to be contributing
factors (65).
Effects on reproduction
There are little data. Feed containing 125 – 500 mg Sn/kg as NaSn2F5 or
NaSn2Cl5, or 156 – 625 mg Sn/kg as SnF2, was given to rats during gestation.
More resorptions were observed in a few of the mothers, nearly all of whom had
been treated with NaSn2F5. The effect was not clearly dose-related and was
considered to have no toxicological significance (61).
Dose-effect / dose-response relationships
Very few reliable measurements of air concentrations of inorganic tin compounds
in work environments have been published, and it is therefore difficult to establish
any direct dose-response or dose-effect relationships. An accumulation of tin in
9the lungs, visible on x-rays but with no discernible effect on lung function
(stannosis) has been observed in workers exposed to dust/smoke of SnO2 for
three years or more. One study reports dust concentrations up to 2.22 mg Sn/m3
in a tin smelter where x-ray changes indicating stannosis were seen in 121 of 215
examined workers (50, 51, 52). No indications of fibrosis or clinically significant
emphysema were observed. Nor did any of the workers have clinical symptoms
that could be attributed to the occurrence of stannosis, and no indication of
reduced lung function was found in lung function tests. In another study
(Hlebnikova 1957, reviewed in Reference 26) it is reported that workers exposed
to aerosols consisting primarily of SnO2 developed stannosis after 6 – 8 years of
employment. The total dust concentration in the air ranged from 3 to 70 mg/m3.
The dust level was reduced to 10 mg/m3 and it is reported that no new cases were
observed in the ensuing ten years.
A dose-dependent increase in sensitivity to respiratory infection was reported
in mice given a single intratracheal injection of 0.01 or 0.1 mg SnCl2 in saline
(calculated to be about 0.25 or 2.5 mg Sn/kg b.w.) and then exposed to a bacterial
aerosol (22). Equivalent air concentrations calculated from this would be about
1.8 or 18 mg Sn/m3 (assuming inhalation of 10 m3 during an 8-hour work day,
100% uptake and a body weight of about 70 kg).
Intake of SnCl2 in fruit juice daily for 20 days had effects on excretion of zinc
and selenium in volunteers, at a dose level of 0.7 mg Sn/kg b.w./day (20, 28, 29).
Inhibition of zinc absorption was reported in another work in which subjects were
given single oral doses of 36 mg Sn as SnCl2, or about 0.5 mg Sn/kg b.w. (63).
Dose-effect relationships observed in experimental animals given tin compounds
orally are summarized in Table 1. Reduced calcium content in bones has been
reported with administration of SnCl2 at a dose level of 0.6 mg Sn/kg b.w./day,
and lower levels of iron, copper and zinc in plasma and tissues at a dose level of
1 mg Sn/kg b.w./day (46, 66).
Conclusions
There are no data from which to derive a critical effect of occupational exposure
to tin and inorganic tin compounds. Accumulation of tin in the lungs has been
shown to occur with occupational exposure to SnO2, but there are no reports of
evidence that this affects lung function or development of fibrosis. Inorganic tin
salts can form acids on contact with water, and in this form can be irritating and
even corrosive to air passages, eyes and skin.
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Table 1. Exposure-effect relationships observed in laboratory animals after oral
administration of inorganic tin compounds.
Exposure Substance Species Effects Ref.
1.4 mg Sn/kg feed,
28 days
(0.14 mg Sn/kg
bw/day)
SnCl2 Rat Minimal or no effects on concentrations of
iron, copper and zinc in tissues and plasma
46
5 ppm
in drinking water,
lifelong
(0.4 mg Sn/kg
bw/day)
SnCl2 Mouse Tin had no toxic effects 53
0.3 mg Sn/kg bw,
twice a day, 90 days
SnCl2 Rat Non-significant reduction of calcium content
in femurs
66
10 mg Sn/kg feed,
28 days
(1 mg Sn/kg bw/day)
SnCl2 Rat Reduced iron content in kidneys, reduced
copper in plasma, liver, kidneys, spleen and
tibias, reduced zinc in kidneys and tibias
46
1 mg Sn/kg bw,
twice a day
up to 28 days
SnCl2 Rat Reduced calcium in femurs, lower activity of
acid and alkaline phosphatases in femurs,
inhibited collagen synthesis in femurs
67,
68
1 mg Sn/kg bw,
twice a day,
90 days
SnCl2 Rat Reduced calcium content in femurs, reduced
activity of succinate dehydrogenase in liver
and acidic phosphatases in femurs
66
2 mg Sn/kg bw,
2 doses
48 h apart
SnCl2 Rat Reduced ALAD activity in blood 65
2 mg Sn/kg bw/day,
5 days
SnCl2 Rabbit No effects on heme biosynthesis, reduced
iron content in kidneys, reduced copper
content in kidneys and liver
69,
70
2 mg Sn/kg bw/day
1 month
SnCl2 Rabbit Higher iron concentration in liver and
kidneys, reduced copper content in bone
marrow, reduced zinc content in bone
marrow, increased zinc content in blood
69
3 mg Sn/kg bw
twice a day
90 days
SnCl2 Rat Reduced relative femur weight and calcium
content, reduced calcium in serum; reduced
activity of succinate dehydrogenase in liver;
acidic phosphatases in femur, LDH and
alkaline phosphates in serum
66
10 mg Sn/kg bw/day
4 months
SnCl2 Rabbit Temporary hemolytic anemia, temporary rise
of iron content in serum, increased total iron-
binding capacity
9
100 mg Sn/kg feed,
27 days
(11 mg Sn/kg
bw/day)
SnCl2 Rat Reduced calcium and zinc content in tibias 30,
31
100 mg Sn/kg feed
4 weeks
SnCl2 Rat Reduced copper content in in duodenum,
liver, kidneys and femurs, reduced zinc
content in kidneys and femurs
65
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Table 1. Continued.
Exposure Substance Species Effects Ref.
13.4 mg Sn/kg
bw/day, 30 days
NaSn2F5 Rat Minimal effects on body weight and serum
glucose
10
0.1% in feed,
4 or 13 weeks
(22-33 mg Sn/kg
bw/day)
SnCl2,
Sn-o-
phosphate,
Sn sulfate,
Sn oxalate,
Sn tartrate
Rat NOEL 14
260 mg Sn/kg
feed, 4 weeks
(29 mg Sn/kg
bw/day)
SnCl2 Rat Reduced hemoglobin, reduced body weights,
changes in intestines
27
0.1% in feed,
105 weeks
(20-50 mg Sn/kg
bw/day)
SnCl2 Rat Significantly higher incidence of thyroid
tumors in males. Substance judged to be non-
carcinogenic
41
300 mg Sn/l
drinking water +
52 mg Sn/kg
feed, 4 weeks
SnCl2 Rat Reduced compression resistance in femurs 43
67 mg Sn/kg
bw/day, 30 days
NaSn2F5 Rat Retarded growth, lower serum glucose, lower
hemoglobin levels
10
0.3% in feed
4 or 13 weeks
(70-100 mg Sn/kg
bw/day)
Sn sulfate
Sn tartrate
SnCl2
Sn-o-
phosphate,
Sn oxalate
Rat Inhibited growth, indications of anemia
Inhibited growth, indications of anemia,
histological changes in liver
14
100 mg Sn/kg bw
single dose
SnCl2 Rabbit Disturbed heme synthesis 8
117 mg Sn/kg
bw/day, 30 days
NaSn2F5 Rat Inhibited growth, lower serum glucose, lower
hemoglobin levels, degenerative changes in
proximal renal tubuli
10
0.1% in feed,
105 weeks
(80-180 mg Sn/kg
bw/day)
SnCl2 Mouse The substance was judged to be non-
carcinogenic
41
0.1-0.8% in feed
13 weeks
(males: 163-310
mg Sn/kg bw/day
females: 153-340
mg Sn/kg bw/day
SnCl2 Rat Both sexes: Slight anemia, elevated relative
kidney and liver weights, irritation of digestive
tract, various degrees of pancreas atrophy
Males: Slight growth inhibition, minor
histological changes in livers
15
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Consensus Report for Cobalt and Cobalt
Compounds
October 22, 2003
This report is an update of the Consensus Report published in 1983 (105)
and is based on the criteria document ”Cobalt and cobalt compounds” (83).
Chemical and physical data. Occurrence.
Cobalt
CAS No.: 7440-48-4
Formula Co
Molecular weight: 58.93
Boiling point: 3100 oC (IARC: 2870 oC)
Melting point: 1493 oC (IARC: 1495 oC)
The average concentration of cobalt (Co) in the earth’s crust is 20 µg/g but higher
concentrations are found in nickel and copper ore deposits from which about
25,000 tons of Co metal are produced annually (65). Co has one naturally occur-
ring isotope, 59Co, and has magnetic properties. It can form alloys and is not
corroded by air or water at ordinary temperature. Co is resistant to alkali but
soluble in acids (38, 49, 71, 103, 118). The main oxidation states are +II and +III.
Most commercially used Co compounds are water soluble bivalent salts (see
Table 1).
The human body contains 1000 to 2000 µg of Co; most of it is found in liver
(vitamin B12), kidney, heart and spleen, and low concentrations in serum, brain
and pancreas (26, 65, 71).
The daily Co intake for the general population ranges between 1.7-100 µg; the
diet being the main source. Environmental airborne Co concentrations are usually
around 1 ng/m3 but in heavily industrialised cities concentrations up to 10 ng/m3
have been reported. Co concentrations in drinking water vary between 0.1-5µg/l.
Tobacco is an insignificant Co source (38).
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Table 1. Identity and solubility of various Co compounds. Data from ref. (40).
Compound name Formula Molecular
weight
CAS no. Solubility in
water1)
Cobalt Co 58.9 7440-48-4 insoluble
Cobalt(II) oxide CoO 74.9 1307-96-6 3.13 mg/l
Cobalt(II,III) oxide Co3O4 240.8 1308-06-1 insoluble
Cobalt(II) chloride CoCl2 129.8 7646-79-9 529 g/l (20oC)
Cobalt(II) chloride hexahydrate CoCl2 x 6H2O 237.9 7791-13-1 767 g/l (0oC)
Cobalt(II) sulphate CoSO4 155.0 10124-43-3 393 g/l (25oC)
Cobalt(II) sulphate heptahydrate CoSO4 x 7H2O 281.1 10026-24-1 604 g/l (3oC)
Cobalt aluminate blue CoO,Al2O3 1333-88-6 insoluble
Stellite* Co(48-58%),
Cr,Ni,W alloy
12638-07-2
Vitallium* Co(56-68%),
Cr,Mo alloy
12629-02-6
Hard metal Co(10-25%),
WC mixture
*Trade mark
The most important use of metallic Co is in alloys with other metals (e.g.
chromium, nickel, copper, aluminium, beryllium and molybdenum). Alloys that
are important regarding occupational exposure are stellite and vitallium (38).
Cobalt is applied in the production of super alloys, permanent magnets, dental and
surgical implants; but hard-metals (cemented carbides) are the most important
(65). Hard-metals are produced using a powder metallurgy process (sintering) in
which tungsten carbide particles and Co metal are mixed, heated in hydrogen
atmosphere, pressed, shaped, sintered and grinded. Co acts as a binder for
tungsten carbide (57). Co has also been used in certain polishing disks of
microdiamonds cemented into ultrafine Co metal powder (22, 65, 109).
Co salts and Co oxides are used as catalysts in organic reactions or as drying
agents in paints, lacquers, varnishes and printing-inks. Co oxides, Co-Zn silicate
and spinels are used as pigments in glass, enamels, ceramic and porcelain
products (24).
The main route of occupational exposure is the respiratory tract (dusts, fumes or
mists containing Co) although skin contact is important (38, 64, 91). Occupational
exposures mainly occur in hard-metal production, processing and use, during the
production of Co powder, in the use of Co-containing pigments and driers and
during regeneration of spent catalysts (38).
In the following overview of Co exposures, only studies using personal air
sampling will be taken into account. Airborne Co exposures are highly dependent
on the type of industry and the stage of the production process (see Table 2). In
general, the highest exposure levels are found in the hard metal industry during
handling of powders and pressing (51). Concentrations of Co in air during wet
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Table 2. Occupational exposure to cobalt in various types of industries and at different
production stages as measured by personal air sampling. The values are rounded off.
type of industry n process mean (µg Co/m3)     lowest   highest Ref.
hard metal mixing
pressing
grinding
459
33
45
7
48
1
6390
2910
482
51
cobalt refinery 82 no distinction 570*
(> 50: 70%)
(> 500: 25%)
2 7700 104
diamond/cobalt 16 mixing room 9 2860 31
saw production 7 oven room 6 51
diamond polishing polishing 5.3-15 0.2 43 78
dental protheses
production
3
3
melting bay
refinishing bay
4
10 3 50
58
dental protheses
production
79 100 (2.5%)
25-100 (13.9%)
<25 (83.6%)
45
dental technicians 8 not described <detection 1600 95
pottery painting 19 plate painting 33 22 80 15
pottery painting 19 plate painting > 50 (20%)** 68 8610 88, 108
welding stellite 5
7
oxy acetylene
MAG welding
5*
175*
29
* calculated arithmetic mean with assumption of normal distribution
** Co-air concentration was 50 µg Co/m3 after improving the ventilation system
grinding may be higher than in dry grinding because of exposure to Co containing
aerosols of cutting/cooling fluids (25, 63, 98, 107). High airborne Co concentra-
tions were also found in Co refineries and during the production of Co containing
diamond saws (31, 104).
The Co exposure in a Swedish hard metal plant was recently reported in an
abstract (96). The air samples showed total dust and tungsten levels well below
Swedish national standards but the Co concentration was sometimes high
(extreme value 1.1 mg/m3). Urine specimen collected at the end of the working
week revealed U-Co levels of ≥15 µg/l in 29% of the workers (n=17) at the
milling and mixing department.
Atomic absorption spectrometry (AAS) or X-ray fluorescence are advised for
Co analysis in environmental samples (59). Blood Co (B-Co) and urine Co (U-Co)
concentrations should be analysed with graphite furnace AAS with Zeeman
background correction, which is a sensitive method (12, 102). More recently,
inductively coupled plasma mass spectrophotometry (ICP-MS) was found to be
a sensitive method for evaluation of environmental samples and U-Co. However,
overestimation of U-Co was found at low concentrations (non-exposed persons).
A high correlation between the formerly used AAS and the more recent ICP-MS
methods suggest that both methods are reliable (115). Inductively coupled plasma
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emission spectrometry and X-ray fluorescence appear to be too insensitive for
determination of Co in biological matrices (38).
Uptake, distribution, elimination
The respiratory tract (dusts, fumes, aerosols or gases) and the digestive tract
are the main routes of absorption (38). Absorption rates of Co or Co compounds
depend on their solubility in biological media (65). The lung retention in 2 human
volunteers after inhalation of cobalt (II,III) oxide particles varied between 64%
and 75% after 90 days for particles with a diameter of 0.8 µm and 1.7 µm,
respectively (10).
Human gastrointestinal absorption of orally supplied Co chloride varies
between 1 and 50% and is influenced by the amount of Co given (71, 99). Uptake
of Co chloride was higher than uptake of Co (II,III) oxide in humans and was
higher in female than in male (15). Absorption was higher in patients with iron
deficiency (71, 100).
Skin exposure to Co and Co compounds may result in significant dermal
absorption. A dermal absorption rate of 2.2 µg Co/cm2/hour was reported after
applying CoCl2 to human skin in vitro (111). For hard metal powder a dermal
absorption rate of 0.033 µg Co/cm2/hour for exposure of humans in vivo can be
calculated from Scansetti et al. (91). Using these data and applying the ECETOC
criteria for skin notation suggests that dermal exposure of workers to hard metal
or CoCl2 may result in significant systemic uptake, see further (83).
After intravenous administration of 60CoCl2 to humans, 60Co was mainly
excreted in urine and to a lesser extent in faeces. The urinary excretion is
characterized by a rapid phase of a few days duration (half-life 0.3 - 0.7 days)
followed by 2 intermediate components (half-lives of 3-8 and 40-80 days) and
a long-term component (half-live of about 800 days) (99). The mean urinary
excretion of orally administered radioactively labeled CoCl2 to humans (20
µmoles) was estimated to be 18% (range 9-23%) of the dose within 24 hours
(100).
Oral administration of cobalt sulphate heptahydrate to pregnant rats has shown
that Co can cross the placenta. Both maternal and fetal blood concentrations
were higher after oral cobalt sulphate heptahydrate treatment compared to cobalt
chloride hexahydrate (106). High Co concentrations in the fetal skeleton (and
cartilaginous structures of the mother) were found after parenteral CoCl2
administration to pregnant mice (38).
Biological monitoring
Urine, serum and whole blood Co concentrations of persons not occupationally
exposed to Co are between 0.1-2 µg/l (38). There is a good correlation between
exposure to soluble Co compounds (metal, salts and hard metal) and U-Co or B-
Co levels when Co exposure is assessed by personal air sampling. These data can
be used for assessing exposure on a group basis (67). U-Co is preferred above B-
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Co since increases in airborne Co can be detected at lower levels (28, 38).
According to Scansetti, et al. Monday end of shift U-Co gives an estimate of the
exposure to hard metal on that day, while Friday end of shift samples are related
to the cumulative exposure of the week (92). Poor correlations between Co in air
concentrations and U-Co or B-Co were reported in Co oxide processing (67).
Toxic effects
Respiratory system
Mixed exposures of metallic cobalt, cobalt salts and cobalt oxides may cause
asthma and obstructive lung function impairment. Hard metal and combined
exposure of Co and diamond particles may give rise to interstitial lung disease
and also to asthma.
An overview of the mechanism of toxicity of cobalt is discussed in the criteria
document (83), see also the mutagenicity section.
Human data
Metallic Co, Co oxides and Co salts
A case-referent study (90) with 21 cases (workers with asthma) and 55 referents
(workers without asthma randomly selected from the whole company) was carried
out in a company, with complex exposure, that consisted of a cobalt, a zinc, and
a sulfur plant. The asthma risk was increased for subjects exposed to Co (age
adjusted OR= 4.8, 95%CI=2.0-11.7), i.e. for those working in the cobalt plant
with exposure to cobalt sulphate or cobalt metal dust. Smoking was not associated
with asthma. The levels ranged from less than 10 to 100 µg Co/m3 in the cobalt
plant (stationary sampling) and from 10 to 50 µg Co/m3 in the cobalt roasting area
(personal sampling). Five of 15 asthmatics regularly exposed to Co had a positive
reaction to CoCl2 in a provocation test and one had a positive reaction to dust
from the Co roasting building. Pre-employment examination forms did not
indicate that any of the cobalt workers had asthma before their current
employment. The median average exposure time before onset of asthmatic
symptoms was 11 month (range 2-36 month) for the 6 workers with positive
provocation test. In 12 of the asthmatic cobalt workers, the asthma disappeared
after removal from exposure. Two were later accidentally re-exposed to Co
(water-soluble Co dust and metallic Co, respectively) and experienced typical
clinical symptoms of asthma and had a positive provocation test to CoCl2 (90).
In a later study in the same plant, an additional case of occupational asthma
with positive reaction to Co in a provocation test has been reported (62).
A cross sectional study among 82 workers of a Co refinery and 82 controls
that were not exposed to lung irritants and were matched for age and sex, was
performed. The workers were exposed to Co metal, oxides and salts at concentra-
tions between 2-7700 µg Co/m3 (geometric mean 125 µg Co/m3, 164 exposure
measurements) and had a mean exposure duration of 8 years. The exposed
workers complained significantly more often of dyspnoea and wheezing,
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especially the smokers. In addition, there was a significant positive relationship
between current concentrations of Co in air or U-Co and dyspnoea during
exercise. A significant relation was also found in the exposed group between
the intensity of current exposure to Co (Co in air and U-Co) and the reduction
of FEV1/FVC (104).
No effect on the lung function was found in a cross sectional study among 224
workers who were exposed to Co metal, oxides and salts at concentrations less
than 50 µg Co/m3 and a mean exposure duration of 7.3 years. The referents
(n=161) worked in a laboratory, office or power plant (90). Lung functions were
also not impaired in a cross sectional study among 49 workers who were exposed
to 520 µg Co/m3 originating from Co metal and oxide. The mean exposure
duration was 10.7 years. The referents (n=46) were not exposed to Co and
were matched for smoking (72).
No interstitial lung disease (see below) was reported in these studies of workers
exposed to Co metal, oxides or salts (62, 72, 104, 110).
Based on these studies it can be concluded that Co metal, oxides and salts may
induce asthma (62, 90). A positive dose-effect relationship between Co exposure,
originating from Co metal, oxides and salts, and obstructive lung function
impairment was reported in one study (103). Two other studies did not find a
relationship (72, 90). Interstitial lung disease was not found in workers exposed
to Co metal, oxides and salts (62, 72, 104, 110).
Hard metal
Interstitial lung diseases are a group of diseases that are characterised by
inflammatory changes in the lung interstitium. These diseases are often
characterised by fibrosis and examples are allergic alveolitis, sarcoidosis,
asbestosis, silicosis and hard metal disease. The signs and symptoms associated
with these diseases include cough, phlegm, restrictive alterations, and decreased
diffusion capacity. In severe cases of hard metal disease the lung function is
severely impaired and death has been reported.
Sprince et al. performed a cross sectional study among 1039 hard metal
production workers (101). Work-related wheeze occurred in 113 participants. The
prevalence of work-related wheeze by present exposure category were ≤50 µg/m3,
9.2%; >50 µg/m3 to ≤100 µg/m3, 18.1%; >100 µg/m3, 15.4%. The odds ratio for
work-related wheeze was 2.1 times (X2=9.5, p<0.002) for present cobalt exposure
exceeding 50 µg Co/m3 compared with exposures ≤50 µg Co/m3 after adjusting
for current smoking, age, gender and race (no relative risk estimate could be
calculated from the data given in the study). Abnormal chest radiographs was
defined as showing profusion of small opacities ≥1/0 (ILO-classification) and
occurred in 26 workers. The odds ratio for profusion ≥1/0 was 5.1 times (X2=4.8,
p<0.029) for average lifetime cobalt exposures exceeding 100 µg Co/m3 compared
with exposures ≤100 µg Co/m3 in those with latency exceeding 10 years after
adjusting for pack-years and age. Average lifetime exposure was defined as
cumulative Co exposure divided by total duration of exposure. Interstitial lung
disease was defined as profusion ≥1/1, FVC or DLCO ≤70% and FEV1/FVC%
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≥75% and occurred in 7 workers (no control group). In two of the subjects with
ILD, lung biopsies were made that showed interstitial fibrosis. Grinders of hard
metal had a lower diffusion capacity for carbon monoxide compared to non-
grinders, even though they were exposed to lower airborne Co concentrations
(101). This phenomenon was also reported by Sjögren et al. and Kennedy et al.
who found a higher prevalence of lung disease and restrictive lung function
impairment among wet grinders (47, 98). Since wet grinders use coolants that
often contain high Co concentrations, additional exposure via skin and/or
gastrointestinal tract may be responsible for the increased toxic effects in grinders.
A cross sectional study was conducted on 425 workers and 88 controls who
were working at one of three hard metal plants. The diffusion capacity for carbon
monoxide was lower in exposed workers than in controls. This difference was
more pronounced in women than in men. Slight abnormalities of chest radio-
graphs were more frequent in exposed men than in controls (prevalence: 19.5% at
a mean Co exposure of 30-220 µg Co/m3 and 24% at 45-272 µg Co/m3). Subjects
with abnormal chest radiographs had a slight restrictive lung function impairment
compared to matched controls. The differences could not be explained by
smoking habits (70).
Symptoms and signs compatible with alveolitis were found in a case study
among hard metal workers (98). In another case study, diffuse interstitial lung
disease was reported among hard metal workers (17). In both studies, exposure
measurements were not well described. No interstitial lung disease was found
among 319 hard metal workers who were exposed to mean Co exposures up to
688 µg Co/m3 during 1-29 years (55) and among 250 hard metal workers divided
into six groups with average exposure concentrations varying between 2 to 60 µg
Co/m3 during 7-11 years, except for the dry grinders who’s mean exposure
duration was 4 years (2).
In a cross sectional Japanese study, 18 of 319 (5.6%) hard metal workers had
asthma (the prevalence of asthma in the general population was not given). All
nine patients with asthma who had a bronchial provocation test with Co chloride
were positive. Mean Co exposures in four cases were 18, 24, >31 and >1203 µg
Co/m3 (52, 55). Shirakawa reported mean Co exposures between 7 – 227 µg/m3 in
8 patients who developed occupational asthma. Four of these eight patients were
atopic and seven showed bronchial hyperresponsiveness to methacholine. All
patients had positive reactions to 1% CoCl2 in the provocation test while the
control subjects, including 6 asthmatic patients with high responsiveness to
methacholine, showed no reaction. Tungsten was incapable of provoking asthma
in challenge tests. Four patients had specific IgE antibodies to cobalt conjugated
human serum albumin based on comparison of serum samples from 60 asthmatic
patients and 25 asymptomatic workers in the same plant (97).
Impaired lung function caused by hard metal exposure was reported in many
studies (2, 47, 53, 55, 70). Two key studies with low exposure levels will be
discussed in detail.
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In eight lumber mills that voluntarily participated in a cross sectional study,
(118 saw filers, 90% participation) were compared with an external population of
bus mechanics (number of bus mechanics not given). The saw filers were divided
in 7 groups that performed different tasks, including wet grinding and dry
grinding. Wet grinding was defined as grinding of tungsten carbide at least 10%
of the time, for which at least 50% of the grinding was performed with a coolant;
dry grinding was similarly defined, but required at least 50% of the grinding
without a coolant. The full shift air Co concentration was determined in every filer
between 1 and 4 times. Co was detected (detection limit 0.64 µg/m3) in 62 of 278
samples (mean 9, max. 106, SD 20 µg/m3). The within subject variability was
very high; therefore exposure was estimated at group levels. Mean Co concen-
trations in used coolants from tungsten carbide grinding machines was 0.7 g/l
(n=29). About three times the rate of cough, phlegm and wheeze related to work
was reported by the filers compared to the bus mechanics. The wet grinders had
significantly lower FEV1 and FVC values compared to the other saw filers and the
bus mechanics, whereas no differences were seen between other saw filers and
bus mechanics. The effects on the wet grinders could not be explained by smoking
habits. The estimated mean Co exposure for dry grinding was 5.4 µg Co/m3 and
for wet grinding 5.6 µg Co/m3. Both Co exposure during wet grinding of tungsten
carbide and duration of work were significantly associated with reductions in
FEV1 and FVC in the wet grinders. The airborne Co exposures were comparable
for wet grinders and dry grinders and the authors speculate that dermal absorption
of Co in the wet grinders might have contributed to systemic uptake. Other
speculations to explain the different effects seen in dry and wet grinders were
that the coolant might have an adjuvant effect or might change the state of Co.
Wet grinders of other metals, eg. stellite and mild steel, using the same coolant,
did not show reductions in lung function (47, 107).
In a cross sectional study, hard metal workers from four major Swedish hard
metal industries were divided in six different exposure groups according to job
category (1, 2). The mean cobalt exposure duration was 7–11 years, except for
dry grinders who had a mean duration of 4 years. Office workers in the same
industries were used as controls; these were matched pairwise to each exposure
group by sex, age, length, and smoking habits. Exposure levels were based on
personal monitoring data (breathing zone) from the same work places. Several
symptoms were more common in the cobalt exposed workers (Table 3).
According to an interview survey, prevalence of irritation of eyes, nose or throat
was significantly elevated in all relevant exposure groups (given mean exposure
levels: 3–60 µg/m3), but with no clear dose-response (Table 3). Cough with
phlegm was also significantly increased in the lowest exposure group, but with
an inconsistent dose-response pattern. Chronic bronchitis was significantly more
frequent in the highest (60 µg Co/m3), but not in lower exposure groups (Table 3).
These chronic symptoms were more common among smokers. Details about
the interview survey are not reported. Lung function tests of the workers in the
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 Table 3. Symptom frequency (% exposed/% control) in different groups occupationally
exposed to cobalt in four hard metal plants in Sweden. Adapted from Alexandersson (2)1.
Job type
(exposure
group)
Office
work
(control)
Quality
inspection2
Surface
grinding
Powder
handling
Wet
grinding
Dry
grinding
Powder
handling
Mean exposure3
(µg Co/m3)
0.8 – 0.9 2 3 5-10 8 12 60
Irritation of
eyes, nose or
throat
- 18/0 35/7 27/0 35/4 32/0 40/2
Breathlessness
or feeling of
heavy to bread
during work
- 9/0 3/0 10/0 16/0 16/0 24/0
Cough without
phlegm
- 14/4 14/17 20/3 23/7 8/8 8/10
Cough with
phlegm
- 21/0 28/3 10/0 23/5 4/4 35/6
Chronic
bronchitis4
- 4/0 0/0 0/0 5/0 0/0 11/0
Chest tightness - 34/18 24/21 33/17 46/18 32/16 27/18
Number of
subjects5
- 44 29 30 57 27 63
1Bold figures indicate significant difference between exposed group and control group (p≤0.05).
2According to authors, symptoms in this group is probably due to selection and not related to cobalt
 exposure.
3Previous exposures were reported to have been higher.
4Diagnosed by physician.
5Exposed and controls were pair wise matched, considering sex, age, height, and smoking habit.
 Asthmatics were excluded.
highest exposure group (60 µg Co/m3) revealed significant impairment in FEV1,
FEV%, and MMF (maximum midexpiratory flow) compared to paired controls
and in FVC, FEV1, and MMF over the working week. In dry grinders exposed to
12 µg Co/m3, tendencies to impairment in FVC compared to controls was seen
and in wet grinders, exposed to 8 µg Co/m3, in FEV1 and MMF over the working
week. No significant impairment of lung function parameters was found in the
other exposure groups. It should be noted that exposure measurements were the
most recent ones, performed within a couple of years (no further details given).
Exposures were markedly higher in the past (2). Thus, the chronic symptoms may
have been caused by earlier, higher exposures. A 5-year follow-up of 27 workers
showed additional FEV1 impairment in smokers. The mean exposure of these
workers decreased from 80 to 30 µg Co/m3 during this period (6). A dose-effect
relationship was demonstrated between U-Co and FEV1 and between B-Co and
FEV1 only in smokers (5).
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Male smoking hard metal exposed workers had decreased values of FEV1, peak
expiratory flow and forced expiratory flow at 50% of vital capacity. This effect
was only seen in hard metal workers who smoked. The workers were stratified in
three exposure groups (≤50, 50-100 and ≥100 µg Co/m3). Smoking habits were
stratified in current smoker, ex-smoker and non-smoker (54).
Sixteen ex-factory workers with diagnosed hard metal disease and with
previous cobalt and solvent exposure were tested for memory deficits. They
had been exposed for 2–35 years (levels not reported) and removed from work
1 month to 8 years prior to testing. Results demonstrated deficits in the allocation
of attentional resources and in short-term verbal memory (42). If these reported
deficits are secondary to hypoxia due to lung function impairment or a direct
effect of Co on the CNS remains to be clarified.
In summary, irritative effects (eyes, nose and throat) from hard metal exposure
has been reported at a mean exposure level of 3 µg/m3 (2). ILD from hard metal
exposure has been reported (17, 70, 98, 101). No epidemiological data are
available on ILD caused by tungsten(carbide) without Co. Restrictive lung
impairment was found among wet grinders exposed to mean Co concentrations
of 5.6 µg/m3 (47). Several studies reported increased lung toxicity for wet grinders
compared to dry grinders, which may be a result of additional dermal Co exposure
from Co containing coolants (47, 98, 101). Hard metal can also induce asthma
(52, 55, 97).
Co containing diamond polishing dust
Demedts et al. reported 5 cases of interstitial lung disease among diamond
polishers using Co containing abrasive disks. No exposure measurements were
available (22).
Bronchial asthma among diamond polishers was described in 3 cases. The
patients had worked with Co containing abrasive disks. All three patients were
positive in a cobalt inhalation challenge test (32).
In a cross-sectional study among 194 diamond polishers working with Co-
containing disks and 59 controls who worked with disks without Co, three dose
groups were formed. The Co exposure of the controls varied between 0.08 and
1.5 µg/m3. The mean Co exposure in the low and high exposure group was 5.3 µg
Co/m3 and 15 µg Co/m3, respectively. Mean U-Co concentrations for the three
dose groups were 2, 7 and 21 µg Co/g creatinine respectively. FVC and FEV1, but
not FEV1/FVC, were significantly lower in the high exposure group compared to
the low exposure group. This was also found when the high exposure group
was compared with the pooled low Co and control group. The effects were more
pronounced in women. The differences were not due to differences in smoking
habits. Both exposure and health measurements were cross sectional, thus a
healthy worker effect may have underestimated the effect of Co exposure on
lung function (78).
A decrease of FVC and FEV1 (but not FEV1/FVC) was reported in a cross-
sectional study among 48 workers producing diamond-Co circular saws and 23
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controls. This was true for smokers and non-smokers. Non-smokers who were
exposed for more than 5 years had a tendency to an obstructive effect. Exposures
varied between 6.2-2875 µg Co/m3 (31).
It can be concluded that combined exposure to Co and diamond particles leads
to interstitial lung disease and induces asthma. Restrictive lung impairment was
reported among workers exposed to both diamond particles and a mean Co
concentration of 15 µg Co/m3.
Vitallium
Exposure to vitallium dust, an alloy of Co (56-68%), chromium and molybdenium,
has been associated with the development of pneumoconiosis in dental technicians
(77, 94, 95).
In a cross-sectional study 37 dental technicians with at least 5 years (range 5-
36 years) exposure to vitallium showed a restrictive lung function impairment
compared with historical reference material. A dose-response relation between
exposure to vitallium dust in hours per week and reductions in both FVC and
FEV1 was found. The reduction was more pronounced in smokers than in non-
smokers and ex-smokers. Six (16%) of the 37 dental technicians showed
radiological evidence of pneumoconiosis. Dust measurements were carried out
for those technicians (10 subjects) who had a minimum weekly working time with
vitallium of 20 hours. Co concentrations in the air between 25 and 1600 µg Co/m3
were measured when no local exhaust was available. When local exhaust
ventilation was available the Co concentrations were lower than 25 µg Co/m3
(95). Dental technicians are exposed to a complex mixture of dust particles and
it is not possible to make a distinction between asbestos or silicon carbide fibres
or other elements such as aluminium silicate, quartz, corundum, or vitallium as
a single causative agent (95).
The mixed dust pneumoconiosis associated with vitallium exposure should
not be confused with interstitial lung disease caused by hard metal dust (66),
since vitallium is a homogenous alloy and hard metal is not. Co in vitallium
is remarkably stable in biological fluid, whereas Co in hard metal is rapidly
solubilized and cannot be found in lung or bronchoalveolar lavage fluid of
patients. No giant cells or desquamative alveolitis have been seen in the dental
technicians (66).
Co-Zn silicate
Impaired lung function was reported in a cross sectional study after exposure
to Co-Zn silicate. The forced expiratory flow rate at 25% and 50% of the vital
capacity was decreased. Co exposures were not well defined since technical
adjustments to the fume cupboards were made during the study (88). In this study,
the number of smokers was higher in the exposed workers than in the controls and
“smoking may be a confounder” (15).
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Animal data
Inhalation exposure of rats to Co sulfate heptahydrate during 13 weeks affected
the lungs. Inflammation (histiocytic infiltrates) of the lung was found at
concentrations equal or higher than 400 µg Co/m3 and more severe inflammation
was found at a concentration equal or higher than 1100 µg Co/m3. Bronchiolar
regeneration, peribronchiolar and septal fibrosis were seen at concentrations equal
or higher than 11000 µg Co/m3 (13, 80). Rats who were exposed to Co sulfate
heptahydrate aerosols during 2 years developed alveolar inflammation and
interstitial fibrosis at 100 µg Co/m3. Mice were less sensitive in this study
(14, 81).
Rabbits were exposed to 400 or 2000 µg Co/m3 as Co chloride aerosols for 14-
16 weeks. At the higher Co chloride concentration an increased number of macro-
phages in bronchoalveolar lavage fluid was found. Lysozyme activity and
oxidative metabolic activity of macrophages were increased in both exposed
groups (41).
Decreased lung compliance and microscopic evidence of interstitial fibrosis
by an increase of septal collagen were found in miniature swine after inhalation
exposure to 100 µg/m3 Co powder during 3 months (48).
Rats exposed via a single intratracheal instillation of a mixture of Co and
tungsten carbide particles in saline (10000 µg/kg bw, corresponding to 600 µg
Co/kg bw), showed acute alveolitis during at least 1 month. No fibrosis was seen
after 4 months. Exposure to either cobalt (600 µg Co/kg bw) or tungsten carbide
(10000 µg/kg bw) resulted in very modest effects. Extension of the treatments to 4
administrations at 1 month interval resulted in interstitial fibrosis after exposure to
the mixture of Co and tungsten carbide. No effects were seen after exposure to Co
or tungsten carbide alone (56).
Hamsters exposed to Co(II)oxide aerosols (8000 µg Co/m3) up to 22 months
developed pneumoconiosis from early on. This was characterised by interstitial
pneumonitis, diffuse granulomatous pneumonia and fibrosis of alveolar septa
(114).
Skin
Skin exposure to cobalt and cobalt compounds may occur in the industries already
mentioned in Table 2, and also in concrete construction work since cement
contains Co. Co is one of the major contact allergens, and 4% of patch-tested
dermatitis patients are patch-test positive to CoCl2 (43). Knowledge about sources
of sensitisation and elicitation is however limited. Solitary Co allergy, without
simultaneous contact allergy to nickel or chromate, is seen mainly among hard-
metal workers and in glass and pottery industry. 5% of 853 hard-metal workers
in a plant were allergic to cobalt (30). Although Co sensitivity generally occurs
simultaneously with allergy to other metals (nickel and/or chromium), this is not
believed to be due to a cross reactivity phenomenon but rather to combined
exposure (37, 61). CoCl2 was classified as a grade 3 allergen in a human
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maximation test (highest: 5), and as grade 5 allergen in a guinea pig maximisation
test. The animals did not react to nickel sulfate or chromate which is in agreement
with the theory of multiple sensitisation rather that cross reactivity (60, 61, 112,
113). Single cases of photocontact dermatitis due to cobalt have been described
(89).
Thyroid gland
Co therapy of patients with anemia caused thyroid hyperplasia associated with
thyroid hypofunction. The applied doses were 3000-4000 µg Co/kg/day during
3-7.5 month (50). Decreases in plasma T3 and T4 and an increase in TSH were
found in 82 workers exposed to 2 – 7700 µg Co/m3 during 8 years (104). In
contrast, an increased T4, marginally reduced T3 and unaltered TSH were found
in 25 plate painters exposed to semi soluble Co-Zn silicates. The mean U-Co of
these workers was 1.17 µg/mmol creatinine. Co-air measurements of about 50
µg/m3 were reported, but no description was given of the measurement strategy
and the analysis of the samples (87). Overall, the data on toxic effects on the
thyroid gland from occupational exposure to Co are inconclusive.
Cardiovascular system and blood and blood-forming organs
Cardiomyopathy was found in heavy beer drinkers after Co chloride or Co
sulfate was added to beer. The estimated daily intake was 6000-8000 µg Co.
Remarkably, patients who were treated with Co chloride up to 100 000 µg/day
did not develop cardiomyopathy. Alcohol intake and bad nutritional status (low
protein) may have contributed to the cardiomyopathy in the beer drinkers (65, 93).
Cardiomyopathy was also described in 2 workers exposed to high concentrations
of dust from Co-containing ores (39) and in some cases in which no exposure data
are available (11, 46). Thirty hard metal workers exposed for 10-15 years had a
normal cardiac function at rest. In hard metal workers with abnormal chest X-ray
findings, the right ventricular ejection fraction was reduced with exercise. This
was probably due to fibrotic pulmonary disease and early cor pulmonale (36, 93).
Alexandersson and Atterhög compared 42 dry grinders, 43 wet grinders and 61
powder handlers with 126 controls. The mean Co exposures of the groups were
10 µg Co/m3 for both the dry and the wet grinders, 60 µg Co/m3 for the powder
handlers and no exposure for the control group. Only the wet grinders had ST- and
T-depressions in the ECG with an overfrequency of ectopic beats but they had no
pulmonary dysfunction. In the other groups no effects on the heart function were
found (3). The small ECG changes in the wet grinders had disappeared after 4
weeks vacation (4).
No excess mortality from diseases of the circulatory system were found in a
French cohort study among Co production workers (born in France), SMR=0.80,
95%CI 0.36-1.51 (73), and in a cohort study among 7459 hard metal workers,
SMR=0.88, 95%CI 0.75-1.03 (74). This is in contrast to a Swedish cohort study
in which increased mortality from ischemic heart disease was found in hard metal
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workers. The effect was only found in the highest exposure group (up to 11000 µg
Co/m3) with more than 10 years employment who had died more than 20 years
after the beginning of exposure (16 cases vs 9.4 expected, SMR=1.69, 95%CI
0.96-2.75 (35). The calculated SMR’s are based on national rates.
In the past, Co was used as a therapy to increase red blood cell number,
hemoglobin, and hematocrit. The applied oral doses were 6200-12400 µg Co/day
during 12-30 weeks (26). In a cross sectional study among 82 Co refinery workers
and 82 age matched controls, a reduction in hematocrit and hemoglobin was
reported, which could not be explained by the authors (104). Co increases
erythropoietin concentrations by simulating hypoxia (7, 33, 65).
Several studies shows that rats, pigs and guinea pigs develop cardiomyopathy
after oral administration of Co salts. The applied doses varied between 3000 and
100 000 µg Co/kg/day during 3 days up till 20 weeks. The results also suggest that
thiamine or protein deficiency may exacerbate this condition (27). ECG changes
were reported in miniature swine after inhalation exposure to 100 µg/m3 Co
powder during 3 months. The ECG changes were loss of QRS voltage indicating
a decrease in ventricular contraction and T-wave changes indicating repolarisation
abnormalities (48).
Male B6C3F1 mice were exposed to cobalt sulfate heptahydrate (mass median
aerodynamic diameter 1.5-1.8 µm) by inhalation of 3.0 mg/m3 (corresponding to
630 µg Co/m3) for 2 years. Arteritis was detected in heart and kidney (75).
Optic atrophy and deafness
Bilateral deafness and visual failure were reported in a case study of a 48 year
old employee exposed to Co powder for 20 months, working 50 hours a week.
No exposure measurements are available. The complaints disappeared after he
stopped working. Optic atrophy was found in a patient who received a total dose
of 73 g CoCl2 in 3 years. Bilateral deafness due to nerve damage was found in a
patient who received a daily dose of 100 000 µg CoCl2 for 6 months. Four out of
16 patients who were treated with CoCl2 complained of tinnitus after 4-16 weeks
of therapy. The effect disappeared after stopping the therapy (69).
Mutagenicity, carcinogenicity
The carcinogenic potential of Co and its compounds was evaluated by IARC
in 1991 (38). The overal evaluation was that Co and its compounds are possibly
carcinogenic to humans (group 2B). This evaluation was based on inadequate
evidence in humans and sufficient, limited or inadequate evidence (depending
on the type of cobalt compound) in experimental animals.
Production of activated oxygen species is a common mechanism of geno-
toxicity for cobalt(II) ions, cobalt metal and hard metal (Co plus tungsten
carbide), and cobalt and cobalt compounds are believed to act as indirect
genotoxicants due to the formation of activated oxygen species. In addition,
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Co(II) ions are known to inhibit DNA repair. Co(II) ions are formed during
the production of activated oxygen species from cobalt and hard metal (68).
In a population (n= 78) of workers selected for Cd exposure, but also exposed
to Co (mean air level: 2.0 µg Co/m3, state of Co not defined) and Pb, levels of
DNA-SSB (single strand breaks) in mononuclear blood cells correlated strongly
to Co levels in air (personal sampler) and in blood. Increased levels of SSB was
recorded at Co levels of between 4–10 µg/m3. An inhibition of repair activity of
DNA adducts (8-oxoguanine) in blood from these workers was also reported, but
referred to as unpublished data. The authors conclude that Co was the strongest
determinant, but that interactions with Cd and/or Pb seem likely (34).
Co ions
Intratracheal instillation of Co chloride to hamsters caused thiol oxidation in
lung tissue indicating oxidative stress (79). Intraperitoneal administration of
Co(II) ions to rats produced oxidative DNA damage caused by hydroxyl radicals
in renal, hepatic and pulmonary chromatin (44). Chromosomal aberrations were
also found in mice after oral administration of Co chloride (82). DNA breakage
was shown in human lymphocytes exposed in vitro to non cytotoxic Co chloride
concentrations (21).
Inhalation exposure of rats and mice to Co sulphate heptahydrate during
13 weeks caused squamous metaplasia of the larynx (13, 80). Co sulphate
heptahydrate was also studied in a 2-year inhalation study. Incidences of
alveolar/bronchiolar neoplasms were significantly increased compared to controls
in both male and female rats and mice. Benign, complex or malignant adrenal
pheochromocytoma were significantly increased in male and female rats. The
overall conclusion was that there is some evidence of carcinogenic activity in
male rats, clear evidence in female rats and clear evidence in male and female
mice (14, 81). The European Union has classified Co chloride and sulphate as
substances which may cause cancer in humans by inhalation (C2 carcinogens)
(68).
It can be concluded that there is evidence that Co(II) exerts carcinogenic effects
in animals. No evidence about genotoxicity or carcinogenicity is available in
humans.
Co metal and Co oxides
No increase in genotoxicity biomarkers in lymphocytes was found in 35 workers
from Co refineries compared with matched controls. The average Co exposure of
the workers was 20 µg Co/m3 (20).
Two cohort studies among workers in an electrochemical plant producing Co
and sodium were performed. The first study (1950-1980) found a significant
excess of lung cancer among workers in the production of Co (SMR 4.66; 95%CI
1.46-10.64) but the number of cases was only 4. Smoking was not taken into
account (76). Extension of the follow up (1981-1988) by the same authors did not
confirm the hypothesis of a relation between lung cancer and Co exposure (SMR
31
0.85; 95%CI 0.18-2.50). No worker died of lung cancer during the extension
of the follow up. Reevaluation of the 4 cases in the first study in which general
practitioners’ records were used to set the number of lung cancers showed that
there was no death certificate for one of the 4 cases. This means that there were
only 3 cases of lung cancer in the latter study (73).
It may be concluded that the epidemiological studies are insufficient to evaluate
the carcinogenic potential for Co metal alone. According to IARC, there is
sufficient evidence that Co(II) oxide is carcinogenic in animals and inadequate
evidence that Co(II,III) oxide is carcinogenic in animals (38). No study examining
the genotoxic or carcinogenic activity of Co oxides was found in the literature
published since the 1991 IARC evaluation.
Hard metal
No increased genotoxic effect in lymphocytes was found in 29 hard metal workers
who were exposed to a mean Co concentration of 20 µg/m3 (20). Hyperplasia of
type II alveolar epithelial lining cells was found in patients with severe restrictive
ventilatory defects (9, 19). A retrospective cohort (1951-1982) of 3163 hard metal
workers showed an excess mortality from lung cancer only in workers with more
than 10 years employment who had died more than 20 years after the beginning of
exposure (7 cases observed versus 2.5 expected; SMR 2.78, 95%CI 1.11-5.72). A
dose-response relationship was not found (35). An increased mortality from lung
cancer was found in a French follow up from 1956-1989 among 709 hard metal
workers (10 cases observed, SMR 2.13, 95%CI 1.02-3.93). This excess was
highest among workers employed in the areas with Co exposures higher than 50
µg/m3 (6 cases observed, SMR 5.03, 95%CI 1.85-10.95). Lung cancer mortality
could not be explained by smoking alone (57). Extension of this study to a cohort
of 7459 workers from all hard metal plants in France (covering years 1968 to
1991) showed again that mortality from lung cancer in this cohort was borderline
significantly increased (63 cases observed, SMR 1.30, 95%CI 1.00-1.66).
Mortality from lung cancer increased slightly with time since first employment.
A nested case control study (61 cases and 180 controls) showed a twofold lung
cancer risk among workers exposed to Co and tungsten carbide when the
exposures during the last 10 years were ignored (OR=1.93, 95%CI 1.03-3.62).
The odds ratio increased with cumulative exposure and duration of exposure.
Smoking could not explain the excess of lung cancer (74). A historic cohort study
(117) was set up in one of the sites already included in the study of Moulin et al.
(74). Full job histories were available in contrast to the study of Moulin that relied
on job exposure matrices. The results of the study (117) were in agreement with
the results of Moulin et al. (74).
The above human mortality studies support a carcinogenic effect of hard metal
particles.
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Other Co compounds
A retrospective cohort study among 874 women exposed to 65-8600 µg Co/m3
of an insoluble Co-aluminate dye showed no increased incidence of lung cancer
compared to 520 non-exposed controls (15, 108).
Reproduction
No information about reproductive effects of Co is available in humans.
In a 13-week inhalation study, mice of each sex were exposed to cobalt
sulphate aerosols, 3, 10 or 30 mg/m3 (1.1, 4, 11 mg Co/m3), 6 hours per day,
5 days per week. Mean body weights of mice exposed to 30 mg/m3 were lower
than those of controls throughout the study and two of 10 males in this group died
before the end of the study. Sperm motility was decreased in male mice at all
three concentrations tested, in a dose-dependent manner, compared to unexposed
controls and increased numbers of abnormal sperm and decreased testis and
epididymal weights occurred in mice exposed to 30 mg/m3. In female mice, the
length of the oestrous cycle was increased in the highest dose group. (13). Rats
exposed in the same way showed no effects on the reproductive system (13).
Orally administered cobalt chloride to male mice showed decreased testicular
weight, decreased sperm concentration, impaired sperm mobility and abnormal
spermatic nuclei (8, 18, 85). Preimplantation losses were found when female mice
were mated with cobalt chloride treated male mice (86). The cobalt concentrations
in these studies were 20 mg Co/kg bw per day or more and the rats were treated
for 10-14 weeks.
The effects on fetal development of cobalt sulphate administrated by gavage to
pregnant mice, rats and rabbits was studied by Szakmáry et al. (106). In mice and
rats the treatment significantly increased the frequency of fetuses with retarded
body weight and produced skeletal retardation (in rats in a dose dependent
manner). A few anomalies in the urogenital system were observed in the treated
groups. Also skeletal malformations, cranium (mice) and vertebra (mice and rats)
were reported. In rabbits no malformations were seen (106). No firm conclusions
about the teratogenic effects of cobalt sulphate in experimental animals can be
drawn from this study since it contains several inconsistencies regarding, e.g. data
presentation, maternal toxicity and dose-response relationships.
Paternain et al. reported no embryotoxic or teratogenic effects in rats after oral
administration of CoCl2 to pregnant rats at concentrations up to 100 mg/kg/day on
day 6-15 of gestation (84). A single injection in the tail vein of pregnant mice of
CoCl2 (dose: 1.2 mg Co/kg bw on day 8 of pregnancy) showed an interference of
the metal with the fetal skeletal ossification (116).
Lowered birth weight after oral administration of cobalt sulphate to pregnant
rats (25 mg Co/kg bw per day, day 1-21 of gestation) compared to controls has
been reported (106). Also a reduction of the number of litters 5 days after birth
and lowered ability in a swimming test (day 18 to 22 after birth) was found.
Domingo et al. also found a lowered birth weight and reduction of the number
33
of litters and a dose-dependent delay in the growth of living pups after oral
administration of cobalt chloride to pregnant rats (12, 24, 48 mg/kg bw per
day, from day 14 of gestation through day 21 of lactation) (23).
Dose-response/dose-effect relationships
In Table 4 and 5, human data on inhalation exposure are presented. Table 4
summarizes the effects of exposure to Co metal, salts and oxides; Table 5
gives an overview of combined exposure of Co and other compounds.
Irritative effects have been shown after exposure to Co containing dust.
Workers in the hard metal industry complained of irritation of eyes, nose and
throat at a mean exposure of 3 µg Co/m3 and diamond polishers at a mean
exposure of 15 µg Co/m3 (Table 5).
Induction of asthma has been reported after mixed exposure to water soluble
Co and Co metal as well as to hard metal at an exposure level of 10-50 µg Co/m3
(Table 4 and Table 5), but no conclusions about dose-response relationships can
be made.
ILD has been reported from hard metal exposure and restrictive lung
impairment was found among wet grinders exposed to mean Co concentrations
of 5.6 µg/m3 (Table 5). In this case the state of absorbed Co might have been
altered by the coolant, or skin absorption might have been involved.
Another study reports reduction of FEV1 and MMF among (hard metal)
grinders at 8 µg/m3, but no reduction among grinders at 3 µg/m3 (Table 5).
Both groups were exposed to cutting fluids.
A reduction of FEV1 and FVC has been reported among diamond polishers ex-
posed to 15 µg/m3 when compared with polishers exposed to 5.3 µg/m3 (Table 5).
An increased risk of abnormal chest radiographs (profusion ≥1/0) has been
reported in hard metal workers at an average life time exposure of >100 µg Co/m3
compared to hard metal workers with an average life time exposure of ≤100 µg
Co/m3 (Table 5).
No epidemiological data are available on ILD caused by tungsten(carbide)
without Co. Animal studies, however, support an interaction between tungsten
carbide and Co in the development of ILD.
Increased levels of DNA damages (SSB) has been reported in workers exposed
to 4-10 µg Co/m3, but interactions with Cd and Pb seem likely.
Animal inhalation studies indicate alveolar inflammation, interstitial fibrosis
and ECG changes at a level of 100 µg Co/m3 and testicular toxicity (decreased
sperm motility) at 1100 µg Co/m3 (Table 6).
Conclusions
The critical effect of occupational exposure to Co and Co compounds is irritation
of eyes, nose and throat. This was found at a mean Co exposure of 3 µg Co/m3.
Other effects on the respiratory system appear at slightly higher levels. Impair-
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ment of lung function was seen among hard metal grinders at 5.6 but not at
3 µg Co/m3. Co and Co compounds can induce occupational asthma, but no
conclusions about dose-response relationships can be made. Pneumoconiosis has
been associated with exposure to hard metal dust, vitallium dust and combined
diamond and cobalt dust. Several studies report a positive interaction between the
effects of Co exposure and smoking (chronic bronchitis and impaired FEV1).
Co is genotoxic presumably via an indirect mechanism involving reactive
oxygen species. Genotoxic potential in vitro has been shown for Co ions and
Co metal particles.
There is evidence that Co ions and Co oxides are carcinogenic in animals. One
study indicates that inhalation of hard metal dust is carcinogenic in humans.
Co and Co compounds are skin sensitisers. Dermal exposure to hard metal and
cobalt chloride may result in significant systemic uptake of cobalt.
Table 4. Effects in humans exposed to Co metal, oxide or salt.
Concentration
(µg Co/m3)
Exposure/duration Effects Ref.
case 1:
<6000-84000
case 2:
64000-103000
Dust from cobalt-
containing ores
case 1: 26 months
case 2: 2 months
Cardiomyopathy in 2 workers 39
10-50 Co roasting, leaching,
packing
water soluble Co, Co metal;
minimum duration:
6 months,
2-4 h/day plus maintenance
operations for all factories
Case-referent study
Age adjusted odds ratio for asthma
4.8 (95%CI: 2.0-11.7)
21 cases with asthma, 55 randomly
selected workers without asthma
6 of 15 Co workers with asthma
were positive in a challenge test with
CoCl2 or dust of Co roasting
90
2–7700
geometric
mean: 125
70% >50
25% >500
Co metal, oxides, salts;
Mean exposure duration was
8 y (0.3-39.4 y)
Significant relationship between the
level of current exposure to Co (Co-
air and U-Co) and reduction in
FEV1/FVC ratio
No signs of pulmonary fibrosis
Decreased T3 and T4, increased
TSH in plasma
(82 workers, 82 age matched
controls)
104
4–10 Pigment prod., battery work,
recycling electronics
Cd and Pb exposure
DNA damage (SSB) 34
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Table 5. Effects in humans exposed to hard metal dust, vitallium or diamond polishing
dust.
Concentration
(µg Co/m3)
Exposure/
duration
Effects Ref.
up to 1600 Vitallium,
5 y or more
Reduction FVC and FEV1
(37 workers, no control group)
95
45-272 (powder)
30-220 (presses)
Hard metal,
13-14 y
Slight abnormalities in chest radiographs
Lower FVC, FEV1, carbon monoxide
diffusion capacity
(425 workers, 88 controls from mechanical
workshops, warehouses and shipping
departments)
70
mean Co conc. in
4 cases of asthma
18, 24, >31, >1203
Hard metal,
latency period:
3 months to 10 y
Occupational asthma in 18 workers
(319 workers, no control group)
55
≥100
“average lifetime
exposures”
Hard metal,
latency >10 y
The relative odds of abnormal chest
radiographs (profusion ≥1/0) was 5.1,
compared with average lifetime exposures
≤100 µg Co/m3
101
AM: 60 Hard metal,
7-11 y
Reduction of FEV1, FEV% and MMF
compared to paired controls (63 workers,
63 controls).
Reduction of FVC, FEV1, and MMF over
the working week (73 workers)
2
0.7-43
AM: 15
Diamond
polishing dust of
Co-containing
abrasive disks,
duration not
given
Irritation of eye, nose and throat
Reduction of FEV1, FVC (unchanged ratio)
compared to a lower exposed group
(92 workers)
78
2-34
AM: 10
Hard metal,
wet grinders,
7-10 y
ST- and T-depressions in ECG and
overfrequency of ectopic beats
3
AM 8 Hard metal
7-11 y
Decreased FEV1 and MMF between
Monday morning and Friday afternoon
Cough with/without phlegm, chest
tightness, breathlessness
(67 workers)
2
5.6, estimated
exposure during
wetgrinding
Hard metal,
mean duration:
6.9 y (0.5-22 y)
Cough, phlegm and wheeze
Reduction of FEV1 and FVC
(118 workers, number of controls [bus
mechanics] is not given)
47
AM 3 Hard metal
7-11 y
No effect on FEV1 and MMF between
Monday morning and Friday afternoon
(32 workers)
2
AM 3 Hard metal
7-11 y
Irritation of eyes, nose and throat
(44 workers and 44 controls [office workers])
2
AM: Arithmetic mean
“Average lifetime exposure”: fraction of cumulative Co exposure and total exposure duration.
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Table 6. Effects in animals from animal inhalation studies.
Concentration
(µg Co/m3)
Exposure/
duration
Species Effects Ref.
400 or 2000 Co chloride
6 hr/day,
5 days/week,
14-16 weeks
rabbits
male
Increased number of macrophages in
the high dose group
Increased lysozyme activity and
oxidative metabolism in
macrophages in both dose groups
41
8000 Co(II)oxide
7 hr/day,
5 days/week,
from age 2 months
until natural death
up to 22 months
hamster Interstitial pneumonitis, diffuse
granulomatous pneumonia, fibrosis
of alveolar septa
114
11000 Co sulfate
6 hr/day,
5 days/week,
13 weeks
mice Decrease of testis and epididymal
weight
Increase of abnormal sperm
Increase of oestrous cycle
13
1100 Decrease of sperm motility 13
11000 Co sulfate
6 hr/day,
5 days/week,
13 weeks
rat Bronchiolar regeneration
Peribronchiolar and septal fibrosis
13
1100 Inflammation of the lungs 13
630 Co sulfate
2 years
mice (male) Arteritis in heart and kidney 75
400 Co sulfate
6 hr/day,
5 days/week,
13 weeks
rat Histiocytic infiltration 13
100 Co metal particles,
6hr/day,
5 days/week,
3 month
Miniature
swine
ECG changes 48
100 Co sulfate
6 hr per day,
5 days/week,
104 weeks
rat Alveolar inflammation, Interstitial
fibrosis
14, 81
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Consensus Report for Synthetic Inorganic
Fibers
December 3, 2003
This document is an update of a previous Consensus Report published in 1988
(60). The Criteria Group also published a Consensus Report for Synthetic
Inorganic Fibers in 1982 (52). Some of the terms, concepts and synonyms used
in works on fibers are defined in Appendix 1, and international classifications are
presented in Appendix 2.
Classification of synthetic inorganic fibers
Synthetically produced fibers of mineral origin (synthetic mineral fibers, or SMF)
are generally grouped under the term Man-Made Mineral Fibers (MMMF). They
may be either crystalline or non-crystalline. The term Man-Made Vitreous Fibers
(MMVF) is sometimes used for fibers having a non-crystalline structure (vitreous
= glass-like). The MMVF include the large product categories continuous fibers,
slag wool, glass wool, rock wool, refractory ceramic fibers and special-purpose
fibers. In Sweden the term syntetiska oorganiska fibrer (synthetic inorganic
fibers) is used in an occupational health context, and covers all such fibers as
well as non-silicate ceramic fibers (such as aluminum oxide fibers) and some
fibers with crystalline structure (such as synthetic graphite fibers).
The vitreous synthetic inorganic fibers comprise fibers produced from melted
glass, slag, rock (diabase/basalt), or kaolin clay (or aluminum oxide and quartz),
by various processes. Differentiation between “continuous fibers,” “mineral wool
fibers” (glass, rock and slag), “refractory ceramic fibers” and “special-purpose
fibers” may be based on the raw materials, the production method, the charac-
teristics of the fiber, and/or the area of use. Continuous fibers are glass fibers of
a specific diameter drawn from molten glass through a nozzle. They are usually
more than 6 µm in diameter and are not thinner than 3 µm. Glass wool, rock
wool and slag wool are often grouped together under the term “mineral wool”
or “insulation wool,” and the non-crystalline fibers from these products are
commonly referred to as mineral wool fibers. The term refractory ceramic fibers
(RCF) refers to fibers produced from molten aluminum silicate. These fibers are
widely used as a substitute for asbestos in various high-temperature applications.
When the non-crystalline refractory ceramic fibers (aluminosilicate fibers) are
exposed to high temperatures their atomic structure changes, and new crystalline
forms can be created. Mullite (crystalline aluminum silicate) is formed at about
1000 °C, and as the temperature rises above about 1080 °C cristobalite (crystalline
silicon dioxide) is also formed. This transformation reaches its maximum at about
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1200 °C, and above this temperature the mullite proportion remains relatively
constant, whereas the cristobalite gradually disintegrates as the temperature
approaches 1400 °C (38, 39, 48). The transformation to cristobalite is slower than
the transformation to mullite (84). The term special-purpose glass fibers applies
primarily to extremely fine glass fibers (microfibers) for specialized applications
(e.g. in filters). There are also coarser special-purpose fibers, but their use is
extremely limited.
The National Swedish Chemicals Inspectorate has adopted the European
Commission classification (25) and defines synthetic vitreous inorganic fibers as
silicate fibers with random orientation and a chemical composition in which the
content of alkali metal oxides and alkaline earth metals is more than 18% by
weight for mineral wool fibers, and up to 18% by weight for refractory ceramic
fibers and special-purpose fibers (50). The International Program for Chemical
Safety (IPCS) (44) has gone somewhat further, and divided the vitreous synthetic
inorganic fibers into nine different categories based on chemical composition
(total content of alkali metal oxides and alkaline earth metals), fiber orientation
(parallel or random) and more, or less, than 1% by weight of various fiber
fractions relevant to health. These fiber fractions are < 4 µm in diameter for
continuous fibers, and < 3 µm or < 1 µm in diameter for other synthetic inorganic
fiber fractions. For both coarse and fine special-purpose fibers, the IPCS gives
the interval 2 – 18% by weight for alkali metal oxides and alkaline earth metals,
but adds that there are fine special-purpose glass fibers exceeding this 18% limit.
The Chemicals Inspectorate’s classification of synthetic inorganic fibers is used
in Appendix 1.
There are several crystalline inorganic synthetic fibers, but the only one taken
up in this document is silicon carbide (SiC), since the question of its possible
toxicity has received particular attention. Silicon carbide, which can occur in
both particle and fiber form, is produced by heating quartz sand, coke, graphite,
sawdust and rice hulls in electric crucibles. The fibrous form of silicon carbide
can occur as whiskers – extremely fine monocrystalline fibers in the same size
range as asbestos fibers, which moreover are virtually insoluble. Silicon carbide
is marketed under such names as Crystalon, Carborundum, Carbonite etc.
Fiber characteristics and fiber definitions
Biological activity
Length and diameter, which determine a fiber’s ability to penetrate respiratory
organs and lung tissue, and resistance, or its ability to remain in lung tissue
without being dissolved or carried away by the defense systems of the lungs
(biopersistence), are generally regarded as the most important factors in assessing
a fiber’s toxic properties.
It is well known that fibers with a diameter below 3 µm are respirable, i.e. can
be deposited in the lungs. Respirable fibers having a length greater than 8 µm and
high biopersistence are regarded as having high biological activity and conse-
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quently toxicity. However, it should be borne in mind that the toxicity and
biological effects of a fiber are not simply a matter of the fiber’s diameter and
length. Characteristics such as chemical composition, surface activity, and
substances or particles that are transported by the fibers into the respiratory
passages can also be relevant. Unlike asbestos, the synthetic vitreous fibers do not
split longitudinally with handling: i.e. they do not break into thinner fibers, though
they may break into shorter ones. Mineral wool products normally produce less
dust than asbestos, primarily because they are treated with mineral oil to contain
dust but also because of the structural difference between asbestos fibers and
mineral wool fibers. The airborne mineral wool fibers generated during handling,
however, are mostly respirable.
Lung tissue can most easily cope with fibers that are shorter than 5 µm. When
the fibers exceed 10 µm in length, it is difficult for the macrophages in the alveoli
to envelop them (phagocytosis) and carry them away to be removed from the
respiratory passages via ciliary clearance. Fibers longer than 15 – 20 µm, once
deposited in the lungs, can therefore remain in lung tissue for a long time. If they
break into shorter particles they become more susceptible to being either carried
away or dissolved by the body’s defense mechanisms (33, 34, 53, 65).
A further factor determining the fiber exposure of the lungs is the solubility
of the fiber in the body. Long fibers that are physically and chemically resistant
remain in lung tissue for a long time once they have been deposited there. The
more soluble a fiber is in body fluids, the shorter should be its stay in the lungs.
Long, thin fibers not dissolved by contact with body fluids tend to remain in the
lungs for a long time after being deposited, which increases the likelihood of toxic
effects on lung tissue and respiratory passages. In general, synthetic inorganic
fibers are 10 to 1000 times less persistent in body tissues than fibers of asbestos.
Experiments made with rats to quantify the biopersistence of fibers (> 20 µm)
of various materials have yielded the following ranking, which roughly indicates
biopersistence in body fluids. The comparison with asbestos (crocidolite and
amosite) is an indicator of the fiber’s ability to remain in lung tissue. The most
biopersistent materials are first on the list (35):
Asbestos (crocidolite) > asbestos (amosite) > refractory ceramic fibers, special-
purpose fibers (E glass and 475 glass), rock wool (traditional) > glass wool >
slag wool > rock wool (new type).
No specific comparison studies have been made with silicon carbide fibers
(whiskers), but these fibers should probably be placed toward the left in the
above ranking (2). In a study in which experimental conditions were not directly
comparable, silicon carbide whiskers had greater biopersistence in rat lung than
amosite (17).
Solubility of synthetic inorganic fibers in aqueous solutions composed to
resemble body fluids has been given considerable attention during recent years,
ever since it was found that solubility in such liquids (solubility in vitro) can be
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used to estimate biopersistence. In the comparative studies that have been made,
the biopersistence of a fiber is closely related to its solubility (37).
Fiber definitions
Length and diameter are the most important physical characteristics in a fiber’s
description. These parameters are the basis for the fiber definition most commonly
used in an occupational health context: a particle that is at least three times as long
as it is wide, or an aspect ratio equal to or greater than 3:1. This was initially a
practical limit for distinguishing a “fiber” from an irregular particle under a
microscope with an acceptable degree of accuracy. To be considered in the
context of occupational exposure limits, a fiber has to be respirable: it has to be
able to reach the lungs and be deposited there after inhalation. The fiber diameter
can therefore not exceed 3 µm. Further, a respirable fiber must be at least 5 µm
long to be included in estimates of hazardous fibers. These fiber criteria are
associated with fiber counts using an optical microscope.
In 1990, a different aspect ratio was introduced in Sweden: at least 5:1 (4). The
reasons given for this were the following (73);
1. The Board of Occupational Health shares the general medical opinion that
it is the long, thin fibers that constitute the greatest risk for tumor formation.
2. Unlike asbestos, the synthetic inorganic fiber materials that are covered by
regulations tend to break rather than split during handling, thus creating
shorter fibers.
3. A new exposure limit was being planned for natural crystalline fibers other
than asbestos, and particle fragments in the aspect ratio interval 3:1 – 5:1
were looked on as a potentially large source of error.
4. With reference primarily to experience with asbestos, it was argued that a
change of the criterion from 3:1 to 5:1 would mean a rise in the exposure
limit in theory, but not in practice.
5. It was considered more important to establish an exposure limit for the
natural crystalline fibers than to wait until the consequences of keeping
the 3:1 limit were known in detail.
To strengthen the argument, there was a small study in which dust samples of
synthetic inorganic fibers were counted using the two different criteria (73). The
fiber count was about 15% lower when the 5:1 criterion was used. This difference
was supported by a later study of refractory ceramic fibers (51) in which fiber
counts for persons who handled the fiber material (and were thus directly exposed
to the fibers) were about 20% lower when the 5:1 criterion was used. For indi-
rectly exposed persons (those who did not handle the material but worked in the
same building) the spread was too large to allow a correlation to be shown. The
reason given was interference from particle fragments in background dust, which
had a particularly large effect on the result when the 3:1 criterion was used.
In general, it can be said that there are compelling reasons to use an aspect ratio
greater than 3:1 when counting actual fibers through an optical microscope. Dr.
Henry Walton, who introduced the 3:1 criterion, has since become one of the
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driving forces behind the movement to change it. The main reason has been the
subsequent discovery that there is often considerable risk that particle fragments
are counted as fibers. In rebuttal it was often argued that nobody knows whether
the fiber-like particles in the 3:1 – 5:1 interval are hazardous to health. The
American unions opposed a change of the original fiber criterion, primarily
because it would mean a loss of continuity in the long history of monitoring
asbestos dust in the U.S. Largely due to this, international efforts to launch the
5:1 criterion stopped within the ISO (45). For ambient air, however, the ISO
published a standard in 1995 for determining asbestos fibers by transmission
electron microscopy (TEM) (46), in which the 5:1 criterion was used as the fiber
definition.
The task of establishing universal fiber criteria was continued by WHO, which
in 1997 published its conclusion that fibers, both natural and synthetic, that should
be considered in a health context should have aspect ratios greater than 3:1,
diameters below 3 µm, and lengths greater than 5 µm (86). The EU also uses
this fiber definition. Despite the strong arguments in favor of introducing the 5:1
criterion, WHO’s final pronouncement of what should be regarded as a fiber in
the context of health should be given precedence. This and the increasing (and
increasingly easy) international exchange of research information – especially
in the field of occupational hygiene – provide reason enough to recommend that
Sweden adopt the WHO fiber definition. Further, during 2002 the ISO published
two monitoring standards, one for determining inorganic fibers in ambient air by
scanning electron microscopy (47) and one for determining air quality by phase
contrast optical microscopy (45), in both of which the fiber criterion > 3:1 is used.
The only practical problem with return to the 3:1 criterion for fibers is that the
laboratories now making fiber counts must be informed of the change. Regarding
exposure limits, attention should be paid to the approximately 20% difference in
fiber counts known to be obtained with the 3:1 versus the 5:1 criterion.
Nominal fiber diameters
The processes used to produce synthetic inorganic fibers may give rise to
inconsistencies in fiber length and diameter. To describe their fiber products the
manufacturers use the term nominal diameter, which is a length-weighted average
diameter. The nominal diameters for continuous fiberglass products range from 3
to 25 µm; for most of them the nominal diameter is about 6 µm or a little more.
Products of mineral wool, such as glass and rock wool, generally have nominal
diameters of 4 to 5 µm. Refractory ceramic fibers are generally produced with
nominal diameters in the range 1.2 – 3 µm. Special-purpose glass fibers are
produced with nominal diameters of 0.1 to 3 µm. Production processes for non-
continuous fiberglass products, however, tend to generate fiber diameters with a
considerable spread around the average value. The final product will thus contain
fibers both much thinner and much thicker than the average. All mineral wool
products contain respirable fibers. There is no information on a nominal diameter
for silicon carbide whiskers, but the average diameters and lengths of industrial
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SiC whiskers have been reported by Cheng et al. (12) and Johnson et al. (49).
They give an average diameter below 1 µm and average lengths ranging from
about 4 to 20 µm.
Monitoring methods for fiber exposure
Occupational exposure to fibers occurs during fiber production, processing and
use, and in connection with installation, replacement and demolition of materials
and products containing fibers. Airborne fibers in work environments are
monitored by sampling with personal monitors equipped with membrane filters
(58). The filter is then made transparent, and the fibers are counted through a
phase-contrast optical microscope. There is nevertheless a lower limit to what can
be discerned through an optical microscope, and for fibers this limit is a diameter
of about 0.2 µm. Fiber counting is a quantitative analysis based on the above-
given criteria for respirable fibers. The count is based on shape alone, since fiber
type cannot be identified by this method. It is instead assumed that the fibers
observed are of the type being monitored – in this case synthetic inorganic fibers.
WHO has published a detailed description of the methodology used for this type
of fiber monitoring (86). If the fibers must be identified, a polarizing microscope
or scanning electron microscope is used. A scanning electron microscope (SEM)
equipped with an energy-dispersing x-ray spectrometer (EDS) must be used to
identify fibers in air samples. WHO has also published a detailed description of
this method (85). Scanning electron microscopy allows fibers > 0.1 µm, i.e.
virtually all vitreous synthetic inorganic fibers, to be both seen and identified.
SEM has also been used experimentally to determine the dimensions of SiC
whiskers (10).
Effects on health
Health effects and test systems
The body responds to inhaled foreign material deposited on lung tissue (including
fibers) with an inflammatory reaction. This is a normal defense mechanism and
usually clears up rapidly. A long-lasting or even permanent reaction can occur
if the fibers, due to their length or composition, resist the body’s normal defense
mechanisms. As long as the fibers remain in the lungs, the body will keep trying
to get rid of them with the inflammatory reaction. Long-term or repeated inhala-
tion of biologically aggressive fibers can result in a chronic reaction in respiratory
passages or lung tissue, notably proliferation of connective tissue (fibrosis) or
tumors (cancer in respiratory passages or lungs, pleural mesotheliomas). Several
animal studies have been made to confirm the ability of various fibers to induce
inflammation and fibrosis in respiratory organs. Exposure levels in these studies
have been much higher than those known to cause symptoms of irritation in
people, and the studies are therefore taken up in this report only in exceptional
cases. Although they confirm that these fibers are able to produce inflammation
50
and irritation in the respiratory passages, dose-effect relationships are difficult to
assess in relevant terms. Skin exposure to fibers can also cause local irritation.
Pulmonary fibrosis
One type of tissue reaction is pulmonary fibrosis. Inhalation and deposition of
fibers and the repair processes triggered by contact with foreign material, if
continued long enough, can lead to destruction of tissue cells and transformation
of connective tissue. A connective tissue change of this sort is a pathological
change, and in advanced stages it is visible on x-rays. It is usually possible to
measure the reduction in lung function caused by fibrosis before the changes are
severe enough to show up on ordinary x-rays.
Lung cancer
Prolonged inhalation exposure to asbestos fibers can increase the risk of lung
cancer, particularly bronchial cancer (cancer in the epithelium of the respiratory
passages). The mechanisms are not known. Some of the available scientific
documentation indicates a connection between development of scar tissue
(fibrosis) in the lungs and cell transformation (tumor initiation) in the affected
tissue. Other data suggest the possibility that asbestos fibers have a direct effect
on the nuclei of cells in the bronchial epithelium (a genotoxic effect). It has also
been proposed that the fibers are carriers of carcinogenic substances. Several
studies have shown a strong synergistic effect between exposure to asbestos fibers
and smoking in the occurrence of lung cancer. Asbestos fibers are mentioned here
as a good example of biologically aggressive fibers. Some kinds of synthetic
inorganic fibers resemble asbestos in one or more ways (e.g. biopersistence),
which should be taken into consideration in estimating their biological effects.
Mesothelioma
Mesotheliomas are malignant tumors in the pleural or peritoneal mesothelium
(the lining of the lung or body cavity). They have been observed in people after
exposure to several kinds of asbestos fiber. They have also been induced in
laboratory animals by inhalation of mineral fibers other than asbestos and by
some kinds of synthetic inorganic fibers. The mechanism by which fibers cause
mesotheliomas is unknown. The fibers are probably transported from the
deposition site in the lungs into direct contact with the mesothelium, where
they can initiate a cell transformation to malignant tumor tissue
 
– either via
development of fibrosis or via the same kind of genotoxic effect they have on
lung tissue. The tendency of some kinds of fibers to cause mesothelioma has been
exploited in cancer research and in the design of test systems for studying the
carcinogenicity of fibers. The experimental exposure to fibers is via inhalation,
intratracheal instillation, or direct injection into the pleural or peritoneal cavity.
Test systems
In general for all test systems, the fibers should be closely defined as to type(s),
length and diameter.
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In assessing animal experiments, the exposure methods used should be ex-
amined. It is now generally accepted that in vivo studies based on intrapleural or
intraperitoneal injection are less specific and thus less relevant to risk assessments
than studies in which the animals inhale the fibers. The injection studies do not
reflect natural exposure conditions and the doses are high, yielding non-specific
results that are difficult to interpret. Moreover, the pleural and peritoneal
membranes lack the mechanisms for removal of foreign material that are
found in the lungs and respiratory passages. The relevance of these studies,
and interpretation of the results in terms of human exposures at the workplace,
have therefore been questioned. In any case, these results should be assessed in
an overall perspective that includes results from other types of tests.
In vitro tests – tests made on cultures of mammalian cells or tissues – have the
disadvantage of being less specific and thus more difficult to interpret in relevant
terms.
The tests specified by the European Commission reflect the prevailing
mechanistic approach, which was summarized in an EC publication in 1999 (26).
This document describes test systems for:
–  biopersistence with short-term inhalation exposure
–  biopersistence with intratracheal instillation
–  carcinogenic effect with intraperitoneal injection (rats)
–  chronic inhalation (rats)
–  sub-chronic inhalation tests for toxicity
Effects on skin
Synthetic inorganic fibers can cause itching and irritation simply by getting on
the skin. Most of this mechanical irritation is probably caused by fibers greater
than 5 µm in diameter (28, 32, 70). This irritation can cause or exacerbate eczema,
especially in persons who have or have had atopic dermatitis. These people are
unusually susceptible to the skin rashes from irritation by synthetic inorganic
fibers (78). Dermatitis caused by synthetic inorganic fibers is a common clinical
and occupational health problem, and can be quite severe for atopics if they do
insulation, construction or electrical work (29, 78). In Sweden, about 20% of
young people today have atopic dermatitis (7).
Allergic contact eczema caused by allergenic substances (usually epoxy and
phenol-formaldehyde resins) used to bond or coat fiber products has been reported
in association with both production and use (29, 78).
Continuous glass fibers
Continuous glass fibers in general have been found to have a low degree of
toxicity to both humans and experimental animals. It should be borne in mind
that most of these fibers are not respirable because they are more than 3 µm in
diameter (usually over 6 µm).
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Human data
Epidemiological studies of occupational groups exposed to continuous glass
fibers and fibers from insulation wool have revealed no correlation between the
exposures and development of chronic lung disease. Nor has it been possible to
show an increase in risk of lung cancer or pleural or peritoneal mesothelioma that
can be definitely attributed to exposure to continuous glass fibers. The studies
have covered large groups occupationally exposed to these fibers. In the
assessment of the IARC, it can not be determined on the basis of present
knowledge whether these fibers are carcinogenic (42),
Animal data
No inhalation studies have been made with laboratory animals. There are a
number of animal studies in which glass fibers were injected into the pleural
cavities of rats and some studies with peritoneal injection into laboratory animals.
The results were negative: there was no difference in tumor incidence between
treated animals and controls. (These studies are reviewed in Reference 42.)
Fibers of glass wool, rock wool and slag wool
Human data
There have been epidemiological studies exploring the possibility of a connection
between mineral wool exposure and lung fibrosis, changes in pleura, chronic
bronchitis, chronic obstructive lung disease, emphysema and asthma. No
convincing evidence of any such connection was found (18, 42). One study
reported an elevated risk for obstructive lung disease among workers exposed
to mineral wool if they were also heavy smokers (31).
Exposure to mineral wool has been connected to irritation of eyes and upper
respiratory passages (coughing, nasal congestion, smarting/burning eyes, nose or
throat) in construction workers who did insulation work. The symptoms increased
in proportion to the number of hours per month they worked with the material
(68). No direct exposure measurements were made in this study, but the exposure
level around this kind of work has been reported to be ≤ 3 fibers/ml (76).
A similar Swedish study (3) is based on medical examinations given to
construction workers throughout the country at intervals of two to three years.
The cohort included men born in 1955 or later who had been given spirometry
tests during the 1984 – 1993 period and for whom both job title and self-reported
exposure information were available (n= 83,993). For the 1989 – 1992 period,
respiratory symptoms were also registered (n= 45,716). Results from at least two
spirometry tests taken in 1984 – 1993, job title, and exposure information given
by the subjects themselves were available for 20,086 men. Exposures were
classified by combining an occupational hygienist’s estimate based on job title
(job-exposure matrix) and the descriptions of exposure given by the subjects at
their physical exams. The analysis models included, in addition to mineral wool,
exposure to quartz, asbestos and isocyanates, as well as smoking habits. An
internal reference material was used for spirometry. No relationships between
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exposure to insulation wool and VC or FEV1 were seen in either a cross-sectional
analysis (n = 83,993) or a longitudinal analysis (n = 20,086). There was, however,
an elevated occurrence (Prevalence Odds Ratio 2.6; 95% CI 2.2 – 3.6) of per-
sistent cough reported at the 1989 - 1992 physical exams by those workers
classified as highly exposed to insulation wool (n = 1747). The requirements for
this classification were both a job title which according to the job-exposure matrix
indicated work with the material (insulation installer, pipelayer, carpenter) and the
subjects’own statements that they had worked with the material for at least 2
hours per day during the previous year. Comparisons were made with construction
workers classified by the same method as unexposed (n = 4280). In the analysis,
adjustments were made for exposure to asbestos and quartz and for smoking
habits, all of which also yielded independent and statististically significant risk
increases. The estimated effect of this high exposure to insulation wool was
comparable to that of smoking (POR 2.6; 95% CI 2.4 – 2.8). For groups with
lower exposure to insulation wool there were smaller but still significant
elevations in risk. Samples of respirable fibers (n = 125), taken with personal
monitors during the 1978 – 1990 period and analyzed by the same occupational
health organization, showed median contents of 0.10 – 0.42 fibers/ml air (75th
percentiles 0.19 – 0.74 f/ml) for insulation installers and carpenters (not available
for pipelayers). Total dust measurements (n = 42) were available only up to 1985,
and showed median contents of 0.98 – 3.15 mg/m3 (75th percentiles 1.00 – 12.9
mg/m3).
Since the early 1970s, numerous large-scale epidemiological studies have been
made to determine whether exposure to synthetic inorganic fibers – especially
fibers of rock, glass and slag wool – increases the risk of cancer, particularly
lung cancer and mesothelioma.
In nearly a dozen cohort studies, several of which were supplemented by
case-control studies within the cohort, elevated mortality due to lung cancer was
observed in workers in mineral wool production industries. (A systematic review
of these studies is found in Reference 5.) The Standardized Mortality Ratio (SMR)
for glass wool fibers ranged from 0.82 to 1.99. For rock wool fibers, SMRs
ranging from 1.22 to 1.53 are reported in three studies (5). In an analysis of the
data collected in these studies it was not possible to definitely connect the
elevations in risk to just these fibers (42). None of these studies revealed a dose-
response relationship between exposure to the studied fibers and risk of death
due to lung cancer. In addition, there are uncertainties in the calculation of SMR,
where national mortality figures were used for comparison without adjustment for
regional variations or socioeconomic differences (including smoking habits) (5,
6). Further factors to consider in assessing the studies are exposure to other
carcinogenic substances such as PAH and arsenic, either along with the mineral
wool fiber or independently. Another difficulty is arriving at a satisfactory
assessment of previous exposures, although asbestos probably did not contribute
to the observed risk increases. The studied groups were chosen to minimize the
risk that exposure to asbestos would be a confounding factor in the analyses. No
elevation in mesotheliomas was observed in these studies, which supports the
54
assumption that asbestos exposure can be eliminated as an explanatory factor (5,
42).
It must be emphasized that in these studies the estimated exposures to fibers
of glass wool, rock wool or slag wool were in general low compared to historical
exposures – to asbestos, for instance – and that any increase in cancer risk can
therefore be difficult to show. For example, one estimate for rock wool exposure
was about 1 f/ml (13, 23), interval 0.03 – 1.42 f/ml (23). Exposure to asbestos at
1 f/ml for 30 years has been estimated to yield a SMR of 1.3 (5, 19).
Animal data – fibers of glass wool and rock wool
Studies in which laboratory animals were exposed by inhalation to fibers of glass
wool or rock wool have shown no effects on tissues or organs in the form of
tumors, and glass wool fibers did not cause lung fibrosis. A few animal studies
made with rock wool fibers showed some changes in connective tissue (42).
Tumor formation in the pleural or peritoneal membrane has been observed in
a large number of studies after direct injection or implantation of fibers of glass
or rock wool. As mentioned previously, however, this type of study is now
considered to be an insufficient basis for assuming that inhaling the fibers could
cause tumors. The studies are mentioned here only because they were previously
considered quite important. (See for example the assessment of man-made mineral
fibers published in 1988 by the IARC: Reference 41).
Special-purpose glass fibers
Human data
There is no epidemiological material in the form of published scientific reports
that can be used for assessing effects on human health.
Animal data
For one kind of special-purpose vitreous microfiber produced at high tempera-
tures, E glass and 475 glass, there is an inhalation study with rats. In the rats (38
animals) exposed to 475 glass fibers there were 4 lung adenomas, which the
authors regarded as not significantly different from controls (38 animals, 1
carcinoma and 1 adenoma). In the rats exposed to E glass fibers (43 animals)
there were 7 carcinomas and 3 adenomas in lungs, and 2 mesotheliomas (16).
There is also a study in which hamsters were exposed to 475 glass: one case
(1/83) of mesothelioma was observed in the exposed group (36, 65). Occurrence
of lung tumors and mesotheliomas has also been reported in studies in which the
animals were exposed to the fibers by intratracheal instillation (71, 72).
Refractory ceramic fibers (RCF)
Production and industrial use of refractory ceramic fibers have been steadily
increasing since the beginning of the 1970s. Since RCF materials liberate fibers
of respirable dimensions when they are processed, and since these fibers are
relatively insoluble in body fluids and have high biopersistence, exposure to RCF
should be regarded as potentially coupled with higher risk than exposure to
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other kinds of synthetic inorganic fibers. When RCF material is used at high
temperature it may be transformed into crystalline forms (silica, crystalline
silicates and cristobalite; described above under Classification of synthetic
inorganic fibers). Samples of RCF that has been heated can contain up to 37%
cristobalite (8), but the variation is considerable and samples of used furnace
linings with little or no cristobalite content have been reported (51). Air samples
from around removal of used furnace linings have contained 4 to 15 % cristobalite
when the furnace lining had been exposed to temperatures in the range 500 –
2550 °C for 130 to 471 hours (30, 61), and 75% of the samples taken with
personal monitors reached or exceeded the exposure limit for cristobalite (30).
Crystallization does not mean that fibers lose their fibrous shape, but the heating
probably makes them more brittle and thus more likely to break during handling
and produce more dust with shorter fibers (51). If the dust released during
removal of the furnace linings contains cristobalite it constitutes a potential
risk for silicosis.
Exposure data from RCF production and use are presented in Appendix 3.
Human data
No epidemiological studies of cancer risk in groups exposed to refractory ceramic
fibers have yet been published.
As to effects other than cancer, the IARC summary published in 2002 mentions
reports of pleural plaque (thickening of the pleural membrane) in workers exposed
to RCF for 20 years or more (55, 59). In a study made by Lockey et al. a correla-
tion was observed between estimated cumulative exposure to RCF (the number
of months of exposure x the content of RCF fibers in inhaled air = fiber months,
or fm) and the occurrence of changes in pleura, primarily pleural plaque.
Significantly higher odds ratios were seen in the groups with the highest (> 135
fm/ml; OR 6.0; 95% CI 1.4 – 31.0) and the next highest (> 45 – 135 fm/ml; OR
5.6; 95% CI 1.5 – 28.1) cumulative exposures, when they were compared with the
lowest exposure group (> 0 – 15 fm/ml). This correlation was seen after control
for previous asbestos exposure. After a latency time of > 20 years, 8% of exposed
subjects had pleural changes (59). In the group with the highest cumulative dose
(> 135 fm/ml) there was also a (not significant) correlation to irregular opacities
seen on lung x-rays (OR 4.7; 95% CI 0.97 – 23.5, adjusted for age, tobacco
consumption etc.).
A study by Cowie et al. (15) of 774 RCF-exposed workers revealed an elevated
incidence of respiratory symptoms (particularly bronchitis) with some indication
of a relationship to increasing cumulative exposure over time. The authors’
interpretation of this observation was that the symptoms were due to local
irritation of respiratory mucous membranes by the fibers. This study also reports
slightly elevated occurrences of pleural changes and pleural plaque related to the
time since initial exposure, which on average was only 9.6 years. Of the 355
exposed workers who had not previously been exposed to asbestos, only 9 had
pleural plaque. A slightly elevated occurrence of changes visible on x-rays (small
opacities in lung tissue) was also reported. These changes, however, could not be
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correlated to the amount of RCF exposure, and the authors report the observation
as uncertain. Among male smokers in the studied population there was (after
adjustment for tobacco consumption) a reduction in lung function (FEV1 and
FVC) that correlated to cumulative exposure to refractory ceramic fibers. The
reduction was about 20 ml for FEV1 and FVC per fiber-year/ml. No effect was
seen in non-smokers. The authors’ interpretation of this observation was that a
slight functional reduction of the restrictive type may occur as a combination
effect of exposure to RCF and tobacco smoking.
Employees in a company producing RCF (production workers as well as
other employees; 592 men and 144 women) were given spirometry tests. Time-
weighted median exposures ranged from 0.01 to 1.0 fibers/ml and median
exposure times were 8.5 years for men and 4.0 years for women. After adjustment
for factors such as tobacco consumption and age-related changes, male smokers
and ex-smokers showed a significant further reduction of FVC (165 ml and 155
ml respectively with 10 years of exposure) and the male smokers also had
a significantly lower FEV1 (135 ml/10 years). Non-smoking women had a
significantly lower FVC (350 ml/10 years) (56). According to the authors, the
observed differences between men and women may be due to differences in
exposure time, or may reflect a sex difference in sensitivity, or may be because
the group of women was small (56).
Dry cough and eye irritation were more common in workers exposed to RCF
concentrations of 0.2 – 0.6 f/ml than among workers with lower exposures. The
odds ratio for dry cough was 2.5 (95% CI 1.3 – 5.1) and for eye irritation 2.2
(95% CI 1.3 – 3.5) (81). There were 628 participants in this study, 617 (98%) of
whom were exposed to concentrations below 1 f/ml. In this study also there was
a correlation between cumulative exposure to RCF and reduction of FEV1 in both
smokers and former smokers. The authors concluded that cumulative exposure to
ceramic fibers can result in obstructive reduction of lung function by amplifying
the effect of smoking (81).
LeMasters et al. (57) report specific causes of death for men employed at two
companies producing RCF. Mortality in this group was lower than that in the
general population, possibly indicating a healthy worker effect. Mortality due
to lung cancer and non-malignant lung diseases was not elevated. No cases of
mesothelioma were observed. The strengths of this study are a reasonable latency
time (median 23 years) and detailed histories of occupation and smoking habits
based on interviews with most of the subjects. Its weaknesses are the above-
mentioned healthy worker effect and the relatively small size and low age of the
cohort (median age 50) at the end of the follow-up period. The statistical power
for discovering, for example, a doubled risk of lung cancer was only 40%, which
greatly limits the study’s information value. An elevated mortality due to cancer
or malignant tumors in the urinary system was seen. This observation was based
on only a few cases (5 observed; 1.45 expected) and the authors draw no conclu-
sions from it regarding a causative relationship between exposure to RCF and
urinary cancer. They point out that the observation was not based on any advance
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hypothesis and that a credible biological mechanism for such damage has not
yet been proposed.
Animal data
In well-designed inhalation experiments, rats that inhaled RCF developed lung
fibrosis and had an elevated incidence of lung tumors (adenomas). Similar tests
made with hamsters have resulted in mesotheliomas. There are also other studies
in which no such results were seen. In a long-term study in which rats were
exposed by inhalation to several types of RCF (62), both lung fibrosis and several
cases of mesothelioma were observed. See also Hesterberg and Hart 2001 (37). In
long-term studies with rats and hamsters, RCF has also been found to yield pleural
fibrosis (62, 64).
Summary comments on refractory ceramic fibers
So far, we have only about 30 years of experience of exposure to RCF. This
leaves the possibility that a risk of mesothelioma, and also lung cancer, may
exist, but with a latency time that will allow it to be observed only in future
epidemiological studies. There are animal studies that support the proposition
that refractory ceramic fibers are carcinogenic and that inhaling them results in
pleural fibrosis.
Refractory ceramic fibers irritate eyes and respiratory passages. There are also
studies indicating that occupational exposure to RCF affects lung function, but it
has not been determined whether the effect is restrictive or obstructive in nature.
The estimated effect of exposure on lung function was (per fiber-year/ml) of the
same magnitude as one pack-year of tobacco consumption, which indicates that it
may be clinically relevant. There are two studies in which exposure to RCF is
associated with development of changes in pleura, primarily pleural plaque. One
of these studies included a control for previous exposure to asbestos, and in the
other study the RCF-exposed workers were judged to have been previously
unexposed to asbestos. However, it is always difficult to estimate prior exposure
to asbestos.
Silicon carbide (SiC)
Silicon carbide is a hard, synthetically produced crystalline compound of silicon
and carbon. It has been used since the 19th century in sandpaper and for cutting
and polishing, and more recently as heat insulation in the semiconductor industry.
Particles of silicon carbide may be coated with amorphous or crystalline silicon
dioxide.
Silicon carbide occurs as amorphous dust, irregularly shaped particles and
crystalline fibers (whiskers). Bye et al. (10) report that 80% of the airborne fibers
resulting from industrial production of silicon carbide are <0.5 µm in diameter
and >5 µm in length. Since they are below 3 µm in diameter they are respirable.
Silicon carbide in non-fibrous form has very low toxicity to both humans and
laboratory animals (9, 67).
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Silicon carbide in fibrous form can generate respirable fibers with demonstrated
biological activity similar to that of asbestos fibers. Inhaled fibers of silicon
carbide have been found to have high biopersistence, meaning that they can re-
main in lung tissue for a long time (77). There are also case reports of pulmonary
fibrosis attributed to silicon carbide. A specific form of pneumoconiosis and
reduced lung function have been observed among employees exposed to silicon
carbide in production of Carborundum.
Human data
For epidemiological studies of exposure to silicon carbide, whether to fibers or
non-fibrous particles, assessment and interpretation of results are made more
difficult by the fact that the exposures are usually mixed and include other
potentially toxic air pollutants. In a work by Dufresne et al. from 1993 (20)
it is reported that examination of the fiber content in the lung tissue of a SiC-
exposed worker revealed that about 30% of the fibers were SiC. The others
were amorphous or crystalline quartz mixed with silicon and iron, and silicon-
containing fibers from kaolinite (20).
The following have been observed in clinical and epidemiological studies:
–  nodular changes in lungs similar in appearance to those of silicosis
–  connective tissue changes associated with the nodular changes
–  reduction in lung function
–  asthma, emphysema and chronic bronchitis
These observations are reported by Dufresne et al. (20, 21), Durand et al.
(22), Osterman et al. (66), Romundstad et al. (75) and others. For a review of
the literature see Vaughan et al. (83). These studies were made in silicon carbide
production facilities and the exposures were complex, making it impossible to
definitely connect exposure to silicon carbide fibers – as distinct from other dust
particles – to effects on the lungs and draw any conclusions on dose-effect or
dose-response relationships.
Evidence of elevated risk of lung cancer associated with production of silicon
carbide has been reported in two epidemiological studies.
In 1994, Infante-Rivard et al. (43) made a retrospective cohort study of silicon
carbide production workers in Quebec, Canada. They identified an elevated risk
of mortality due to respiratory diseases other than cancer (SMR 2.0; 95% CI 1.2 –
3.2) as well as lung cancer (SMR 1.7; 95% CI 1.1 – 2.5). Lung cancer mortality
increased weakly with cumulative exposure to total dust. However, it should be
remembered here that the exposure to silicon carbide was combined with exposure
to other air pollutants and that only total dust was measured.
A Norwegian study reported by Romundstad et al. (74) covered 2,620 men
exposed to silicon carbide. In addition to silicon carbide fibers, the exposure
consisted of particulate silicon carbide and crystalline silicon dioxide. There were
strong correlations between all these exposures and between each of them and
lung cancer. In analysis of the correlation between exposure and development of
lung cancer, cumulative content of silicon carbide fibers showed a dose-response
relationship but crystalline silicon dioxide did not, when both exposures were
59
included. Elevated risk of lung cancer was also seen in the lowest exposure group
(0.1 – 0.9 fiber-years/ml). However, exposure to silicon carbide fibers could
not be differentiated from exposure to particulate silicon carbide. There was an
elevated risk of lung cancer for the entire cohort: a SIR (Standardized Incidence
Ratio) of 1.9 (95% CI 1.5 – 2.3) (74). As in other studies, this group of industrial
workers had been simultaneously exposed to other air pollutants: particulate
silicon carbide, sulfur dioxide, crystalline silicon dioxide (including cristobalite)
and low levels of polyaromatic hydrocarbons.
Animal data
The biological activity of silicon carbide fibers has been confirmed in animal
experiments. It is summarized by Vaughan et al. (82) as macrophage death,
connective tissue formation and chronic accumulation of inflammatory cells.
Silicon carbide fibers have been shown to cause tumors in laboratory animals:
fibers injected directly into the pleural cavity resulted in mesotheliomas (79).
Lapin et al. (54), in a 13-week inhalation study in which rats were exposed to
three extremely high dose levels of silicon carbide whiskers (630, 1746 and 7276
f/ml, 6 hours/day, 5 days/week) reported effects in the form of:
–  inflammatory reaction in the respiratory passages
–  hyperplasia and adenomatosis in mucous membranes
–  bronchiolitis-alveolitis with thickened walls
–  focal fibroses in pleural tissue
and also dose-response relationships between exposure levels and these effects.
In a study with intratracheal instillation, Petran et al. (69) observed
inflammatory reaction, destruction of normal lung structure, and lung fibrosis in
guinea pigs after a single 50-mg dose of SiC fibers. SiC fibers instilled into the
trachea have been found to cause an inflammatory reaction that increases with
exposure time and is accompanied by formation of inflammatory granulomas, but
not tumors (82). Similar changes have been observed after exposure to asbestos
fibers (crocidolite). It should be observed that the doses used in these experiments
were high, implying that the effects might also be ascribed to overloading the
lungs with particles, including fibers. The results can not be unreservedly accepted
as effects of the fibers alone.
Studies have also been made in which rats were given intrapleural inoculations
of silicon carbide whiskers, resulting in mesotheliomas (49). Exposure of cell
cultures to silicon carbide fibers (in vitro method) has yielded evidence of
cytotoxic effects corresponding to those of amosite asbestos.
Summary comments on silicon carbide
It is clear that fibers of silicon carbide are biologically active. The critical organ
for their effects appears to be lung tissue. Workers exposed to silicon carbide have
silicosis-like changes in lungs, but their simultaneous exposure to other substances
(including quartz) makes it impossible to definitely correlate these changes to
their exposure to silicon carbide fibers. It is reported in two epidemiological
studies that exposure to silicon carbide fibers during manufacture of products
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containing silicon carbide is associated with an elevated risk of lung cancer. In
both of these studies the workers were simultaneously exposed to other substances
of a type that makes it impossible to definitely attribute the observation to the
exposure to silicon carbide fibers.
Dose-response / dose-effect relationships
Symptoms of irritation in eyes and upper respiratory passages have been reported
after exposure to mineral wool at estimated exposure levels of ≤ 3 f/ml (68).
Persistent cough has been reported at a median exposure of 0.1 to 0.42 f/ml (75th
percentiles ranged from 0.19 to 0.74 f/ml) to insulation wool (3).
A large amount of epidemiological data has been collected, but no correlation
between lung cancer and exposure to mineral wool has been shown. Exposure
levels in many of the studied populations have been low, however – around
1 fiber/ml or lower. The possibility of a cancer risk at higher exposures has
not been examined. The IARC assessment (42) is the same.
Dry cough and eye irritation were more common among workers exposed to
refractory ceramic fibers at levels of 0.2 to 0.6 f/ml than among workers with
lower exposures (81).
Declines in lung function (FEV1 and FVC) have been reported in male smokers
with an average exposure to RFC levels of 0.9 – 2.1 f/ml, with an estimated
reduction of about 100 ml per 5 fiber-years/ml for both values (15). Further, a
reduction of FVC has been observed in male smokers and former smokers, and a
reduction of FEV1 in male smokers, after 8.5 years (median) of exposure to 0.01 –
1.0 f/ml. Non-smoking women showed a significant reduction of FVC at the same
exposure level and a median exposure time of 4.0 years. There were only a few
women in this study, however (56).
A significant increase in the number of pleural changes, primarily pleural
plaque (indicating that the fibers had come into contact with the pleural
membranes), was reported in RCF-exposed workers at a cumulative exposure
of > 45 – 135 fm/ml, in comparison to a group with lower exposure (59). A
further observation in this study was that lung changes visible on x-rays tended
to be more frequent in the group with the highest cumulative dose (>135 fm/ml).
Silicosis-like changes have been observed in the lungs of workers exposed to
silicon carbide, but the correlation to exposure to SiC fibers is not clear and no
conclusions on a dose-effect or dose-response relationship can be drawn. Two
epidemiological studies have shown a connection between exposure to silicon
carbide and development of lung cancer (43, 74), but the degree to which silicon
carbide fibers contributed to the elevation in risk is not clear. In the study by
Romundstad et al. an elevated risk of lung cancer was found even in the lowest
exposure group (0.1 – 0.9 fiber-years/ml) (74).
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Conclusions
The critical effect of occupational exposure to mineral wool fibers is irritation
of the respiratory passages (persistent cough). This has been observed at median
exposure levels of 0.1 to 0.4 fibers/ml.
There are no data on which to base a critical effect of occupational exposure
to special-purpose glass fibers. These fibers, including E glass and 475 glass,
are considered to be potentially carcinogenic to humans.
The critical effect of occupational exposure to refractory ceramic fibers
(RCF) is reduction in lung function. This has been observed in a small group
of non-smoking women after 4 years (median) of exposure to 0.01 – 1.0 f/ml. At
this exposure level there was also a reduction of FVC in male smokers and former
smokers, and a reduction of FEV1 in male smokers after a median 8.5 years of
exposure. Irritation of eyes and respiratory passages has been observed at a
minimum exposure level of 0.2 – 0.6 fibers/ml. There are indications that, for
humans, long-term exposure to RCF can result in changes in pleura, primarily
pleural plaque. RCF exposure has been shown to result in pleural fibrosis in
laboratory animals. Data on biopersistence and the results of animal experiments
indicate a carcinogenic potential, and RCF has been judged to be possibly
carcinogenic to humans.
Studies of workers exposed to silicon carbide fibers are very difficult to
interpret, since the exposures are always mixed and also contain crystalline quartz.
Elevated occurrences of silicosis-like changes in lung tissue have been observed
in these studies. An elevated risk of cancer has been correlated to many years of
exposure to a level of 0.1 – 0.9 f/ml, but the exposure was mixed. Silicon carbide
is regarded as possibly carcinogenic to humans.
For synthetic inorganic fibers in general, it can be stated that fibers more
than 5 µm in diameter can cause itching, skin irritation and eczema (mechanical
effects), especially in sensitive persons (atopics).
As to fiber definitions, Swedish criteria should be brought into line with the
criteria established by WHO in 1997.
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Appendix 1. Definitions and applications of some of the words used on the
subject of fibers.
Aerodynamic diameter: the diameter of a spherical particle with the density of 1 g/cm3
which in still air or in air with laminar flow has the same rate of descent as the particle
being described, whatever its actual size, shape or density.
Aspect ratio: the length:diameter ratio of a fiber.
Binder: a substance or compound that makes fibers in a product adhere to each other so
that they can be shaped. Binders are usually phenol-formaldehyde or urea-formaldehyde
resins.
Biopersistence: ability to remain in the body after being deposited there. A fiber’s
biopersistence in the lungs is determined by its solubility and by the lungs’ ability to
remove it.
Continuous fibers: Glass fibers of a specified diameter, usually exceeding 6 µm, drawn
from molten glass through a nozzle.
Crystalline fibers: fibers with atoms arranged in a network/crystal lattice.
Fiber: a particle with an aspect ratio greater than 3:1 (WHO definition).
Microfiber: a fiber, usually a special-purpose glass fiber, with a diameter below 1 µm.
Also called superthin fiber.
Mineral wool fibers: synthetic vitreous silicate fibers made from melted glass, rock or
slag, in which the total content of alkali metal oxides and alkaline earth metals exceeds
18%. Fibers in mineral wool products are randomly oriented.
MMMF: man-made mineral fiber.
MMVF: man-made vitreous fiber, a sub-category of MMMF comprising the non-
crystalline fibers. It includes fiberglass and insulation wools (glass wool, rock wool, slag
wool).
Nominal diameter: a length-weighted average diameter of the fibers in a product
composed of mineral wool.
Refractory: capable of enduring high temperature.
Respirable fiber: a fiber with a diameter of < 3 µm (as defined by WHO); to be included
in a fiber count it must also be longer than 5 µm.
Silicate fibers: fibers consisting of compounds of Si, O and one or more metals.
SMF: synthetic mineral fibers.
Special-purpose fibers: usually fine, synthetic silicate fibers made from melted glass, in
which the total content of alkali metal oxides and alkaline earth metals can range from
2% to more than 18%.
Refractory ceramic fibers; synthetic vitreous fibers produced from molten
aluminosilicates, in which the total content of alkali metal oxides and alkaline earth
metals is 18% or less.
Vitreous fiber: non-crystalline fiber.
Vitreous synthetic inoganic fibers: non-crystalline synthetic fibers produced from
silicates.
Whiskers: inorganic monocrystalline fibers.
WHO fibers: All fibers with a diameter less than 3 µm, length at least 5 µm, and aspect
ratio greater than 3:1.
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Appendix 2. International classifications.
European Union
It is worth mentioning that the classification of mineral fibers has long been a
source of controversy between the member nations of the EU (formerly the EEC).
The Germans have long argued that fibers are in principle carcinogenic but may
be exempted from this classification because of:
–  chemical composition and a carcinogenicity index calculated on this basis
–  the results of animal experiments in which the fibers are injected into pleural
or peritoneal cavities
–  the results of animal experiments with long-term inhalation or bronchial
instillation of the fibers
In November of 1997 the European Commission established criteria for
classification and risk labeling of synthetic inorganic fibers, based on assessments
of possible effects on health. The document is the 23rd revision (97/69/EC) of the
European Commission’s Dangerous Substances Directive (67/548/EEC). In the
EC system, all mineral wools of synthetic mineral fibers are classified as locally
irritating and can in addition be classified as carcinogens in accordance with the
Commission’s separate system for this. The EC system for classification of
carcinogens is partly, but not entirely, the same as the IARC system. The EC
categories are:
1. carcinogenic
2. probably carcinogenic
3. possibly carcinogenic
According to the rules of the European Commission, fibers of mineral wool are
in class 2 or 3 above, depending on their chemical composition and the results of
solubility tests performed according to EC guidelines (26) for:
–  biopersistence of mineral fibers –  inhalation
–  biopersistence of mineral fibers –  intratracheal instillation
–  carcinogenicity tests –  intraperitoneal injection (rats)
–  chronic toxicity test (rats) –  inhalation of mineral fibers (rats)
–  subchronic toxicity test (rats) –  inhalation of mineral fibers (rats)
It should be observed that these test methods are not part of the Dangerous
Substances Directive 67/548/EEC. They have the status of “methods
recommended by the European Commission” but no legal status in the EU
member countries unless they have been granted such by national legislation.
See also the pro memoria (ILSI Workshop Report) from the European
Commission’s Scientific Committee on Occupational Threshold Limits 2001 (27).
IPCS 1987
The International Programme for Chemical Safety (IPCS), run jointly by the
World Health Organisation (WHO), the International Labour Organisation (ILO)
and the United Nations Environmental Program (UNEP), produced a report in
1987 (44) containing appraisals of the health effects of mineral fibers. The IPCS
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paid special attention to the local irritation of skin and mucous membranes
of respiratory passages. Regarding carcinogenicity, the IPCS limited itself to
observing that certain mineral fibers might cause lung cancer and recommending
the use of personal protective equipment in situations involving occupational
exposure to high air concentrations.
IARC 2002
In 1988, the International Agency for Research on Cancer (IARC) in Lyon,
France (the cancer research institute of WHO), reviewed the available material on
mineral fibers and on this basis made carcinogenicity assessments of them (41).
At that time the IARC assessment for fibers of rock wool and slag wool was that
there was ‘limited evidence’ that they caused cancer in humans, and fibers of
glass, slag and rock wool were therefore placed in Group 2B - the substances were
judged to be ‘possibly carcinogenic to humans.’ In November 2001 the IARC
convened an expert group to make a comprehensive review of current and
relevant scientific literature on the carcinogenic effects of mineral fibers and
a new series of assessments.
The report containing these assessments has since been published (42). In the
assessments made by the IARC in 2001, it was concluded, after examination
of a large amount of scientific material, that only mineral fibers with high
biopersistence should retain their classification as ‘possibly carcinogenic to
humans’ (IARC Group 2B). This classification applies to refractory ceramic fiber
(RCF) used industrially for insulation in high-temperature furnaces, as well as
some special-purpose glass wool products not used for insulation. Fibers of the
most commonly used mineral wool products, here meaning glass wool, rock wool
and slag wool for insulation, no longer need be classified as carcinogenic to
humans. They were judged by the IARC working group to belong in Group 3:
“not classifiable with regard to carcinogenicity.” The group placed continuous
glass fibers in the same category.
In its report (42) the IARC summarized its findings as follows:
–  There is inadequate evidence in humans for the carcinogenicity of glass
wool.
–  There is inadequate evidence in humans for the carcinogenicity of
continuous glass filaments.
–  There is inadequate evidence in humans for the carcinogenicity of rock
(stone) wool/slag wool.
–  There is inadequate evidence in humans for the carcinogenicity of refractory
ceramic fibers.
–  There is sufficient evidence in experimental animals for the carcinogenicity
of special-purpose glass fibers including E-glass and ‘475’ glass fibers.
–  There is sufficient evidence in experimental animals for the carcinogenicity
of refractory ceramic fibers.
–  There is limited evidence in experimental animals for the carcinogenicity of
insulation glass wool.
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–  There is limited evidence in experimental animals for the carcinogenicity of
rock (stone) wool.
–  There is limited evidence in experimental animals for the carcinogenicity of
slag wool.
–  There is limited evidence in experimental animals for the carcinogenicity of
certain newly developed, more biopersistent fibers including fiber H.
–  There is inadequate evidence in experimental animals for the carcinogenicity
of continuous glass filaments.
–  There is inadequate evidence in experimental animals for the carcinogenicity
of certain newly developed, less biopersistent fibers including the alkaline
earth silicate (X-607) wool, the high-alumina, low-silica (HT) wool and
fibers A, C, F and G.
The following system has been used by the IARC to classify substances with
regard to carcinogenicity:
Group 1: The agent (mixture) is carcinogenic to humans
Group 2A: The agent (mixture) is probably carcinogenic to humans
Group 2B: The agent (mixture) is possibly carcinogenic to humans
Group 3: The agent (mixture) is not classifiable as to its carcinogenicity
to humans
Group 4: The agent (mixture) is probably not carcinogenic to humans
and the overall assessments of the IARC for man-made vitreous fibers, after
weighing all the evidence from studies of humans and laboratory animals, are:
–  special-purpose glass fibers such as E glass and 475 glass are possibly
carcinogenic to humans: IARC classification Group 2B.
–  Refractory ceramic fibers are possibly carcinogenic to humans: IARC
classification Group 2B.
–  Fibers from insulation material of glass, fibers of continuous glass filaments,
and fibers of rock wool and slag wool are not classifiable with regard to
their carcinogenicity to humans: Group 3.
The IARC working group chose not to make an overall evaluation of the
newly developed fibers designed to be less biopersistent, such as the alkaline earth
silicate or high-alumina, low-silica wools. This decision was based partly on the
lack of human data (notwithstanding that the materials, in the cases where they
have been studied, have been found to have low carcinogenic potential in
experimental animals) and was partly due to the difficulties that the group
encountered in trying to make a meaningful categorization of fibers based on
their chemical composition.
It should be noted that, with regard to fibers of glass wool, rock wool and slag
wool, the IARC has changed the assessments it made in 1988 (41).
Germany
In Germany, tests involving injection into the pleural or peritoneal cavities of
laboratory animals are given greater weight than in most other European countries
or the United States.
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Appendix 3. Exposure data for refractory ceramic fibers.
Since refractory ceramic fibers are not produced in Sweden, there are no Swedish
exposure data. There are, however, several studies from other countries. Esman et
al. (24) studied exposures at three production facilities in the United States, and
report factory averages of 0.05 to 2.6 f/ml. The highest measured value for a
single task was 56 f/ml and was measured around post-production processing,
including hand sawing and packaging in unventilated rooms. The large difference
between factory averages was explained by differences in work methods and
ventilation. In a European study by Cherrie et al. (14) covering 7 factories, the
factory averages for processing workers ranged from 0.2 f/ml to about 7 times
that: 1.36 f/ml. Several explanantions for the differences were proposed, including
ventilation systems and manual handling procedures for the fiber material. The
highest measured value, 3.4 f/ml, was reported in the group of ‘secondary
production’workers. Hori et al. (40) report averages of 0.27 – 0.66 f/ml around
production of refractory ceramic fibers. These values were obtained by stationary
monitors. Values obtained by personal monitors were reported to be at least twice
as high.
On the user side, Cheng et al. (11) have mapped fiber concentrations around
both installation and removal of linings in high-temperature furnaces. Around
lining removal the range of measured averages was 0.02 – 1.3 f/ml with a single
peak of 17 f/ml. Around replacing the lining the range of average values was 0.14
– 0.62 f/ml, with a peak of 2.6 f/ml. Strübel (80) reports average fiber levels of 7.5
f/ml (1.06 – 23.0 f/ml) around furnace lining removal and 1.04 f/ml (0.38 – 2.45
f/ml) around replacing the lining. Krantz et al. (51) report a median content of 1.6
f/ml for a number of furnace lining removals in various smelters and foundries. A
few extreme values of 210 f/ml were recorded around work under generally
unventilated conditions. For replacing the furnace linings, the median value was
0.44 f/ml with a peak of 5 f/ml. The fiber concentrations for exposure category 1
(those directly exposed to the fibers) ranged from 0.26 – 1.2 f/ml (factory
averages for the 4 studied factories).
With the exception of some extremely dusty post-processing tasks on the
production side and removal of furnace linings on the use side, the reported
exposure levels from both production and use are in the interval 0.1 – 2.6 f/ml,
which should indicate that under normal circumstances dust conditions are
probably comparable. On the other hand, the ACGIH (1) reports, with reference
to 2 studies – Esman et al. (24) and Maxim et al. (63) – that 80% of the samples
from production are below 1 f/ml and 90% of the samples from use are below 3
f/ml, which could indicate that, in general, use is dustier than production.
Although any general conclusions should be drawn with caution, it can be said
with some assurance that removal of used furnace linings and other dry manual
work with refractory ceramic fibers can generate fiber concentrations of 10 f/ml or
higher.
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Consensus Report for 4,4´-methylene-
bis(2-chloroaniline) (MOCA)
February 4, 2004
Chemical and physical data
CAS No: 101-14-4
Synonyms: 4,4´-methylene-di-(2-chloroaniline)
4,4´-methylene-bis-orthochloroaniline
methylene-bis-ortho chloroaniline
di(4-amino-3-chlorophenyl)methane
4,4’-diamino-3,3´-dichlorophenylmethane
MBOCA
Formula: C13H12Cl2N2
Structure:
Molecular weight: 267.16 g/mol
Boiling point: 360 °C
Melting point 100 – 109 °C
Vapor pressure: 1 x 10-5 Pa at 25 °C,
0.0017 Pa at 60 °C
Saturation concentration: 0.0001 ppm at 25 °C
Solubility: 0.139 g/100 g water
Distribution coefficient: log P octanol/water = 3.94
Uses
Pure methylene-bis(2-chloroaniline), or MOCA, at room temperature is a
crystalline powder with a slight amine odor. It dissolves readily in alcohol,
benzene and ether, but is much less soluble in water (17). MOCA is used
primarily as a hardener in the manufacture of polymers and plastics, where it
is added to modify the hardness, flexibility and impact resistance of the prod-
ucts (10).
Occupational exposure may occur via inhalation or skin uptake (30). The most
important exposure pathway is probably through the skin, after contact with
contaminated surfaces (6, 22). MOCA and its metabolites have been detected in
CH2NH2
Cl
NH2
Cl
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urine and plasma from workers exposed to MOCA (7, 38). Judging from the
low MOCA levels measured in air samples from the work environments and the
relatively high amounts of MOCA in urine samples from the workers, it is skin
uptake rather than inhalation that is the primary path of absorption (22). Most
occupational exposure occurs during production of MOCA or polymers
containing MOCA (6, 22).
Uptake, biotransformation, excretion
Uptake
MOCA in workplace air occurs mainly as dust, and is absorbed via inhalation
and through the skin. Several reports describe skin uptake as the primary path
of exposure (6, 8, 22). Chin et al. showed that MOCA was rapidly taken up in
neonatal foreskin in vitro during 4 hours. Uptake was most rapid during the first
two hours and then declined. Uptake was dependent on temperature (5). In
another study with human skin (from breast) uptake was small – 2.4 to 5.9% of
the applied dose had been absorbed after 72 hours (16). There are no data from
which to calculate quantitative skin uptake.
Attempts to estimate uptake of MOCA in work environments have been
made, and air samples have shown relatively low levels of MOCA. The highest
air concentrations were measured by personal samplers worn by workers in close
contact with MOCA (≤ 0.70 µg/m3) and in floor dust near the melting vats (1.9 ±
2.9 mg/m2). Air samples taken in the breathing zones of two mixers who handled
MOCA directly (skin contact) were 0.34 and 0.06 µg/m3. To estimate skin
exposure, gauze pads were fastened to their hands. These bits of gauze were
found to contain on average 24.6 ± 16 and 4.7 ± 2.4 µg MOCA after a workshift.
These two workers also had relatively high levels of MOCA in urine (29.9 ± 15
and 94 ± 46 µg/l). Skin uptake was estimated in the same way for two other
workers who mixed melted MOCA either by hand or automatically: MOCA
concentrations in the gauze were 7.3 ± 9.5 and 3 ± 2.4 µg, and these workers had
urine levels of around 15 µg MOCA/liter (6). The samples were taken over one
workshift. In a similar study of a worker who (without protective clothing) mixed
melted MOCA and was exposed to a MOCA mist, a 7- hour air sample showed a
MOCA content of 8.9 ± 0.5 µg/m3. MOCA in urine of this worker ranged between
50 and 120 µg/g creatinine during the entire work week (18).
In a study with rats it was found that MOCA concentration was highest in liver
24 hours after a single oral dose of 281 µmol/kg b.w. MOCA concentrations were
ranked as follows: liver > kidney > lung > spleen > bladder > testes > brain >
lymphocytes (2).
Biotransformation
Biotransformation has been found to play an important role in the toxicity,
genotoxicity and elimination of MOCA. Numerous MOCA metabolites have
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been identified. MOCA is metabolized mostly in the liver by cytochrome P-450
enzymes (primarily CYP3A4) (1, 42). N-hydroxy MOCA has been identified as
the most reactive and the primary carcinogenic metabolite (4). In addition to
oxidation, the metabolism of MOCA involves conjugation with acetyl, sulfate and
glucuronide groups (30). It has been suggested that MOCA conjugates formed in
the liver are transported to the bladder where the acid environment hydrolyzes
them to N-hydroxy MOCA (19). β-N-glucuronide MOCA has been identified as
the primary metabolite in the urine of exposed workers (7). The MOCA-DNA
adduct most commonly found in urine from MOCA-exposed workers is N-
(deoxyadenosin-8-yl)-4-amino-3-chlorobenzyl alcohol (19).
Excretion
MOCA is excreted in both urine and feces. The relative proportions reported in
animal studies vary with species and method of administration. High levels of
MOCA in the urine of workers have been reduced by introducing improved
occupational hygiene, protective clothing, gloves, goggles and better ventilation.
In addition, in many countries regular biological monitoring of MOCA in urine is
used to detect any uptake (28). Workers with high amounts of MOCA in urine
have usually been working in direct contact with MOCA, and often without using
gloves (6, 30). Several analyses of urine from exposed workers have shown that
the half time for MOCA in urine is about 23 hours (7, 28). The half time for
MOCA-globin adducts in blood has been estimated to be 16 days, and the half
time for MOCA-albumin adducts 4.6 days (2).
Rats (single i.p. dose of 13 or 100 mg/kg) and dogs (10 mg i.v.) given
radioactively labeled MOCA excreted only a few percent of the dose in
unmetabolized form (10, 23). A study with rats in which the labeled MOCA
was given orally (5.5 – 5.6 mg/rat) showed that most MOCA is eliminated in
the first 24 hours, primarily in feces (31 to 50%) and urine (16 to 27%) (26). In
another study the substance (10 mg) was applied to the skin of dogs: of the total
dose, 1.3% of the radioactivity was eliminated in urine and 0.62% in bile, and
90% remained in the skin after 24 hours (23). Only 0.4% of the MOCA detected
in urine was unmetabolized. In another study, 2.5 mg radioactively labeled
MOCA was applied to the skin of rats, and 2.5% of the radioactivity was excreted
in urine within 72 hours. The rate of excretion was fairly constant for 3 days.
MOCA apparently had a long retention time in the skin, however – 40 to 60%
remained in the body after 72 hours (11).
Biological exposure monitoring
Gas chromatography/mass spectrometry (GC-MS) and high-performance liquid
chromatography (HPLC) are the most commonly used analysis methods for
detecting MOCA in urine and as hemoglobin adducts in blood (30). Determi-
nation of MOCA in urine is best used for measuring exposure during a workshift.
The amount of unmetabolized MOCA in urine is usually quite low. It is possible
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to obtain higher levels of “free MOCA” by hydrolysis of urine samples containing
MOCA. Analysis of free MOCA after hydrolysis is a recommended method for
monitoring MOCA exposure using urine samples from workers (7). To estimate
longer exposures, a method has been developed for quantitative analysis of
MOCA bound to hemoglobin (3). There are no data correlating MOCA con-
centrations in air with those in urine.
Toxic effects
Human data
A few incidents of accidental exposure to MOCA have been reported. In 1987 a
worker had MOCA spilled on his skin and involuntarily swallowed some of it. He
later complained of eye irritation and nausea. Five hours after the exposure the
MOCA level in urine was 1400 µg/g creatinine, and 23 hours after the exposure
it had dropped to 30 µg/g creatinine. The urine sample taken 5 hours after the
accident also contained large amounts of protein, possibly due to kidney damage
(15).
In an accidental spill, a 30-year-old man had about 3 gallons (11 liters) of
melted MOCA sprayed over his chest, back, arms and legs. The man was wearing
protective clothing (with the sleeves rolled up) with face mask, protective gloves
and goggles, and he showered for 45 minutes after the incident. He complained
later of reddened, “sunburned” skin. A high level of MOCA (2169 µg/g creatin-
ine) was detected in a urine sample taken 4 hours after the accident; 4 days later
the level had dropped to 78 µg/g creatinine (28). The half time was calculated to
be 23 hours (28). No effects other than the skin burn described above were
reported.
Animal data
In cancer studies in which MOCA was given to rats in diet, weight gain was
lower at both 500 and 1000 ppm. In these studies it was observed that at these
dose levels life spans were significantly shorter for rats on both the standard diet
and the low-protein diet (500 ppm was the highest concentration in the low-
protein diet) (20). In a study with dogs, daily oral intake of 100 mg MOCA
resulted in significantly higher levels of glutamic-pyruvic transaminase (GPT)
activity, indicating liver damage, and increased numbers of erythrocytes,
leukocytes and epithelial cells in urine (36). Another study reports elevated
mortality in female mice receiving high doses of MOCA in diet (2000 ppm).
There was also reduced weight gain in rats receiving 1000 ppm in diet (31),
see also Table 1.
Mutagenicity, genotoxicity
MOCA has been shown to be genotoxic and mutagenic in both in vitro and in vivo
tests. MOCA was mutagenic in Salmonella typhimurium strains TA98 and TA100
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only after activation with S-9 mixture from hepatic cells (13, 21, 29). The N-
acetyl metabolites were not mutagenic under the same conditions (13). MOCA
has been found to induce DNA repair in hepatocytes from rats, mice and hamsters
(24, 25). In addition, lymphocytes from workers exposed to MOCA (supervisors,
laboratory personnel and production workers) had higher numbers of sister
chromatid exchanges than those from unexposed controls. Precise exposure data
are not given. Elevated numbers of sister chromatid exchanges were also observed
in lymphocytes from rats exposed to MOCA (5 daily i.p. injections of 125 or 250
mg/kg b.w.) (9).
Examination of exfoliated urothelial cells in the urine of MOCA-exposed
workers revealed that they contained significantly higher numbers of micronuclei
than those from controls. The MOCA workers had various jobs at the factory, and
most of them worked with polyurethane casting. MOCA concentrations in urine
from the workers ranged from 0.4 to 48.6 µmol/mol creatinine, whereas urine
from controls contained no MOCA at all. There was no correlation between the
micronuclei and MOCA levels in urine. In this study, smoking had no discernible
effect on the number of micronuclei in either in the exposed workers or in the
controls. There were only a few smokers in the study, however (5 in each group)
(27).
MOCA-DNA adducts and MOCA-hemoglobin adducts have been identified
in several studies (3, 23, 33, 34). Urine from a worker involuntarily exposed to
MOCA was analyzed for MOCA-DNA adducts. High levels of adducts were
observed in the urine 4 hours after the exposure. A dramatic drop in DNA adducts
in the urine was observed during the following 17 hours, after which the rate of
reduction slowed (19).
Carcinogenicity
The International Agency for Research on Cancer (IARC) has classified MOCA
as “probably carcinogenic to humans” (Group 2A) (17). The evidence from
animal experiments is regarded as sufficient to justify this classification despite
the lack of evidence that MOCA causes cancer in humans. The results of cancer
studies with rats, mice and dogs are summarized in Table 2 and below.
Human data
Three cases of bladder cancer in MOCA workers have been reported. Urine and
cell samples from 385 (of a total of 552) workers at a MOCA production plant
were analyzed. The median interval between initial exposure and the time the
samples were taken was estimated to be about 11.5 years. Sixteen of the workers
had blood in urine and 21 had atypical cell samples. After the first cancer case
was discovered, 200 workers were given a more thorough examination with
cystoscopy. Two more cancer cases were discovered, although neither of these
workers had blood in urine (hematuria). All three subjects had been employed at
the plant for only a short time (1.5 months to 1 year) but had probably been
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exposed to high levels of MOCA. Two of the workers, 28 and 29 years old, were
non-smokers, and according to the report had never worked with other chemicals
suspected of causing bladder cancer. The latency times from initial exposure to
diagnosis were 8 and 11 years. The third worker was 44 years old, a smoker, and
had previously worked with other chemicals. The latency time between initial
exposure and diagnosis was 16 years (39, 40). At the request of the Polyurethane
Manufacturers Association (PMA), Hogan (14) tried to reconstruct exposures in
these three cases. He arrived at the conclusion that the workers may have been
exposed to other carcinogens, including other aromatic amines. Hogan’s exposure
estimates have been questioned (41).
Animal data
MOCA has been shown to cause cancer in rats that are given the substance in
diet. A low-protein diet yielded a higher tumor incidence than the standard diet,
and it has therefore been suggested that protein plays a protective role in MOCA-
induced cancer. The tumors occurred primarily in lungs, liver and breast (35), see
also Table 2. Russfield et al. demonstrated that MOCA induced liver tumors and
hemangiosarcomas in mice, and lung and liver tumors in rats (31). Dogs devel-
oped bladder cancer after 9 years of exposure to MOCA (36). Grundmann et al.
showed that MOCA in the diet induced lung and liver tumors in rats (12), see
also Table 2.
In vitro studies have shown that N-hydroxy MOCA can transform non-
tumorigenic cell lines to tumorigenic ones. Injection of these cells into naked
mice induced tumors within 17 weeks (37).
Effects on reproduction
No teratogenic or other effects on reproduction have been reported.
Dose-effect / dose-response relationships
There are no data on which to base a dose-effect or dose-response relationship
for either human or animal exposures. Toxic and carcinogenic effects observed
in animal experiments are summarized in Tables 1 and 2.
Conclusions
There are not sufficient data for defining a critical effect for MOCA. Judging from
animal experiments, the critical effect is cancer. MOCA exposure is primarily via
skin uptake. MOCA is genotoxic in vitro and forms DNA adducts in vivo. MOCA
is carcinogenic to experimental animals and should be regarded as carcinogenic to
humans.
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Table 1. Toxic effects of experimental exposure to MOCA.
Species Dose, exposure
method
Exposure
time
Effects Ref
Mouse
HaM/ICR
25 males
25 females
0, 1000, 2000 ppm
in standard diet
per os
18 months 2000 ppm females:  elevated
mortality
31
Rat
ChR-CD
25 males
0, 500, 1000 ppm
in standard diet
per os
18 months 1000 ppm:  lower weight gain 31
Rat
ChR-SD
100, 100, 75,
50 males
0, 250, 500, 1000 ppm
in standard diet
per os
18 months 500 ppm:   lower weight gain, shorter
life span*
1000 ppm:  lower weight gain,
shorter life span*
20
Rat
ChR-SD
100, 100, 75,
50 males
0, 125, 250, 500 ppm
in low-protein diet
per os
18 months 500 ppm:   shorter life span* 20
Beagle
6 females**
0, 100 mg/day
in capsule
per os
9 years 100 mg/day:   elevated GPT activity*,
elevated erythrocytes, leukocytes
and epithelial cells in urine
36
* significantly different from controls
** one of which died early
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Table 2. Results of cancer tests with laboratory animals.
Species Dose, exposure
method
Exposure
time
Effects Ref
Mouse
HaM/ICR
males
females
0, 1000,
2000 ppm in
standard diet
per os
18 months 0 ppm males:  hepatoma 3/18, pulmonary adenoma 5/18
1000 ppm males:  hepatoma 3/13, hemangioma 2/13,
hemangiosarcoma 1/13, pulmonary adenoma 3/13
2000 ppm males:  hepatoma 4/20, hemangioma 5/20,
hemangiosarcoma 3/20, pulmonary adenoma 2/20,
pulmonary adenocarcinoma 2/20
0 ppm females:   hemangioma 1/20, pulmonary adenoma
4/20, pulmonary adenocarcinoma 2/20, lymphosarcoma
4/20, reticulosarcoma 6/20
1000 ppm females:   hepatoma 9/21*, pulmonary adenoma
3/21, lymphosarcoma 3/21, reticulosarcoma 3/21
2000 ppm females:   hepatoma 7/14*, hemangioma 4/14,
hemangiosarcoma 2/14, pulmonary adenoma 2/14,
lymphosarcoma 1/14
31
Rat
Wistar
males
females
1000 ppm in
low-protein
diet, total dose
27 g/kg
per os
535-565
days
0 ppm males, females:  breast fibroadenoma 2/50
1000 ppm males:  multiple hepatoma 22/25, primary lung
tumor 8/25
1000 ppm females:   multiple hepatoma 18/25, primary lung
tumor 5/25
12
Rat
ChR-CD
males
0, 500,
1000 ppm in
standard diet
per os
18 months 0 ppm:   cholangiocarcinoma 1/22, pulmonary adenoma 1/22
500 ppm:   hepatoma 1/22, pulmonary adenomatosis 3/22,
pulmonary adenoma 1/22, pulmonary adenocarcinoma
1/22, bladder cancer 2/22, glioma 1/22
1000 ppm:   hepatoma 4/19, pulmonary adenomatosis 4/19,
pulmonary adenoma 1/19, pulmonary adenocarcinoma
1/19, stomach adenocarcinoma 1/19, sebaceous adenoma in
ear 1/19
31
Rat
ChR-CD
males
females
0, 1000 ppm
in standard diet
per os
548-560
days
0 ppm males:  pulmonary adenomatosis 1/44, leukemia
2/44, lymphoma 2/44, breast fibroadenoma 1/44, pituitary
adenoma 4/44.
1000 ppm males:  pulmonary adenomatosis 14/44*,
pulmonary adenocarcinoma 21/44*, pulmonary squamous-
cell carcinoma 1/44, pleural tumor 4/44, pleural lipoma
1/44, hepatocellular adenoma 3/44, hepatocellular
carcinoma 3/44, leukemia 1/44, lymphoma 4/44, breast
fibroadenoma 1/44, breast adenocarcinoma 3/44, pituitary
adenoma 4/44, interstitial adenoma in testes 4/44, renal
adenoma 1/44
0 ppm females:   pulmonary adenomatosis 1/44, pleural
lipoma 1/44, lymphoma 1/44, breast fibroadenoma 17/44,
breast adenocarcinoma 3/44, breast fibrosarcoma 1/44,
pituitary adenoma 12/44
1000 ppm females:   pulmonary adenomatosis 11/44*,
pulmonary adenocarcinoma 27/44*, pulmonary squamous-
cell carcinoma 1/44, pleural tumor 2/44, hemangioma 1/44,
hepatocellular adenoma 2/44, hepatocellular carcinoma
3/44, cholangioma 1/44, leukemia 1/44, lymphoma 3/44,
breast fibroadenoma 18/44, breast adenocarcinoma 5/44,
pituitary adenoma 1/44*, vaginal fibrosarcoma 1/44, renal
adenoma 1/44, renal adenocarcinoma 1/44
35
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Table 2. Continued.
Species Dose, exposure
method
Exposure
time
Effects Ref
Rat
ChR-CD
males
females
0, 1000 ppm
in low-protein
diet
per os
400 - 423
days
0 ppm males:  pulmonary adenomatosis 1/21
1000 ppm males:  pulmonary adenomatosis 8/21*,
pulmonary adenocarcinoma 5/21*, pleural tumor 1/21,
hepatocellular adenoma 5/21*, hepatocellular carcinoma
11/21*, skin squamous cell carcinoma 1/21, lymphoma
1/21, renal lipoma 1/21, ganglioneuroma 1/21
0 ppm females:   pulmonary adenomatosis 1/21, breast
fibroadenoma 7/21
1000 ppm females:   pulmonary adenomatosis 14/21*,
pulmonary adenocarcinoma 6/21*, pleural tumor 1/21,
hepatocellular adenoma 2/21, hepatocellular carcinoma
1/21, breast fibroadenoma 1/21*, breast adenocarcinoma
6/21*, peritoneal lipoma 1/21, ileal adenocarcinoma 1/21
35
Rat
ChR-SD
males
0, 250, 500,
1000 ppm in
standard diet
per os
18 months 0 ppm:   primary lung tumors 1/100, breast adenocarcinoma
1/100, Zymbal’s gland tumor 1/100, hemangiosarcoma
2/100, pituitary adenoma 42/100
250 ppm:   pulmonary adenocarcinoma 14/100*, primary
lung tumor 23/100*, breast adenocarcinoma 5/100,
Zymbal’s gland tumor 8/100*, hepatocellular carcinoma
3/100, hemangiosarcoma 4/100, pituitary adenoma 36/100.
500 ppm:   pulmonary adenocarcinoma 20/75*, primary lung
tumor 28/75*, breast adenocarcinoma 8/75*, Zymbal’s
gland tumor 5/75, hepatocellular carcinoma 3/75,
hemangiosarcoma 3/75, pituitary adenoma 19/75*
1000 ppm:   pulmonary adenocarcinoma 31/50*, primary
lung tumor 35/50*, breast adenocarcinoma 14/50*,
Zymbal’s gland tumor 11/50*, hepatocellular carcinoma
18/50*, hemangiosarcoma 0/50, pituitary adenoma 2/50*
20
Rat
ChR-SD
males
0, 125, 250,
500 ppm in
low-protein
diet
per os
18 months 0 ppm:   hemangiosarcoma 1/100, pituitary adenoma 23/100
125 ppm:   pulmonary adenocarcinoma 3/100, primary lung
tumor 6/100*, breast adenocarcinoma 1/100, Zymbal’s
gland tumor 0, hepatocellular carcinoma 0,
hemangiosarcoma 2/100, pituitary adenoma 16/100
250 ppm:   pulmonary adenocarcinoma 7/75*, primary lung
tumor 11/75*, breast adenocarcinoma 3/75, Zymbal’s gland
tumor 4/75*, hepatocellular carcinoma 0, hemangiosarcoma
4/75, pituitary adenoma 9/75*
500 ppm:   pulmonary adenocarcinoma 8/50*, primary lung
tumor 13/50*, breast adenocarcinoma 3/50*, Zymbal’s
gland tumor 6/50*, hepatocellular carcinoma 9/50*,
hemangiosarcoma 4/50*, pituitary adenoma 10/50
20
Beagles
females
0, 100 mg/day
in capsules
per os
9 years Controls:   Breast nodules 5/6, breast adenocarcinoma,
carcinoma or carcinosarcoma 4/6
100 mg/day:   bladder cancer (papillary transitional cell
carcinoma) 4/5*, urethra (transitional cell carcinoma and
adenocarcinoma) 1/5, liver nodules 3/5
36
* significantly different from controls.
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This document is based on published articles registered in the data bases Medline
and Toxline through 2003 and on recently published reviews of the literature.
Chemical and physical data. Use
CAS No.: 54-11-5
Synonym: 3-(1-methyl-2-pyrrolidinyl)pyridine
Formula: C10H14N2
Structure:
NN
Molecular weight: 162.2
Density: 1.01 (20 °C)
Boiling point: 247 °C
Melting point: - 79 °C
Vapor pressure: 5.7 Pa (20 °C)
Saturation concentration: 56 ppm
Distribution coefficient: 1.17
   (log Poctanol/water)
Conversion factors: 1 mg/m3 = 0.149 ppm (20 °C)
1 ppm = 6.73 mg/m3 (20 °C)
Nicotine is a tertiary amine with a pyridine and a pyrrolidine ring. It is an oily,
colorless/pale yellow to dark brown liquid, and has a fishy odor when heated. It is
hygroscopic and forms water-soluble salts. Nicotine is a weak base, with a pKa of
7.9.
Background exposure
In assessing nicotine exposure in work environments, it is essential to know the
background exposure. Nicotine is a drug used regularly – usually daily – by
a third to a half of the world’s population. This portion of the population has
extremely high nicotine exposure from smoking cigarettes, cigars and pipes,
taking snuff and chewing tobacco. A single cigarette yields a dose of about 1 to
1.2 mg nicotine. Most of the population is exposed to nicotine daily via “passive
smoking”: exposure to environmental tobacco smoke (ETS). On average,
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however, this exposure is only 1/100 to 1/1000 of the exposure of a smoker.
Exposure to environmental tobacco smoke can be particularly high if people
smoke in small, closed-in spaces such as automobiles or homes. If a home
contains two smokers, the total nicotine dose from ETS is on average about 10
times that in a home in which there are no smokers. There are numerous studies
and exposure data on passive smoking in home environments (92). Background
exposure to nicotine in indoor air is about 3 µg/m3 (93), but can be much higher in
indoor environments containing smokers (95, 97). In one study it was found that
the air content of nicotine in a bus where smoking had previously occurred was
about 30 µg/m3 due to the dust from the seats and other interior surfaces (93).
Nicotine content in food, on the other hand, does not make a measurable
contribution to the nicotine or cotinine in body fluids (94). A median value for
cotinine content in the urine of people who neither smoke nor use snuff, do not
work in a smoky environment and are not exposed to passive smoking at home
is 2 µg/l (92), see also Table 1. A group that completely avoided exposure to
environmental tobacco smoke (in an experimental situation) had a level one
tenth of that (93).
Table 1. Biological exposure measurements: cotinine in plasma and urine after nicotine
exposure from cigarette smoking, environmental tobacco smoke, tobacco harvesting and
production of pharmaceuticals containing nicotine.
Exposure Plasma cotinine
(µg/l)
Urine cotinine
(µg/l)
Ref.
Environmental tobacco smoke
110 µg/m3, 2 hours
13 93
Environmental tobacco smoke
110 µg/m3*
180 92
Environmental tobacco smoke
500 µg/m3*
730 92
Environmental tobacco smoke
10 µg/m3*
(restaurant work 8 hrs/day)
16 91, 92
Smoking 3.9 cigarettes per day
(1 cig. ≈ 1 – 1.2 mg absorbed dose)
54 14
Smoking 5 cigarettes per day 70 14
“Smokers”
(plasma nicotine = 20 – 30 µg/l)
>300 >2,500 14, 90
Production of nicotine
pharmaceuticals
(skin absorption + inhalation)
(plasma nicotine = 0 – 0.3 µg/l)
3 – 70 96
Tobacco harvesters (symptom-free) 15 100 24
*at steady state, after about 100 hours
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Nicotine exposure in work environments
Working with tobacco, especially tobacco harvesting (skin uptake) and spraying
nicotine as an insecticide (uptake from skin and digestive system), can result in
high nicotine exposure, but in Sweden such jobs are virtually non-existent. There
are a few published reports with data on nicotine uptake due to exposure to
tobacco leaves (see Table 1). The nicotine content in dew from tobacco leaves
was reported in one study to be 1.9 µg/l; the tobacco leaves themselves contained
20 mg/g (24). Tobacco harvesters are known to have high nicotine exposure (39,
60). Measurements of cotinine in saliva indicated that the harvesters had higher
nicotine exposure than other tobacco workers (72).
However, the pharmaceutical industry has now begun to process nicotine (skin
uptake, inhalation). There are no published exposure data, but some information
can be found in internal company reports; there is also a study from manufacture
of pharmaceutical products to help people quit smoking (96), see Table 1. In
production of nicotine patches, the highest exposure is associated with powder
mixing (the nicotine is bound to an ion exchanger, nicotine resinate). The material
is mixed inside closed boxes where the measured air concentration was 20,000
µg/m3. The exposure of workers outside the boxes is 100 – 200 µg/m3 (96). The
concentration in the breathing zone around receiving the finished patches is at
most 100 µg/m3. To avoid the heavy skin exposure associated with packaging the
nicotine patches, workers wear double nitrile gloves and change them every 20
minutes (101).
There are also new data on nicotine exposure (inhalation) via environmental
tobacco smoke. Restaurant workers in particular are likely to be exposed to high
levels of ETS, since they often work in crowded, poorly ventilated rooms where
passive smoking can be high – although it usually does not exceed 100 µg/m3 air.
There are some exposure data on passive smoking in work environments (see
Table 1). In general, nicotine exposure during work in smoky environments is
10 to 100 times higher than in work where no smoking occurs (28, 58, 91, 92).
It is clear from the above that occupational exposure to nicotine varies over a
wide range.
Uptake, biotransformation, excretion
Uptake of nicotine through the skin depends on the nicotine concentration, the pH
and the solvent. For example, an application of 50% nicotine in water is absorbed
about 15 times faster than pure nicotine, and a 1% solution buffered to pH 7 yields
the same uptake as pure nicotine. Uptake is reduced if the pH is lowered or if the
nicotine is dissolved in ethanol (101). One study (101) reports that human skin in
vitro absorbs pure nicotine at the rate of 82 µg/cm2/hour. Applying ECETOC’s
criteria for skin notation (29), i.e. exposure of 2000 cm2 skin (equivalent to hands
and lower arms) for 1 hour (equivalent to exposure of 250 cm2 skin, or 70% of a
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hand, for 8 hours) and using the absorption rate above yields a dermal absorbed
dose of 164 mg. This is about 70 times as much as the 2.5 mg resulting from
8 hours of exposure to the SCOEL (Scientific Committee for Occupational
Exposure Limits) limit of 0.5 mg/m3 (32) (assuming inhalation of 10 m3 air
in 8 hours and 50% absorption in the lungs). Skin exposure to nicotine can
thus result in significant absorption with systemic effects.
Nicotine is absorbed very rapidly from the lungs, and with cigarette smoking
the blood concentration peaks after only 10 to 20 seconds (12). Uptake via
mucous membranes in the mouth (chewing tobacco, snuff, nicotine chewing gum)
is much slower, and blood concentration rises slowly to a maximum value after
about 30 minutes. Data on uptake via the human digestive tract are much less
abundant, but nicotine is absorbed readily (1).
After absorption in the lungs, nicotine concentrates in the brain, kidneys,
stomach, adrenal medulla, nose and salivary glands (13).
Nicotine passes the placental barrier and has been measured in amniotic fluid.
It also passes into breast milk (13). Nicotine concentrations in amniotic fluid,
placenta and plasma from umbilical blood have been found to exceed the plasma
nicotine level in the mother (59).
Nicotine is metabolized rapidly and extensively, primarily in the liver but also
to some extent in lungs and kidneys. Excretion via kidneys depends on pH and
urine flow, and in humans accounts for 2 to 35% of total elimination (11). The
half time of nicotine in blood, urine and saliva is about 2 hours (36). The primary
metabolites are cotinine and nicotine-N-oxide. Cotinine has a half time of about
19 hours (93).
Biological measures of exposure
Using air measurements to monitor nicotine exposure can be misleading, since
uptake is often predominantly via the skin. Cotinine has been found to be an
excellent biomarker for nicotine exposure (93). Excellent methods for determining
cotinine, notably gas chromatography/mass spectrometry, have been in use for
several years, and mass spectrometry yields accurate results below the µg/liter
level (77). Methods have been published for calculating the nicotine dose using
cotinine in urine (U-cotinine) (43, 92), plasma (24) and blood (14):
           daily nicotine dose (mg) = [plasma cotininess (µg/l)] x 0.08 (24)
Since steady state (ss) levels, which are attained after about 100 hours, are pro-
portional, daily nicotine intake can thus be calculated from the cotinine content
in plasma, saliva or urine. The daily nicotine dose can be calculated in mg by
multiplying plasma cotinine (in µg/l) by 0.08 (see above equation) (24), or multi-
plying the cotinine content in urine (in µg/l) by 0.012 (92, 94). Correcting for
creatinine or density is not important, and can even be misleading at the individual
level. It has little effect on the average level of cotinine in urine (µg/g creatinine is
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about the same as µg/l). It is best to standardize sampling time, using morning
urine samples. In one study the saliva:plasma ratio was 1.1 (94).
Manufacture of nicotine-containing pharmaceutical products designed to help
people quit smoking was associated with urine cotinine levels ranging from 3 to
70 µg/l, depending on the task. The highest level corresponds to a nicotine dose
of 0.8 mg/day from skin and inhalation exposure (see Table 1) (96). Since the
workers in this study wore protective clothing and double nitrile gloves, it is
likely that most of this uptake was from inhalation.
Ten healthy tobacco workers (and 5 controls) wearing good protective clothing
(raincoats and rubber gloves) had greatly elevated nicotine levels in blood after a
workshift (average 3.5 µg/l). Cotinine levels were 15 µg/l in plasma and 100 µg/l
in urine. Calculating with the formula given above, this corresponds to a daily
dose of 1.2 mg (24), or smoking 1 cigarette per day. Working conditions were
described as good. Cotinine levels about 10 times higher (range 30 – 3000 µg/l)
are reported by Gehlbach et al. (39) in tobacco harvesters, 25% of whom had
symptoms. Even higher levels, and a higher prevalence of symptoms (53%) are
reported in a study by Ghosh et al. (40). This study, however, is marred by poor
control of smoking habits and protective clothing, and by analysis method.
The median value for urine cotinine in a group of restaurant employees was
about 16 µg/l (range 10 – 28 µg/l) (91). This value would indicate an average
nicotine exposure of 10 µg/m3 during an 8-hour workday (urine cotinine maximum value
= 30 µg/l) with a 16-hour exposure-free interval (calculated backward from results
of experimental exposure to environmental tobacco smoke) (92).
For assessing nicotine exposure, cotinine in urine provides a more reliable
estimate of actual dose than air concentration because of the risk of substantial
skin uptake.
Toxic effects
Acute poisoning
The high toxicity of nicotine has been known for a century. There are many
reported cases of acute poisoning, most of them due to oral or skin uptake –
especially in the 1920s and 1930s when nicotine (nicotine sulfate) was a popular
insecticide. Some fatal occupational exposures have been reported. Symptoms of
severe poisoning can appear within a few minutes. The LD50 for oral intake of
nicotine is reported to be 3.3 mg/kg for mice and 53 mg/kg for rats (56). Although
there is no precise documentation, the lethal dose for humans is taken to be around
50 to 60 mg (56). There are several reported cases of poisoning due to suicide
attempts with nicotine patches (99). Severe poisoning causes convulsions, heart
arrhythmia and death within a few minutes to an hour.
With less severe poisoning, the usual symptoms are nausea, vomiting, diarrhea,
headache, confusion, rapid heartbeat, elevated blood pressure and excessive
salivation. Slight to moderate nicotine poisoning is not uncommon in processing
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workers and insecticide users. The most common form, Green Tobacco Sickness
(GTS), has been described in several studies of tobacco field workers (39, 40, 60,
71). The symptoms are dizziness, vomiting, headache, weakness, stomach pains,
cramps, salivation and sweating, and frequently occur among non-smokers – often
in up to half of a group of tobacco workers. Uptake occurs via the skin. The
workers who picked tobacco leaves had the highest cotinine levels (average 890
µg/g creatinine, which is about the same in µg/l), and 25% of these had GTS
symptoms (39). Workers who wore plastic raincoats had much lower values.
The workers with symptoms (dizziness and nausea) were found to have elevated
excretion of nicotine and cotinine (39, 40), but the level associated with the
appearance of symptoms was not given. People who are unaccustomed to
smoking and smoke 3 to 6 cigarettes within an hour get the same symptoms, and
their nicotine/cotinine levels are about the same as those of tobacco harvesters
with symptoms. Symptoms (runny eyes and blurry vision) were reported in
significantly higher frequency (p< 0.04) in non-smoking tobacco growers with
urine cotinine levels of ≥ 50 µg/l/m2 (range 50 – 290 µg/l/m2) when they were
compared with workers who had levels below 50 µg/l/m2. The correlation was
seen only after the urine cotinine concentration had been corrected with body
surface area (68). The authors propose that the symptoms are due to GTS, but
observe that they may also be due to exposure to organic phosphates.
Acute and chronic cardiovascular effects
There is a lot of information, both human data and results from experiments
with laboratory animals, about exposure and cardiovascular effects of cigarette
smoking (53). The rapid nicotine uptake and high levels that result from smoking
are believed to stimulate the sympathetic nervous system and produce systemic
catecholamine secretion with effects on hemodynamics (17). Although there are
little human data on the cardiovascular effects of exposure to nicotine alone, there
are some animal data.
As a rule, high doses, similar to those from smoking, have been used in animal
studies. Only a few give measured nicotine levels in plasma, but levels around 25
µg/l (the levels seen in smokers) are reported at doses ranging anywhere from 0.5
to 2 mg/kg/day (10). Male rats were given nicotine in drinking water in 3 groups:
0 (n = 80), 1.14 (n = 100) and 4.56 (n = 100) mg/kg/day for 34 weeks and then
exposed to hypoxia (89). With hypoxia treatment, there was an elevation in
mortality at the highest nicotine dose, or about the level measured in heavy
smokers (>20 cigarettes/day). No effect on hematocrit was seen. In other animal
studies, high intramuscular (i.m.) or subcutaneous (s.c.) injections of nicotine have
resulted in changes in plasma lipoproteins (37, 84). Similar changes in lipo-
proteins have been observed in smokers (23, 38). Only minimal changes were
seen in human studies with transdermal nicotine applications, however (4, 73).
Rabbits with hypercholesterolemia that were given intramuscular or subcutaneous
injections of high doses (11 mg/kg/day) developed atherosclerosis (84). Their
cholesterol levels, however, were higher than those regarded as clinically relevant.
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Lower doses of nicotine (1 mg/kg/day) and a low-cholesterol diet had no effect
in a study by Fisher et al. (37). The vascular toxicity of nicotine has been clearly
shown in animal experiments with exposures higher than those associated with
smoking. The effect on smooth muscle morphology in cultured arterial smooth
muscle cells was dose-dependent and quite small at levels associated with
smoking (85). In an inhalation experiment, rats (n = 68) were exposed to 0.5
mg/m3 nicotine 20 hours/day, 5 days/week for two years and compared with
controls (n = 34). Mortality and arteriosclerosis were no higher among the
exposed rats, but they weighed less than controls. The exposure resulted in
plasma cotinine levels above 100 µg/l (about double that of a smoker) (88).
Ahmed et al. (2) report abnormal left ventricle function and interstitial fibrosis
in the hearts of beagles (18 months old at the start of the study) after 22 months of
exposure to cigarette smoke via tracheostoma (7 cigarettes/day, equivalent to 377
µg/kg; n = 9) or to nicotine alone via intramuscular injection (210 µg/kg, twice a
day; n = 8), when compared with controls (n = 7). The fact that the effects were
observed in both treated groups suggests that nicotine has a role in cardiovascular
effects.
There are only a few human studies. In a large prospective study of construction
workers, an elevated mortality due to heart and circulatory diseases was identified
for snuff users (19). The risk, however, was lower than that for smokers. The
relative risk (RR) was 1.4 (95% CI 1.2 – 1.6) for snuff users (compared with a
group that did not use tobacco) and 1.9 (95% CI 1.7 – 2.2) for smokers (> 15
cigarettes/day); see Table 2. The analysis included only snuff users who had
never smoked. Mixed tobacco use or pipe smoking was not studied. In a smaller
retrospective case-control study of patients with myocardial infarctions, however,
Huhtasaari et al. (47) found no elevated risk for snuff users. In this study the
relative risk for cigarette smokers was 1.87 (95% CI 1.40 – 2.48) and for snuff
users 0.89 (95% CI 0.62 – 1.29). ‘Tobacco users’ were defined as anyone smoking
or taking snuff at least once a day. This study, like the others, includes no analysis
of mixed tobacco use or other nicotine use. Another study by Huhtasaari et al. was
also negative regarding a correlation between snuff use and cardiovascular effects
(48).
Hansson et al. (42) had healthy subjects inhale aerosols of nicotine solutions
(1 – 8 mg/ml; 0.01 ml/inhalation). In one study each subject inhaled 21 times in 5
minutes, inhaling a total of 0, 0.4, 0.8 or 1.7 mg nicotine. Effects on systolic blood
pressure and heart rate were observed during a subsequent 30-minute observation
period even after the lowest dose (0.4 mg). Coughing was also observed after a
single inhalation of a solution containing 4 mg nicotine/ml. The lowest dose that
triggered coughing was 0.04 mg. The authors conclude that nicotine stimulates
the coughing reflex locally via nerve ends in the bronchial mucosa (see also
Respiratory effects and hypersensitivity).
Snuff users have about the same average nicotine exposure as smokers (90).
It can be assumed that the harmful effects of nicotine are greater with the lung
exposure from smoking than with other methods/pathways of administration,
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since high arterial peak concentrations are reached more quickly (16). Further, it
is generally accepted that the effects of smoking are due to the combined action of
nicotine and several other substances in the smoke, such as carbon monoxide (16).
It is thus not clear how large a role nicotine plays in cardiovascular disease. It has
been shown that nicotine, at levels about the same as those found in smokers and
snuff users (plasma nicotine > 10 – 20 µg/l), stimulates the sympathetic nervous
system, accelerates heart rate and raises blood pressure, and can also affect lipid
metabolism and cause endothelial damage related to development of arterio-
sclerosis. There is no convincing evidence of nicotine effects at lower exposure
(17).
The central nervous system and nicotine addiction
The effects of nicotine on the CNS are complex (15), see also Effects on
reproduction. Alertness and relaxation are affected. Because of the dependency-
inducing nature of nicotine most smokers can not quit, although in several studies
the majority of them have expressed a desire to do so. Nicotine changes the
spectrum of EEG activity (69). Activation of nicotinic acetylcholine receptors
(nAChRs) in the CNS is related to dependence (15). Studies with rats have shown
that the mesolimbic dopamine system is central to the dependency-inducing
effect of nicotine. Dose, rate of uptake and tolerance development are the most
important factors in nicotine addiction. The rapid uptake with inhalation is
probably correlated to the addictive effect more closely than is the amount of
nicotine (13). Inhalation provides the quickest and highest exposure in the brain.
Smoking one cigarette for about 5 minutes (equivalent to an absorbed dose of
about 1 – 1.2 mg nicotine) gives an initial peak concentration in the brain within
10 to 20 seconds after the first puff. It can be expected that there is a less addictive
effect of 8 hours of occupational exposure to the same dose a smoker gets within 5
minutes. Support for this is that nicotine patches are less dependency-producing
than other nicotine preparations (70). The threshold for the dependency-producing
effect is poorly documented. Benowitz (12) states that there is a risk of depend-
ency with smoking 2 cigarettes per day. On the other hand, the same author states
in a later publication that the threshold dose for inducing dependency is probably
about 5 mg nicotine per day (though this statement is unsupported). The author
refers to a group of smokers (about 10%) who smoke fewer than 5 cigarettes per
day and don’t seem to be dependent (14). These individuals can go without
smoking for one or several days without abstinence symptoms. Five mg nicotine
per day should, according to the formula given earlier (under Biological measures
of exposure), yield cotinine levels of about 60 µg/l plasma and about 400 µg/l
urine.
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Other effects
A large number of other effects have been reported at high exposure levels:
Respiratory effects and hypersensitivity
Inhaled nicotine causes a dose-dependent coughing and airway constriction
similar to the effects of capsaicin. High exposures cause severe coughing and
breathing difficulty (42), see also Table 2. In pharmaceutical production, cleaning
the work spaces/machines where powder containing nicotine (nicotine resinate or
nicotine ß-cyclodextrin) is processed often leads to coughing attacks (96).
Nicotine in very high doses is strongly irritating to skin and eyes: it can cause
severe eye irritation in pharmaceutical production workers dealing with a machine
malfunction in a closed system (see Nicotine exposure in work environments) if
they do not wear protective goggles. There are several case reports of local
vasculitis caused by nicotine patches (87).
Neuromuscular effects
Nicotine stimulates Renshaw cells, reducing muscle tonus in spastic patients. On
the other hand, nicotine can also increase EMG (electromyogram) activity in the
trapezius muscle (33).
Endocrine effects
The levels of the catecholamines adrenaline and noradrenaline in plasma rise after
cigarette smoking (17). Acetylcholine, vasopressin, growth hormone, dopamine,
serotonin, cortisol and ACTH levels also rise with smoking, which is assumed to
be related to nicotine (9, 12).
Mutagenicity, carcinogenicity
There is an enormous amount of documentation on the risks of smoking; among
other things, there are a large number of carcinogens in tobacco smoke (45, 49).
Until recently, it was assumed that nicotine alone was not carcinogenic and was
of no importance in the etiology of tobacco-related cancer (12). ETS exposure was
also connected to an elevated risk of lung cancer (50), but it was not associated
with nicotine. The past few years, however, have provided evidence that nicotine
can play an important role in carcinogenesis by acting as a growth promoter,
inhibiting apoptosis and inducing oxidative stress leading to DNA damage (see
References 8 and 21 and references cited therein).
No increase in tumor frequency was observed in a 2-year inhalation study in
which rats were exposed to twice the amount of nicotine absorbed by a smoker
(88). The nicotine exposure was 0.5 mg/m3, 20 hours/day, 5 days/week. The
plasma nicotine level in the animals was a bit over 100 µg/l, more than twice
that of a smoker.
Nicotine has been negative in most short-term tests for mutagenicity and
genotoxicity. Induction of sister chromatid exchanges (SCE) in CHO cells was
not seen in a study made by Doolittle et al. (27), but was observed in a study by
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Trivedi et al. (86). Nicotine was negative in Ames’ tests with Salmonella
typhimurium in several studies (20, 26, 27, 61). Nicotine had no effect in a
bacterial genotoxicity test based on chemiluminescence, but the test was positive
for cotinine (100).
A large prospective study of construction workers (mentioned above) revealed
no increase in cancer risk for the subjects who used snuff (19) (see also Table 2).
A Swedish case-control study on the connection between snuff and cancers of the
mouth, throat and esophagus revealed that snuff use had little or no effect on the
occurrence of these forms of cancer. If only persons who had never smoked were
included, there were only 9 cases and 10 referents who used snuff alone. The
relative risk was 10.5 (95% CI 1.4 – 117) for former snuff users and 3.3 (95% CI
0.8 – 12.0) for current snuff users (57). An earlier study from northern Sweden
had shown a tendency to elevated risk of lip cancer in former snuff users (RR =
1.8, 95% CI 0.9 – 3.7) (75).
Effects on reproduction
No studies were found dealing with toxic effects on human reproduction caused
by exposure to nicotine alone. In Sweden, nicotine as a pharmaceutical is placed
in category C with regard to pregnancy (substances which are known to, or on
good grounds are presumed to, pose a risk to the fetus or newborn, without being
directly teratogenic) and in group III with regard to nursing (substances which, at
therapeutic doses, enter milk in amounts large enough to pose a risk of effects
on the child) (34).
Exposure to tobacco smoke has been associated with several toxic effects
on human reproduction: placenta previa, premature detachment of placenta,
premature birth, intrauterine growth restriction, low birth weight, multiple
malformations, miscarriage/spontaneous abortion, sudden infant death syndrome
(SIDS), disturbances in neurological development (including hyperactivity,
learning difficulties and memory problems), a higher frequency of respiratory
infections and below-average lung function (5, 6, 25, 44, 54, 55, 64, 74, 76).
Significantly higher risks of preeclampsia (the preliminary stage of eclampsia)
and premature birth have been noted in pregnant women who use snuff (30).
Judging from a large number of experiments with laboratory animals, most of
these toxic effects can be suspected to be caused directly or indirectly by nicotine
(67, 83). A few representative studies and studies with low exposure levels are
described below.
Nicotine can have non-specific effects by causing blood vessel constriction,
which leads to hypoxia/ischemia, and more specific effects by binding to nicotinic
acetylcholine receptors and affecting proliferation and differentiation of nerve
cells in both the central and peripheral nervous systems (82, 83). Both the size of
the dose and the method of administration affect the toxicity. High single doses
(e.g. 2 x 3 mg nicotine/kg b.w./day s.c.), which produce high peaks in plasma,
given to pregnant rats for several days, inhibit growth of both mothers and fetuses
– in the fetus probably mostly because each injection causes hypoxia/ischemia.
94
Continuous infusion of 6 mg nicotine/kg b.w./day (yielding a plasma nicotine
level of about 84 µg/l, somewhat higher than that of a heavy smoker) has also
been shown to inhibit growth without giving visible signs of hypoxia/ischemia
such as pale skin or cyanosis (63, 82, 83). With infusions of lower doses, such
as 2 mg/kg b.w./day (yielding a plasma nicotine level of about 28 µg/l, equivalent
to smoking about one pack of cigarettes per day), no inhibition in growth was
observed in either mothers or fetuses (63, 66, 82, 83).
Pregnant mice were given daily s.c. injections of 0.9, 1.8, or 2.7 mg nicotine/kg
b.w. (divided into 2 injections per day) during days 0 – 6 of gestation (the first
trimester), days 7 – 12 (second trimester) or day 13 –parturition (third trimester).
Significant reductions in length of gestation were observed at the lowest and
highest doses given in the third trimester (65). These doses roughly correspond
to smoking 10, 20 or 30 cigarettes per day.
Rats were given 6.0 mg nicotine/kg b.w. daily (in 2 s.c. injections) on days 4 –
20 of gestation: the treatment resulted in lower growth rates and higher maternal
mortality, increased total fetus resorption and lower brain and body weights in
young. An increase in ornithine decarboxylase activity in the brain was seen in
young, both pre- and postnatal. The effect was most pronounced in the cerebellum
and could be observed 20 days after termination of exposure (18 days after
parturition). Changes in DNA (synthesis, amount and concentration) were also
observed in some parts of the brain: these were also most pronounced in the
cerebellum (78). Similar results were obtained with the same dose given by
infusion, but the changes were no longer most pronounced in the cerebellum (79).
The authors interpret these results as an indication that prenatal nicotine exposure
affects early biochemical events that govern nerve cell proliferation and differ-
entiation (78, 79).
In a study in which pregnant rats were exposed by continuous s.c. infusion to
2 or 6 mg nicotine/kg b.w./day on days 5 to 22 of gestation, the high dose caused
lower weight gain in the mothers and a small but significant reduction in birth
weights of the pups. The day after birth the pups in the high-dose group had much
higher mortality after hypoxia provocation (5% 02 for 60 or 75 minutes) than
either the low-dose group or controls. Further, in comparison with controls, the
high-dose group (the low-dose group was not further studied) had lower release
of catecholamines from the adrenal medulla during the hypoxia provocation,
fewer adrenergic β-receptors in the heart, lower basal noradrenaline metabolism
in the brain and a much higher liberation of noradrenaline in the brain after the
hypoxia provocation (80).
In a study by Navarro et al. (66), pregnant rats were given continuous s.c.
infusions of 2 mg nicotine/kg b.w./day from day 4 to day 21 of gestation. The
treatment had no effect on either maternal weight or resorption frequency, nor did
it affect the pre- or postnatal weight gain of the pups. However, in the brains of
the pups (both pre- and postnatal) there was an increase in nicotine binding sites
and changes in ornithine decarboxylase activity. Further, DNA in the cerebellum
was reduced postnatally, in both concentration and total amount – which the
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authors interpret as an indication of a reduced number of cells (66). With nicotine
doses of 2 or 6 mg/kg b.w./day administered by the same method on days 4 to 21
(but not if given on days 4 to 12) there was a fairly persistent increase of mRNA
that codes for c-fos (a proto-oncoprotein) in the brains of the pups. This increase
was seen both prenatally (day 18) and postnatally (on day 2, 3 days after the
nicotine infusion was stopped) but without any significant effect on brain weight.
The authors discuss the possibility that apoptosis (via activation of c-fos), in
addition to inhibiting replication, contributes to the reduction of cells in the central
nervous system after prenatal nicotine exposure (81).
Rats were exposed to nicotine by continuous infusion: 0.53, 1.05 or 2.11 mg/kg
b.w./day from day 6 or 7 of gestation, resulting in serum nicotine levels of 8, 19
and 35 µg/l respectively. On day 20 the concentrations of nicotine in fetal serum
ranged from 91% to 240% of the levels in maternal serum. The ability of the pups
(5 or 6 days old) to recover after repeated anoxic provocation was significantly
lower for the two higher dose groups (35).
A possible explanation for the weakened defense reaction to hypoxia is
provided by Holgert et al. (46) in a study of 3-day-old rats. They observed effects
of nicotine (0.6 mg/kg b.w., intraperitoneal injections) on peripheral arterial
chemoreceptors, which may increase sensitivity to hypoxia and lower the defense
reflex in an apnea/hypoxia period. The group later proposed that the β2 subunit in
nicotinic acetylcholine receptors (nAChRs) has an important role in the effect of
nicotine on parts of the nervous system that govern respiration (both peripheral,
on the carotid chemoreceptors, and central, in the brain stem). Mice 35 to 48 days
of age had a depressed reaction (lower increase of respiration volume per minute)
to hypoxia during sleep after a single i.p. injection of nicotine tartrate (0.5 mg/kg;
equivalent to 0.18 mg nicotine/kg b.w.). The nicotine exposure had no effect on
mutant mice lacking the β2 subunit of the receptor (22).
Pregnant rhesus monkeys (n = 3) given s.c. infusions of 1.0 mg nicotine/kg
b.w./day from day 26 to delivery (by C-section) on day 134 were no lower in
weight than controls (n = 3). The concentration of nicotine in amniotic fluid was
15.5 µg/l. The treatment reduced birth weight by 8%, increased the number of
nicotine binding sites and increased the expression of nicotinic acetylcholine
receptors in the lungs; pulmonary hypoplasia and effects on alveolar development
were also observed (76).
Pregnant sheep were exposed to nicotine by continuous s.c. infusion (0.18
mg/kg b.w./day) from day 98 until parturition on day 147 (the third trimester)
(41). The exposure yielded a plasma nicotine level of 7 µg/l and a plasma cotinine
level of 18 µg/l. Five days after birth, lambs in the nicotine-exposed group (n = 7)
had lower respiratory and heart rate responses and slower arousal than controls (n
= 11) with hypoxia provocation (10% O2) during sleep. The authors regard these
results as compatible with an effect on peripheral and/or CNS chemoreceptors
(41).
Pregnant mice were given s.c. injections of 0.5 mg nicotine/kg b.w./day for 9 or
10 days beginning on day 10 of gestation. Their young had lower postnatal weight
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gain (they were followed until day 21), delayed hair growth, eye opening and
reflex development, and hyperactivity that persisted until they were mature (3).
Male mice (3, 10 and 19 days old) were given nicotine in s.c. injections of 66
µg/kg b.w., twice a day for 5 days (31). On the day after the final injection, no
low-affinity nicotine-binding sites could be detected in cerebral cortex in any of
the three groups. In the control groups (given the same treatment with saline
solution), 13 to 29% low-affinity nicotine-binding sites were detected. At 4
months of age the mice were examined again for binding sites with low nicotine
affinity, spontaneous behavior (“motor activity, locomotion, rearing”) and
nicotine-induced behavior (provocation with 40 or 80 µg nicotine/kg b.w., s.c.).
None of the groups was any different from controls with regard to spontaneous
behavior, but the group that was treated on days 10 – 14 still lacked low-affinity
nicotine-binding sites and exposure to nicotine resulted in hypoactive behavior.
The other two groups were no different from controls with regard to either binding
sites or nicotine-induced behavior (increased activity) (31). In similar experiments
with rats, lasting effects on nicotine binding in the CNS were seen after treatment
with 0.1 mg nicotine/kg b.w. s.c. twice a day on days 8 to 16 after birth. When
these animals were compared with controls at the age of 115 days, they had no
low-affinity nicotine-binding sites and more high-affinity nicotine-binding sites
(62).
In a study by Ankarberg et al. (7), groups of 10-day-old male mice were
exposed 3.3, 33 or 66 µg nicotine/kg b.w. s.c. twice a day for 5 days. Four months
later they were examined for spontaneous and nicotine-induced motor behavior
(provocation with 40 or 80 µg nicotine/kg b.w., s.c.). In the two higher dose
groups the nicotine exposure elicited hypoactivity, whereas the lowest dose group
was no different from controls, i.e. the nicotine caused hyperactivity. Mice in the
highest dose group were also tested for learning and memory functions at 4 and 7
months of age. At 4 months there was no difference from controls but at 7 months
these skills were significantly lower (7).
Eighteen female Sprague-Dawley rats 25 to 29 days old (6 per group) were
given injections of 6.25 ng nicotine/g b.w. (i.p.) at intervals of 6, 8 or 12 hours.
For each dose level there were 6 controls given saline solution (18). Twelve hours
into the treatment all of them were given (s.c.) 20 IU horse serum gonadotropin to
induce follicular development, followed 48 hours later by 10 IU human chorionic
gonadotropin (hCG) to induce ovulation. After a further 18 to 20 hours the
animals were killed, serum samples were taken, and oviducts were dissected to
determine the number of oocytes. There was a dose-dependent reduction in the
number of ovulating oocytes, with the LOEL at the lowest dose. S-estradiol
concentration was lower in the 2 higher dose groups (no effect at the lowest dose).
The study is difficult to interpret, however, since it might have been a local effect
on the ovaries. A similar experiment was performed with cotinine but no effects
were observed.
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Witschi et al. (98) showed that nicotine patches applied to pregnant Sprague-
Dawley rats, delivering doses of 3.5 mg/day (plasma level 240 µg/l) or 1.75
mg/day (40 µg/l) interrupted pregnancy in 100% and 50% of them, respectively.
Kavitharaj et al. (51) report a LOAEL of 0.2 mg/kg for testicular effects on
male rats given s.c. injections of nicotine for 21 days. This study, however, is
poorly documented.
Dose-response / dose-effect relationships
Dose-effect data for human exposure to nicotine are shown in Table 2.
In addition to exposure from personal use of tobacco, occupational exposure to
nicotine occurs via passive smoking, during tobacco cultivation and processing,
and in production of pharmaceuticals. These three exposure situations doubtless
present a wide variation in absorption kinetics and different effects.
Inhalation of as little as 0.04 mg nicotine can cause local irritation and cough-
ing, and a dose of 0.4 mg affects the heart and circulatory system (42). Systemic
effects were observed in rats after i.p. injection of about 0.02 mg/kg (equivalent
to 1.4 mg for a human weighing 70 kilos) (18). Effects at such low doses can
probably be explained by rapid uptake. It would require high air concentrations
of nicotine (> 1 mg/m3) to achieve the same effect with passive smoking.
Nicotine induces dependency, but the threshold dose for inducing dependency
is not known. It has been reported, but not substantiated, that smoking 2 to 5
cigarettes (about 2 to 5 mg nicotine) per day should be habit-forming, and that the
rapid and high nicotine intake from inhalation (active smoking) is accompanied
by a high risk of dependence. Doses that are associated with addiction in smokers
(2 to 5 mg) may not have that effect if uptake is by inhalation over a longer period
such as an 8-hour workday.
There are no reports of nicotine dependency initiated by occupational exposure.
For tobacco harvesters, skin uptake from the leaves is predominant and may
contribute to the toxic picture (Green Tobacco Sickness). Field workers who
harvested the leaves had a median value of 890 µg cotinine/g creatinine (about the
same in µg/l) in urine, and 25% of them had symptoms. This cotinine concentra-
tion in urine corresponds to an intake of about 10 mg nicotine/day (≈ 8 to 10
cigarettes per day). Assuming a 50% uptake and an inhaled air volume of 10 m3,
this corresponds to an air concentration of about 2 mg/m3.
In pharmaceutical manufacture it is again inhalation exposure that seems to be
most important (if adequate protective clothing is worn). Production conditions
are probably reflected best in the animal experiments that report an effect in the
form of weight loss at an air concentration of 0.5 mg/m3 (see below). High air
concentrations of nicotine compounds in powder form irritate airways (coughing).
In several studies pertinent in this context, exposure levels were calculated from
metabolites in urine or plasma. There is a simple formula that can be used to
calculate the dose. Where skin uptake may be relevant, urine and blood will
usually provide a more accurate dose estimate than air concentration.
98
Rats were exposed by inhalation to 0.5 mg/m3 nicotine, 20 hours/day, 5
days/week for two years (plasma nicotine 100 µg/l, about twice that of a smoker).
There was no elevation in mortality or arteriosclerosis, although these rats had
lower weights than controls (88).
Nicotine has been shown to have toxic effects on reproduction in laboratory
animals (see Table 3). Rats given high doses of nicotine (6 mg/kg b.w./day, s.c.)
during gestation have higher frequencies of fetal absorption and bear pups with
lower birth weights and lower postnatal growth rates. A maternal dose of 2 mg
nicotine/kg b.w./day (equivalent to smoking a pack of cigarettes a day) resulted in
an increase in nicotine binding sites, changes in ornithine decarboxylase activity
and reduction of the amount of DNA in the central nervous systems of the young.
A depressed response to hypoxia/anoxia was observed in the young of rats
exposed to 1.05 mg nicotine/kg b.w./day (plasma nicotine level 19 µg/l) and in
lambs when their mothers had been exposed to 0.18 mg nicotine/kg b.w./day
(plasma nicotine 7 µg/l, plasma cotinine 18 µg/l) during gestation. Effects on
lung development have been observed in the young of rhesus monkeys exposed to
1.0 mg nicotine/kg b.w./day during gestation. Delayed hair growth, eye opening
and reflex development, lower postnatal weight gain and hyperactivity persisting
until maturity were observed in the young of mice exposed to 0.5 mg nicotine/kg
b.w./day during gestation. Lack of low-affinity nicotine-binding sites was
observed in the CNS of adult rats and mice treated with 200 or 132 µg nicotine/kg
b.w./day, respectively, from birth until about 2 weeks of age. Effects on memory
and learning functions were observed in 7-month-old mice treated from 10 to 15
days of age with 132 µg nicotine/kg b.w./day (s.c.), and at a dose of 66 µg there
were changes in nicotine-induced motor behavior at 4 months of age. No effect
was observed at 7 µg. A dose of 66 µg/kg b.w./day given to mice (LOAEL) is
equivalent for humans to inhalation exposure to an air concentration of 0.13
mg/m3, assuming a body weight of 70 kg, a caloric factor of 7 (52), 50%
absorption in the lungs, and an inhaled air volume of 10 m3 during 8 hours.
Using the same calculation for a dose of 7 µg/kg (the NOAEL) yields an air
concentration of 0.014 mg/m3.
Conclusions
Available scientific material is not sufficient to identify a critical effect of
occupational exposure to nicotine. Judging from animal experiments, the critical
effect of nicotine exposure is its effect on reproduction, with effects on the
development of the nervous system in the young. Changes in nicotine-induced
motor behavior have been observed in 4-month-old mice treated from 10 to 15
days of age with 66 µg nicotine/kg b.w./day (divided into 2 s.c. injections/day).
Recalculated to job-related inhalation exposure, this dose correspond to an air
level of about 0.1 mg nicotine/m3.
Symptoms of acute poisoning – Green Tobacco Sickness, with dizziness,
vomiting, headache, weakness, stomach pain, cramps, salivation, sweating – are
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common among tobacco harvesters, where nicotine exposure is primarily via skin
uptake. The symptoms have been observed at cotinine levels of about 900 µg/l in
urine (median), which corresponds to an inhalation exposure of about 2 mg/m3.
Nicotine is addictive, but the threshold dose for the addictive effect is not
known.
Nicotine exposure equivalent to smoking also has acute cardiovascular effects.
Animal experiments have not shown that nicotine is carcinogenic. There are no
carcinogenicity studies of humans exposed to nicotine alone.
Nicotine is easily absorbed through the skin, and skin exposure may lead to
acute poisoning with severe outcome.
Table 2. Dose-effect / dose-response relationships observed in studies in which human
subjects were exposed to nicotine.
Exposed groups,
study design
Urine cotinine
(µg/l)
Effects Ref.
Tobacco harvesters,
non-users of tobacco,
good protective clothing
N = 10; 5 controls
100
(median)
No symptoms 24
Tobacco harvesters,
non-users of tobacco,
poor protective clothing
N = 43
0 – 24 pre-shift
26 - 2930
(median 890)
next morning
25% had Green Tobacco Sickness
symptoms: dizziness, vomiting, headache,
weakness, stomach pain, cramps,
excessive salivation and perspiration
39
Tobacco harvesters,
poor control of tobacco use,
poor protective clothing
N = 289
3800 53% with GTS symptoms 40
Three groups: snuff users,
smokers, no tobacco use
Prospective cohort study
12 years
N = 135,036
- * Elevated mortality from heart and
circulatory diseases for snuff users
(RR = 1.4, 95% CI 1.2-1.6) and smokers
(RR = 1.9, 95% CI 1.7-2.2);
no increase of cancer deaths for snuff
users (RR =1.1, 95% CI 0.9- 1.4)
RR for smokers 2.5 (95% CI 2.2-3.0)
19
Two groups:
snuff users/no tobacco use
Case-control study
N = 585/589
- * No elevation in risk for heart infarct for
snuff users (RR = 0.89, 95% CI 0.62 -
1.29)
47
Healthy volunteers
21 inhalations of 0.01 ml
nicotine aerosol,
concentration
interval 0 - 64 mg/ml
N = 24
- Elevated blood pressure and heart rate,
dose-dependent increase of airway
resistance, coughing attacks.
LOAEL 2 mg/ml; 0.4 mg
42
* Smokers and snuff users have plasma nicotine levels around 20 to 30 µg/l and urine cotinine around
2000 - 3000 µg/l.
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Table 3. Effects of nicotine exposure on reproduction of laboratory animals.
Dose
(mg/kg/day),
Exposure method
Species Exposure
time
Plasma
nicotine
(µg/l)
Effects Ref.
6, infusion Rat prenatal 84 Growth inhibition 63, 82,
83
2, infusion Rat prenatal,
days 4-21
28 Reduced concentrations and amounts
of DNA, changes in ornithine
decarboxylase activity, increase of
nicotine-binding sites and mRNA
coding for c-fos in CNS
63, 66,
81, 82,
83
2.7, injection* Mouse prenatal, day 13
to birth (day 19)
Shortened gestation 65
1.8, injection* Mouse prenatal, day 13
to birth (day 19)
--
0.9, injection* Mouse prenatal, day 13
to birth (day 19)
Shortened gestation
2.11,
infusion
Rat prenatal,
day 6-7 to birth
35 Impaired recovery after anoxia 35
1.05,
infusion
Rat prenatal,
day 6-7 to birth
19 Impaired recovery after anoxia
0.53,
infusion
Rat prenatal,
day 6-7 to birth
8 No observed effect
1.0,
infusion
Rhesus
monkey
prenatal, day
26 to C-section
on day 134
** Effects on lung development. Increase
of nicotine-binding sites and receptors
in lungs
76
0.5,
injection
Mouse prenatal, day 10
to day 19 - 20
Lower postnatal weight gain, delayed
hair growth, eye-opening and reflex
development; hyperactivity persisting
to maturity
3
0.2,
injection*
Rat postnatal,
days 8-16
At 115 days, lack of low-affinity
nicotine-binding sites and increased
number with high affinity
62
0.18,
infusion
Sheep prenatal, day 98
to birth (day 147)
7 *** Weakened arousal with hypoxia 41
0.132,
injection*
Mouse postnatal, days
10 to 14
At 4 months, lack of low-affinity
nicotine-binding sites and hypoactive
behavior with nicotine provocation
31
0.132,
injection*
Mouse postnatal,
days 10 to 14
Lower learning and
memory at 7 months
7
0.066,
injection*
Mouse postnatal,
days 10 to 14
Hypoactivity with nicotine
provocation at 4 months (LOAEL)
0.007,
injection*
Mouse postnatal,
days 10 to 14
No effect (NOAEL)
*divided into 2 injections/day
**15.5 µg nicotine/l in amniotic fluid
***18 µg cotinine/l in plasma
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This Report is based primarily on a criteria document compiled by the Nordic
Expert Group (28).
Chemical and physical data
CAS No. 96-48-0
Synonyms: dihydro-2(3-H)-furanone; 4-butyrolactone;
tetrahydro-2-furanone; 1,2-butanolide;
1,4-butanolide; 4-hydroxybutyric acid lactone
Formula: C4H6O2
Structure: O O
Molecular weight: 86.1
Boiling point: 206 °C
Melting point: - 44 °C
Flash point: 98 °C (open cup)
Vapor pressure: 0.15 kPa (20 °C)
Saturation concentration: 1480 ppm (20 °C)
Water solubility: mixes with water
pH: 4.51 (10% in water)
Conversion factors: 1 ppm = 3.57 mg/m3 (20 °C)
1 mg/m3 = 0.28 ppm (20 °C)
γ-Butyrolactone (GBL) is a colorless, oily liquid with relatively low vapor
pressure and a mild, caramel-like odor. It is soluble in e.g. methanol, ethanol,
acetone and benzene, and mixes with water. There is a pH-dependent equilibrium
between GBL and γ-hydroxybutyrate (GHB). In basic media GBL is hydrolyzed
quite rapidly to GHB, but in acidic media the hydrolysis is slow. Complete
transformation to GHB occurs within a few minutes at pH 12, whereas an
equilibrium mixture of 2:1 GBL:GHB occurs after months in pure water and
within days at pH 2 (28).
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Occurrence and use
GBL occurs in nature, and has been identified in some foods (e.g. meat, tomatoes,
coffee) and in alcoholic drinks (28). GBL is used as a solvent, in paint removers,
as a pH regulator, in vulcanizing, to modify viscosity, in etching, and as a
chemical intermediate in production of pyrrolidones, herbicides/pesticides and
medicines (28). Use of GBL as a dietary supplement, tranquilizer and treatment
for alcoholism has also been reported. GBL is also used as a “party drug” (1, 5).
In Sweden, GBL in pure form is used primarily as a solvent in the electronics
industry and in manufacturing of various products, and the major products
containing GBL are paint removers (graffiti removers), cleaners, paints,
electrolytes and developers (20, 23).
In other countries GHB has been used as an anesthetic and tranquilizer and in
treatment of narcolepsy, alcoholism and opiate addiction. The substance has also
appeared as a dietary supplement used by body-builders and dieters. GHB is also
used as a recreational drug, and in recent years has been classified as a narcotic
in several countries, including Sweden (9, 23)
Uptake, biotransformation, excretion
GBL can be absorbed via the skin. The reported absorption rate for human skin
in vitro is 110 µg/cm2/hour at steady state (32). Using this absorption rate and
applying the ECETOC criterion for skin notation (8), i.e. exposure of 2000 cm2
skin (equivalent to hands and lower arms) for 1 hour, yields a skin uptake equal
to about 25% of uptake via inhalation exposure to 50 ppm for 8 hours (the
provisional Danish threshold limit for GBL), assuming inhalation of 10 m3 air and
50% uptake of GBL. When GBL was applied to the skin of rats (546 mg/kg b.w.),
the highest GHB concentrations in plasma were seen after 0.5 to 2 hours. At least
10% of the applied dose of GBL was absorbed (11). Uptake of GBL via the
digestive tract is rapid and complete (28). GBL is absorbed from the digestive
tract more rapidly, and yields higher plasma levels, than GHB (5, 15, 19, 26).
When rats were given GBL in oral doses of 136 or 546 mg/kg b.w., plasma
concentrations of GHB peaked within 1 hour (11, 19). No data on inhalation
uptake were found (28).
GBL is transformed in blood and liver to the neurologically active metabolite
GHB within a few minutes. This hydrolysis is catalyzed by the enzyme lactonase.
GHB also occurs naturally in micromolar concentrations in the brain and
peripheral tissues (9, 23, 28). GHB passes through the blood-brain barrier and
the placental barrier (9). GBL is more fat-soluble than GHB and has a different
distribution pattern – producing, for example, higher concentrations in the brain.
Thus, despite the rapid hydrolysis of GBL in blood, there is some accumulation
in various tissues of this precursor to GHB (15, 19). Metabolism of GHB is not
completely understood, though it is known to vary with plasma level and the
organ involved (28). The average half time for GHB in rat blood after intravenous
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administration of GBL (500 mg/kg b.w.) is reported to be about 45 minutes (28).
Elevated excretion of glycolate, S-3,4-dihydroxybutyrate and other substances has
been observed in human urine after oral administration of GBL, which suggests
metabolism via β-oxidation. Acetyl-CoA, and ultimately CO2 (via the citric acid
cycle) are formed via this metabolic pathway (18, 28). In an alternative metabolic
pathway, GBL is oxidized to succinate, which enters the citric acid cycle (1).
Metabolization from GHB to γ-aminobutyrate (GABA) has also been reported
(33). When rats were given a single intravenous injection of 14C-labeled GHB,
60% of the radioactivity was excreted as 14CO2 within 2.5 hours (28). Similar
results were obtained with GBL. GBL is thus eliminated primarily as metabolites
in urine and as CO2 via the lungs (28).
Toxic effects
Human Data
No reports on effects of occupational exposure were found. Several cases of
poisoning due to oral intake of GBL or GHB for recreational purposes have been
described, however. Symptoms and clinical findings after intake of GBL and
GHB are similar, although it is not clear whether repeated use can result in
permanent damage (23, 28). Acute toxic effects include bradycardia, hypothermia,
CNS depression, loss of consciousness (usually for 1 or 2 hours), confusion,
aggressiveness, and uncontrolled movements (28). There are large differences in
the nature and degree of symptoms shown by different individuals, however (9).
One patient with symptoms of poisoning is reported to have taken about 90 mg
GBL/kg b.w. (negative blood ethanol test) (5). In another study, unconsciousness
is reported in 2 men who drank 50 ml of a nail polish remover containing 50%
GBL and 50% ethanol. Bradycardia was detected and treated, and the patients
recovered after a couple of hours (2).
Pulmonary edema and acute effects on the nervous system with coma were
observed in a child who had drunk (and probably also inhaled) a product
containing GBL (24). Chronic use of GBL can lead to addiction and neurotoxic
effects including anxiety, depression and tremor (13).
In general, a single oral dose of about 1 to 4 grams (≈ 15 – 60 mg/kg b.w.) is
necessary to achieve a sedative effect in humans (23). Clinical experience has
shown that GBL is more effective than GHB in putting patients to sleep (19).
GHB is reported to cause short-term memory loss and hypotonia at an oral dose
of 10 mg/kg b.w., euphoria at 20 – 30 mg/kg, anesthesia at 50 mg/kg, and coma at
50 – 70 mg/kg (4, 9, 23, 28). An intravenous dose of 50 to 60 mg/kg b.w. causes
general anesthesia within 5 minutes (9). Poisoning with GHB is usually a result of
using the substance as a “party drug” (often together with alcohol) at oral doses
of around 2 to 3 g (about 35 mg/kg b.w.). The CNS effects are potentiated by
simultaneous intake of alcohol. A lethal dose of GHB alone can be roughly
estimated to be about 20 to 30 grams (≈ 300 – 400 mg/kg b.w.) or higher (9, 23).
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Animal data
GBL has moderate to low acute toxicity to laboratory animals. Animal data
also show that GBL is more potent than GHB with oral as well as parenteral
administration (19). The toxic picture is characterized by CNS effects with
anesthesia. In rats, a biphasic effect has been observed at relatively low doses of
GBL, with an initial reduction in activity followed by hyperactivity (21, 28). The
LD50 for GBL has been reported to be 5600 mg/kg b.w. for skin application to
guinea pigs, and 500 – 1800 mg/kg b.w. for oral administration to rats, mice and
guinea pigs (28). Temporary changes in EEG and behavior (including immobility)
have been reported in juvenile rats after a single intraperitoneal injection of 50 mg
GBL/kg b.w., and in adult rats at 150 mg/kg b.w. (29). In tests measuring
spontaneous activity and coordination, a temporary decline was observed in mice
after a single intraperitoneal injection of 55 mg GBL/kg b.w.; the effect was also
noticeable at 22 mg/kg b.w. (27). In an unpublished study with rats reversible
effects including lassitude, shallow breathing and clear nasal secretion, but no
deaths, are reported with 4 hours of inhalation exposure to a dose level of 5100
mg GBL/m3 (28). In another unpublished rat study, the LC50 for 4 hours of
exposure is reported to be >2680 mg/m3 (10).
Mice and rats were given GBL by gavage on 12 days during a 16-day period.
Doses were 0, 87, 175, 350, 700 or 1400 mg/kg b.w./day for mice and 0, 75, 150,
300, 600 or 1200 mg/kg b.w./day for rats. Immediately after the dosing, inactivity,
and in some animals irregular respiration/breathlessness, was observed in the mice
at doses of 350 mg/kg and above, and in the rats at 600 mg/kg and above. Lower
weight gain was noted in the female rats given 600 mg/kg b.w. Nearly all the rats
and mice given the highest dose died (1200 and 1400 mg/kg b.w., respectively)
(21, 28).
In a 13-week study, mice and rats were given GBL by gavage 5 days/week.
Doses were 0, 65, 131, 262, 525, or 1050 mg/kg b.w. for the mice and 0, 56, 112,
225, 450 or 900 mg/kg b.w. for the rats. No noteworthy histopathological changes
were observed. Inflammation in nasal mucosa was seen in the rats, but was
attributed to reflux of GBL during the dosing. Temporary immobility after
administration was seen in all the rats given 900 mg/kg, and during week 8 all
the males and one female in this dose group died. During the first 2 to 3 weeks,
the rats receiving 225 or 450 mg/kg had lower activity levels immediately after
dosing, but then they seemed to develop tolerance. Male rats receiving 450 mg/kg
also had lower weight gain. GBL-related deaths were also seen in mice given the
highest dose (1050 mg/kg b.w./day). Males in this dose group also had lower
growth. Moderate inactivity after dosing was seen in mice given 262 mg/kg, and
at higher doses the mice were inactive for several minutes. These acute reactions,
however, faded after 3 – 4 weeks in groups receiving 525 mg/kg or less (21, 28).
It is reported in a cancer study (see below, Mutagenicity, carcinogenicity) that
female rats given oral doses of 450 mg GBL/kg b.w./day, 5 days/week for 2 years,
had lower growth but showed no indications of toxicity. No noteworthy effects
were reported in either sex at 225 mg/kg b.w./day. Inhibited growth was also
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observed in male and female mice given 262 or 525 GBL/kg b.w. on
the same schedule, and in the high-dose groups (525 mg/kg/day) there were
indications of CNS effects shortly after the dosing. Elevated mortality was
also reported for male mice in the high-dose group (aggression and stress-
related effects) (21, 28).
No acceptable studies of skin irritation were found, making it difficult to draw
any clear conclusions. However, there are some older data indicating that GBL
can have a weak skin-irritating effect (6, 28). GBL has also been reported to cause
eye irritation, but not lasting eye damage, to laboratory animals (28). In older,
unpublished studies, instillation of GBL is reported to cause severe irritation to
conjunctiva and damage to cornea, iris and conjunctiva (6, 28). In more recent
studies, GBL has been described as irritating to eyes in vivo as well as in vitro (12,
28). According to an estimate based on structure-activity relationship, GHB, but
not GBL, should be expected to irritate the eyes. “Respiratory hypersensitivity”
was also predicted for GHB but not GBL (25).
Mutagenicity, carcinogenicity
GBL has been studied in many in vitro tests and some in vivo tests. It is not
mutagenic in bacterial tests and has not been found to be mutagenic or genotoxic
in tests on yeasts (28).
GBL also yielded negative results in several in vitro test systems for primary
DNA damage. Regarding tests on mammalian cells in vitro, chromosome aber-
rations and sister chromatid exchanges were observed in one study with high
concentrations of GBL (and addition of exogenic metabolizing systems), but were
not observed in two other studies with lower concentrations. Negative results were
also reported in in vitro gene mutation tests. Oncogenic transformation of mam-
malian cells was observed in one of two studies, but this test has been judged to
be of little value in predicting carcinogenicity. In tests with Drosophila, neither
oral administration of up to 2.8% in feed nor injection of 1.5% GBL was observed
to cause genetic mutations or recombinations. Nor was any increase in
micronuclei observed in bone marrow cells of mice given intraperitoneal
injections of GBL (2 x 560 or 2 x 984 mg/kg b.w.) (21, 28). GBL was also
negative in a test measuring mutagenicity in mouse germ cells (100 – 400 mg/kg
b.w., i.p.) and in a sperm morphology assay (5 x 0.1 – 1 mg/kg b.w./day, i.p.) (22,
31). One work reports structure-activity predictions indicating that GBL may be
active in in vivo tests for SCE and micronuclei. The overall assessment, however,
is that GBL was probably not genotoxic (25).
In an NTP study, GBL was given by gavage to rats and mice 5 days/week for
up to 2 years. Doses were 0, 112 or 225 mg/kg b.w. for male rats, 0, 225, or 450
mg/kg b.w. for female rats, and 0, 262 or 525 mg/kg b.w. for the mice. There
was no evidence of carcinogenic activity in either the rats or the female mice.
However, in the female rats there were lower incidences of cysts and fibro-
adenomas in mammary glands and of pituitary cysts. The results for male mice
were difficult to interpret, largely because of the low survival rate in the high-
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dose group. An elevated incidence of proliferative damage in the adrenal medulla,
especially focal hyperplasia, was noted in male mice in the low-dose group. A
reduced incidence of hepatic-cell tumors was also observed in the male mice (21,
28). In other studies no increase in tumor incidence definitely attributable to GBL
has been seen in mice or rats given GBL by oral administration, skin application
or subcutaneous injection (28).
Assessments based on chemical structure and genotoxicity and toxicity tests
indicate that it is unlikely that GBL has a carcinogenic effect (14, 25, 30). The
IARC assessment published in 1999 stated that it could not be determined whether
GBL is carcinogenic to humans, but that data indicate it is not carcinogenic to
experimental animals. GBL was therefore placed in Group 3: “not classifiable
as to its carcinogenicity to humans” (28).
Effects on reproduction
In a study in which rats were given single i.p. injections of GBL in doses ranging
from 62.5 to 750 mg/kg b.w., a significant reduction of luteinizing hormone (LH)
in serum was observed at doses of 250 mg/kg and higher. Reduction of follicle-
stimulating hormone (FSH) in serum was observed at 500 mg/kg (anesthetic dose)
and higher. A reduction in the number of ovulating rats was noted at all dose
levels, and at 750 mg/kg (anesthetic dose) ovulation was blocked in all animals.
At this level uterus weight was also significantly elevated (3). A direct effect on
oocytes, resulting in inhibited maturity, was indicated in an in vitro study with
GBL (17).
In an incompletely reported study, greatly reduced testes weights were
observed in prepubertal rats given 0.5% or 1% GBL in drinking water (≈ 550 or
1100 mg/kg b.w./day), probably for 20 days. There was no observed difference
in serum prolactin levels between treated animals and controls (7, 28).
Rats were given GBL by gavage in doses of 10, 50, 125, 250 or 500 mg/kg
b.w./day on days 6 to 15 of gestation: somewhat reduced placental weights were
reported at all dose levels and significantly higher fetal weight in some dose
groups (50 – 250 mg/kg/day). No other exposure-related effects were observed
in either embryos or fetuses, and there were no significant differences in pre- or
post-implantation losses (16).
Dose-effect / dose-response relationships
There are no data that can be used directly to estimate a dose-effect or dose-
response relationship for occupational exposure to GBL. Dose-effect relationships
for oral administration of GBL are not well studied either, but one study reports
that a patient with symptoms of poisoning had taken about 90 mg GBL/kg b.w.
(5). GBL is transformed rapidly in the body to the neurologically active
metabolite GHB, and symptoms and clinical observations of patients after intake
of either substance are about the same (23, 28). However, there are quantitative
differences in uptake and metabolism. GBL is taken up from the digestive system
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more rapidly and produces higher plasma levels than GHB. GBL is also more fat-
soluble than GHB, and the distribution pattern is different: GBL yields higher
concentrations in the brain, for example (19). Both clinical experience and animal
experiments also show that GBL is more potent than GHB with both oral and
parenteral administration (19). GHB given orally is reported to cause short-term
memory loss and hypotonia at 10 mg/kg b.w., euphoria at 20 – 30 mg/kg,
anesthesia at 50 mg/kg and coma at 50 – 70 mg/kg (4, 9, 23, 28). An oral dose of
about 1 to 4 g (≈ 15 – 60 mg/kg b.w.) is usually required to achieve a tranquilizing
or sedating effect in humans (23). A lethal dose of GHB can be roughly estimated
to be around 20 – 30 g (300 – 400 mg/kg b.w.) or more (9, 23).
Using dose-effect data for oral doses of GHB, the following calculation can be
made. Acute CNS effect on humans after oral intake of GHB have been reported
at about 10 to 50 mg/kg body weight. Recalculating to an 8-hour inhalation
exposure, and assuming 100% uptake, 70 kg body weight and 10 m3 inhaled air,
yields a level of 70 to 350 mg GHB/m3 (16 to 81 ppm). Extrapolating in this
manner from oral to inhalation exposure, however, tends to overestimate the risk
of inhalation, since CNS effects are probably related to the peak level of GHB in
plasma, and oral doses yield a higher peak than inhalation of the same total dose
over an 8-hour period.
Taking the dose-effect relationships for oral administration of GHB and re-
calculating for GBL, the inhalation level for GBL would be 58 – 290 mg/m3 (16 –
81 ppm). Since GBL seems to be more toxic than GHB, however, this calculation
probably provides an underestimate of the risk.
Dose-effect relationships observed in laboratory animals treated with GBL are
shown in Table 1.
Conclusions
There are no data on which to establish a critical effect of occupational exposure
to GBL. Experience with GBL and its metabolite GHB from cases of oral intake
for the purpose of becoming intoxicated, cases of poisoning and animal data all
indicate that the critical effect of GHB is its acute effects on the central nervous
system. Limited animal data indicate that GBL may affect fertility. GBL in direct
contact with eyes can cause eye irritation. Skin exposure to GBL in liquid form
can result in significant systemic exposure.
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Table 1. Effects of GBL on mice and rats. (i.p. = intraperitoneal, p.o. = per os)
Exposure Species Effects Ref.
22 mg/kg bw
single dose, i.p.
Mouse Temporary reduction in mobility and
coordination
27
50 mg/kg bw/day
days 6-15 of
gestation, p.o.
Rat Increased fetal weight, somewhat lower
placental weight
16
50 mg/kg bw
single dose, i.p.
Rat
(juvenile)
Temporary EEG changes and effects on
behavior (including inactivity)
29
55 mg/kg bw
single dose, i.p.
Mouse Temporary declines in activity and
coordination
27
62.5 mg/kg bw
single dose, i.p.
Rat Inhibited ovulation in 22% of animals 3
125 mg/kg bw
single dose, i.p.
Rat Inhibited ovulation in 20% of animals 3
150 mg/kg bw
single dose, i.p.
Rat Temporary EEG changes and effects on
behavior (including inactivity)
29
175 mg/kg bw/day
12 days, p.o.
Mouse NOAEL 21
225 mg/kg bw/day
5 days/week,
13 weeks, p.o.
Rat Slight inactivity after dosing during the first
few weeks
21
250 mg/kg bw
single dose, i.p.
Rat Inhibited ovulation in 63% of animals,
reduction of LH in serum
3
262 mg/kg bw/day
5 days/week,
13 weeks, p.o.
Mouse Moderate inactivity after dosing during the first
few weeks
21
262 mg/kg bw/day
5 days/week
2 years, p.o.
Mouse Inhibited growth
Males: elevated incidence of proliferative
damage in the adrenal medulla
21
300 mg/kg bw/day
12 days, p.o.
Rat NOAEL 21
350 mg/kg bw/day
12 days, p.o.
Mouse Inactivity after dosing, irregular respiration 21
450 mg/kg bw/day
5 days/week
13 weeks, p.o.
Rat Slight inactivity after dosing during the first
few weeks
Males: lower weight gain
21
450 mg/kg bw/day
5 days/week,
2 years, p.o.
Rat
(females)
Inhibited growth 21
500 mg/kg bw
single dose, i.p.
Rat Anesthetic effect, inhibited ovulation in 71%
of animals, reduction of LH and FSH in serum
3
0.5% in drinking water,
(≈550 mg/kg/day)
probably 20 days
Rat 40% reduction in testes weight 7
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gränsvärde, Kobolt, Koboltföreningar, MOCA, Nikotin, Riskvärdering,
SMF, Syntetiska oorganiska fibrer, Tenn, Tennföreningar, Toxikologi,
Vetenskapligt underlag.
En svensk version av dessa vetenskapliga underlag finns publicerad i Arbete och Hälsa
2004:16.
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APPENDIX
Consensus reports in this and previous volumes
Substance Consensus date Volume in Arbete
och Hälsa (No.)
Acetaldehyde February 17, 1987 1987:39 (VIII)
Acetamide December 11, 1991 1992:47 (XIII)
Acetic acid June15, 1988 1988:32 (IX)
Acetone October 20, 1987 1988:32 (IX)
Acetonitrile September 12, 1989 1991:8 (XI)
Acrylamide April 17, 1991 1992:6 (XII)
Acrylates December 9, 1984 1985:32 (VI)
Acrylonitrile April 28, 1987 1987:39 (VIII)
Aliphatic amines August 25, 1982 1983:36 (IV)
Aliphatic hydrocarbons, C10-C15 June 1, 1983 1983:36 (IV)
Aliphatic monoketons September 5, 1990 1992:6 (XII)
Allyl alcohol September 9, 1986 1987:39 (VIII)
Allylamine August 25, 1982 1983:36 (IV)
Allyl chloride June 6, 1989 1989:32 (X)
Aluminum April 21, 1982 1982:24 (III)
revised September 14, 1994 1995:19 (XVI)
p-Aminoazobenzene February 29, 1980 1981:21 (I)
Ammonia April 28, 1987 1987:39 (VIII)
Amylacetate March 23, 1983 1983:36 (IV)
revised June 14, 2000 2000:22 (XXI)
Aniline October 26, 1988 1989:32 (X)
Anthraquinone November 26,1987 1988:32 (IX)
Antimony + compounds December 8, 1999 2000:22 (XXI)
Arsenic, inorganic December 9, 1980 1982:9 (II)
revised February 15, 1984 1984:44 (V)
Arsine October 20, 1987 1988:32 (IX)
Asbestos October 21, 1981 1982:24 (III)
Barium June 16, 1987 1987:39 (VIII)
revised January 26, 1994 1994:30 (XV)
Benzene March 4, 1981 1982:9 (II)
revised February 24, 1988 1988:32 (IX)
Benzoyl peroxide February 13, 1985 1985:32 (VI)
Beryllium April 25, 1984 1984:44 (V)
Borax October 6, 1982 1983:36 (IV)
Boric acid October 6, 1982 1983:36 (IV)
Boron Nitride January 27 1993 1993:37 (XIV)
Butadiene October 23, 1985 1986:35 (VII)
1-Butanol June 17, 1981 1982:24 (III)
Butanols June 6, 1984 1984:44 (V)
Butyl acetate June 6, 1984 1984:44 (V)
Butyl acetates February 11, 1998 1998:25 (XIX)
Butylamine August 25, 1982 1983:36 (IV)
Butyl glycol October 6, 1982 1983:36 (IV)
γ-Butyrolactone June 2 2004 2005:7 (XXV)
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Cadmium January 18, 1980 1981:21 (I)
revised February 15, 1984 1984:44 (V)
revised May 13, 1992 1992:47 (XIII)
revised February 5 2003 2003:16 (XXIV)
Calcium hydroxide February 24, 1999 1999:26 (XX)
Calcium nitride January 27, 1993 1993:37 (XIV)
Calcium oxide February 24, 1999 1999:26 (XX)
Caprolactam October 31, 1989 1991:8 (XI)
Carbon monoxide December 9, 1981 1982:24 (III)
Cathecol September 4, 1991 1992:47 (XIII)
Chlorine December 9, 1980 1982:9 (II)
Chlorine dioxide December 9, 1980 1982:9 (II)
Chlorobenzene September 16 1992 1993:37 (XIV)
revised April 2 2003 2003:16 (XXIV)
o-Chlorobenzylidene malononitrile June 1, 1994 1994:30 (XV)
Chlorocresol December 12, 1990 1992:6 (XII)
Chlorodifluoromethane June 2, 1982 1982: 24 (III)
Chlorophenols September 4, 1985 1986:35 (VII)
Chloroprene April 16, 1986 1986:35 (VII)
Chromium December 14, 1979 1981:21 (I)
revised May 26, 1993 1993:37 (XIV)
revised May 24, 2000 2000:22 (XXI)
Chromium trioxide May 24, 2000 2000:22 (XXI)
Coal dust September 9, 1986 1987:39 (VIII)
Cobalt October 27, 1982 1983:36 (IV)
Cobalt and cobalt compounds October 22 2003 2005:7 (XXV)
Copper October 21, 1981 1982:24 (III)
Cotton dust February14, 1986 1986:35 (VII)
Creosote October 26, 1988 1989:32 (X)
Cresols February 11, 1998 1998:25 (XIX)
Cumene June 2, 1982 1982:24 (III)
Cyanamid September 30, 1998 1999:26 (XX)
Cyanoacrylates March 5, 1997 1997:25 (XVIII)
Cycloalkanes, C5-C15 April 25, 1984 1984:44 (V)
Cyclohexanone March 10, 1982 1982:24 (III)
revised February 24 1999 1999:26 (XX)
Cyclohexanone peroxide February 13, 1985 1985:32 (VI)
Cyclohexylamine February 7, 1990 1991:8 (XI)
Desflurane May 27, 1998 1998:25 (XIX)
Diacetone alcohol December 14, 1988 1989:32 (X)
Dichlorobenzenes February 11, 1998 1998:25 (XIX)
1,2-Dibromo-3-chloropropane May 30, 1979 1981:21 (I)
Dichlorodifluoromethane June 2, 1982 1982:24 (III)
1,2-Dichloroethane February 29, 1980 1981:21 (I)
Dichloromethane February 29, 1980 1981:21 (I)
Dicumyl peroxide February 13, 1985 1985:32 (VI)
Dicyclopentadiene March 23, 1994 1994:30 (XV)
Diesel exhaust December 4 2002 2003:16 (XXIV)
Diethanolamine September 4, 1991 1992:47 (XIII)
Diethylamine August 25, 1982 1983:36 (IV)
2-Diethylaminoethanol January 25, 1995 1995:19 (XVI)
Diethylene glycol September 16, 1992 1993:37 (XIV)
Diethyleneglycol ethylether + acetate December 11, 1996 1997:25 (XVIII)
Diethyleneglycol methylether + acetate March 13, 1996 1996:25 (XVII)
Diethyleneglycol monobutylether January 25, 1995 1995:19 (XVI)
Diethylenetriamine August 25, 1982 1983:36 (IV)
revised January 25, 1995 1995:19 (XVI)
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Diisocyanates April 8, 1981 1982:9 (II)
revised April 27, 1988 1988:32 (IX)
Diisopropylamine February 7, 1990 1991:8 (XI)
N,N-Dimethylacetamide March 23, 1994 1994:30 (XV)
Dimethyl adipate December 9, 1998 1999:26 (XX)
Dimethylamine December 10, 1997 1998:25 (XIX)
N,N-Dimethylaniline December 12, 1989 1991:8 (XI)
Dimethyldisulfide September 9, 1986 1987:39 (VIII)
Dimethylether September 14, 1994 1995:19 (XVI)
Dimethylethylamine June 12, 1991 1992:6 (XII)
Dimethylformamide March 23, 1983 1983:36 (IV)
Dimethyl glutarate December 9, 1998 1999:26 (XX)
Dimethylhydrazine January 27, 1993 1993:37 (XIV)
Dimethyl succinate December 9, 1998 1999:26 (XX)
Dimethylsulfide September 9, 1986 1987:39 (VIII)
Dimethylsulfoxide, DMSO December 11, 1991 1992:47 (XIII)
Dioxane August 25, 1982 1983:36 (IV)
revised March 4, 1992 1992:47 (XIII)
Diphenylamine January 25, 1995 1995:19 (XVI)
4,4'-Diphenylmethanediisocyanate (MDI) April 8, 1981 1982:9 (II)
reviderat May 30 2001 2001:20 (XXII)
Dipropylene glycol May 26, 1993 1993:37 (XIV)
Dipropyleneglycol monomethylether December 12, 1990 1992:6 (XII)
Disulfiram October 31, 1989 1991:8 (XI)
Enzymes, industrial June 5, 1996 1996:25 (XVII)
Ethanol May 30, 1990 1991:8 (XI)
Ethanolamine September 4, 1991 1992:47 (XIII)
Ethylacetate March 28, 1990 1991:8 (XI)
Ethylamine August 25, 1982 1983:36 (IV)
Ethylamylketone September 5, 1990 1992:6 (XII)
Ethylbenzene December 16, 1986 1987:39 (VIII)
Ethylchloride December 11, 1991 1992:47 (XIII)
Ethylene December 11, 1996 1997:25 (XVIII)
Ethylene chloride February 29, 1980 1981:21 (I)
Ethylene diamine August 25, 1982 1983:36 (IV)
Ethylene glycol October 21, 1981 1982:24 (III)
Ethylene glycol methylether + acetate June 2, 1999 1999:26 (XX)
Ethyleneglycol monoisopropylether November 16, 1994 1995:19 (XVI)
Ethyleneglycol monopropylether + acetate September 15, 1993 1994:30 (XV)
Ethylene oxide December 9, 1981 1982:24 (III)
Ethylenethiourea September 27, 2000 2001:20 (XXII)
Ethylether January 27, 1993 1993:37 (XIV)
Ethylglycol October 6, 1982 1983:36 (IV)
Ferbam September 12, 1989 1991:8 (XI)
Ferric dimethyldithiocarbamate September 12, 1989 1991:8 (XI)
Flour dust December 10, 1997 1998:25 (XIX)
Formaldehyde June 30, 1979 1981:21 (I)
revised August 25, 1982 1983:36 (IV)
Formamide December 12, 1989 1991:8 (XI)
Formic acid June 15, 1988 1988:32 (IX)
Furfural April 25, 1984 1984:44 (V)
Furfuryl alcohol February 13, 1985 1985:32 (VI)
Gallium + Gallium compounds January 25, 1995 1995:19 (XVI)
Glutaraldehyde September 30 1998 1999:26 (XX)
Glycol ethers October 6, 1982 1983:36 (IV)
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Glyoxal September 13, 1996 1996:25 (XVII)
Grain dust December 14, 1988 1989:32 (X)
Graphite December 10, 1997 1998:25 (XIX)
Halothane April 25, 1985 1985:32 (VI)
2-Heptanone September 5, 1990 1992:6 (XII)
3-Heptanone September 5, 1990 1992:6 (XII)
Hexachloroethane September 15, 1993 1994:30 (XV)
Hexamethylenediisocyanate (HDI) April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
Hexamethylenetetramine August 25, 1982 1983:36 (IV)
n-Hexane January 27, 1982 1982:24 (III)
2-Hexanone September 5, 1990 1992:6 (XII)
Hexyleneglycol November 17, 1993 1994:30 (XV)
Hydrazine May 13, 1992 1992:47 (XIII)
Hydrogen bromide February 11, 1998 1998:25 (XIX)
Hydrogen cyanide February 7 2001 2001:20 (XXII)
Hydrogen fluoride April 25, 1984 1984:44 (V)
Hydrogen peroxide April 4, 1989 1989:32 (X)
Hydrogen sulfide May 4, 1983 1983:36 (IV)
Hydroquinone October 21, 1989 1991:8 (XI)
Indium March 23, 1994 1994:30 (XV)
Industrial enzymes June 5, 1996 1996:25 (XVII)
Isocyanic Acid (ICA) December 5 2001 2002:19 (XXIII)
Isophorone February 20, 1991 1992:6 (XII)
Isopropanol December 9, 1981 1982:24 (III)
Isopropylamine February 7, 1990 1991:8 (XI)
Isopropylbenzene June 2, 1982 1982:24 (III)
Lactates March 29, 1995 1995:19 (XVI)
Lactate esters June 2, 1999 1999:26 (XX)
Lead, inorganic February 29, 1980 1981:21 (I)
revised September 5, 1990 1992:6 (XII)
Lithium and lithium compounds June 4 2003 2003:16 (XXIV)
Lithium boron nitride January 27, 1993 1993:37 (XIV)
Lithium nitride January 27, 1993 1993:37 (XIV)
Maleic anhydride September 12, 1989 1991:8 (XI)
Manganese February 15, 1983 1983:36 (IV)
revised April 17, 1991 1992:6 (XII)
revised June 4, 1997 1997:25 (XVIII)
Man made mineral fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Mercury, inorganic April 25, 1984 1984:44 (V)
Mesityl oxide May 4, 1983 1983:36 (IV)
Metal stearates, some September 15, 1993 1994:30 (XV)
Methacrylates September 12, 1984 1985:32 (VI)
Methanol April 25, 1985 1985:32 (VI)
Methyl acetate March 28 1990 1991:8 (XI)
Methylamine August 25, 1982 1983:36 (IV)
Methylamyl alcohol March 17, 1993 1993:37 (XIV)
Methyl bromide April 27, 1988 1988:32 (IX)
Methyl chloride March 4, 1992 1992:47 (XIII)
Methyl chloroform March 4, 1981 1982:9 (II)
4,4´-methylene-bis-(2-chloroaniline) February 4 2004 2005:7 (XXV)
Methylene chloride February 29, 1980 1981:21 (I)
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4,4'-Methylene dianiline June 16, 1987 1987:39 (VIII)
revised October 3 2001 2002:19 (XXIII)
Methyl ethyl ketone February 13, 1985 1985:32 (VI)
Methyl ethyl ketone peroxide February 13, 1985 1985:32 (VI)
Methyl formate December 12, 1989 1991:8 (XI)
Methyl glycol October 6, 1982 1983:36 (IV)
Methyl iodide June 30, 1979 1981:21 (I)
Methylisoamylamine September 5, 1990 1992:6 (XII)
Methylisoamylketone February 6 2002 2002:19 (XXIII)
Methylisocyanate (MIC) December 5 2001 2002:19 (XXIII)
Methyl mercaptane September 9, 1986 1987:39 (VIII)
Methyl methacrylate March 17, 1993 1993:37 (XIV)
Methyl pyrrolidone June 16, 1987 1987:39 (VIII)
α-Methylstyrene November 1 2000 2001:20 (XXII)
Methyl-t-butyl ether November 26, 1987 1988:32 (IX)
revised September 30, 1998 1999:26 (XX)
Mixed solvents, neurotoxicity April 25, 1985 1985:32 (VI)
MOCA February 4 2004 2005:7 (XXV)
Molybdenum October 27, 1982 1983:36 (IV)
Monochloroacetic acid February 20, 1991 1992:6 (XII)
Monochlorobenzene September 16,1993 1993:37 (XIV)
Monomethylhydrazine March 4, 1992 1992:47 (XIII)
Mononitrotoluene February 20, 1991 1992:6 (XII)
Monoterpenes February 17, 1987 1987:39 (VIII)
Morpholine December 8, 1982 1983:36 (IV)
revised June 5, 1996 1996:25 (XVII)
Naphthalene May 27, 1998 1998:25 (XIX)
Natural crystallinic fibers (except asbestos) June 12, 1991 1992:6 (XII)
Nickel April 21, 1982 1982:24 (III)
Nicotine June 2 2004 2005:7 (XXV)
Nitroethane April 4, 1989 1989:32 (X)
Nitrogen oxides December 11, 1985 1986:35 (VII)
Nitroglycerin February 13, 1985 1985:32 (VI)
Nitroglycol February 13, 1985 1985:32 (VI)
Nitromethane January 6, 1989 1989:32 (X)
Nitropropane October 28, 1986 1987:39 (VIII)
2-Nitropropane March 29, 1995 1995:19 (XVI)
Nitroso compounds December 12, 1990 1992:6 (XII)
Nitrosomorpholine December 8, 1982 1983:36 (IV)
Nitrotoluene February 20, 1991 1992:6 (XII)
Nitrous oxide December 9, 1981 1982:24 (III)
Oil mist April 8, 1981 1982:9 (II)
Organic acid anhydrides, some September 12, 1989 1991:8 (XI)
Oxalic acid February 24, 1988 1988:32 (IX)
Ozone April 28, 1987 1987:39 (VIII)
Paper dust February 7, 1990 1991:8 (XI)
Pentaerythritol November 16, 1994 1995:19 (XVI)
1,1,1,2,2-Pentafluoroethane February 24, 1999 1999:26 (XX)
Pentyl acetate June 14, 2000 2000:22 (XXI)
Peroxides, organic February 13, 1985 1985:32 (VI)
Phenol February 13, 1985 1985:32 (VI)
Phosphorous chlorides September 30, 1998 1999:26 (XX)
Phosphorous oxides February 11, 1998 1998:25 (XIX)
Phthalates December 8, 1982 1983:36 (IV)
Phthalic anhydride September 12, 1989 1991:8 (XI)
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Piperazine September 12, 1984 1985:32 (VI)
Plastic dusts December 16, 1986 1987:39 (VIII)
Platinum June 4, 1997 1997:25 (XVIII)
Polyaromatic hydrocarbons February 15, 1984 1984:44 (V)
Polyisocyanates April 27, 1988 1988:32 (IX)
Potassium aluminium fluoride June 4, 1997 1997:25 (XVIII)
Potassium cyanide February 7 2001 2001:20 (XXII)
Potassium dichromate May 24, 2000 2000:22 (XXI)
Potassium hydroxide Marsh 15, 2000 2000:22 (XXI)
2-Propanol December 9, 1981 1982:24 (III)
Propene September 13, 1996 1996:25 (XVII)
Propionic acid November 26, 1987 1988:32 (IX)
Propylacetate September 14, 1994 1995:19 (XVI)
Propylene glycol June 6, 1984 1984:44 (V)
Propylene glycol-1,2-dinitrate May 4, 1983 1983:36 (IV)
Propylene glycol monomethylether October 28, 1986 1987:39 (VIII)
Propylene oxide June 11, 1986 1986:35 (VII)
Pyridine May 13, 1992 1992:47 (XIII)
Quartz March 13, 1996 1996:25 (XVII)
Resorcinol September 4, 1991 1992:47 (XIII)
Selenium December 11, 1985 1986:35 (VII)
revised February 22, 1993 1993:37 (XIV)
Sevoflurane May 27, 1998 1998:25 (XIX)
Silica March 13, 1996 1996:25 (XVII)
Silver October 28, 1986 1987:39 (VIII)
Sodium cyanide February 7 2001 2001:20 (XXII)
Sodium hydroxide August 24, 2000 2000:22 (XXI)
Stearates, metallic, some September 15, 1993 1994:30 (XV)
Stearates, non-metallic, some November 17, 1993 1994:30 (XV)
Strontium January 26, 1994 1994:30 (XV)
Styrene February 29, 1980 1981:21 (I)
revised October 31, 1989 1991:8 (XI)
Sulfur dioxide April 25, 1985 1985:32 (VI)
Sulfur fluorides March 28, 1990 1991:8 (XI)
Synthetic inorganic fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
revised December 3, 2003 2005:7 (XXV)
Synthetic organic and inorganic fibers May 30, 1990 1991:8 (XI)
Talc dust June 12, 1991 1992:6 (XII)
Terpenes, mono- February 17, 1987 1987:39 (VIII)
Tetrabromoethane May 30, 1990 1991:8 (XI)
Tetrachloroethane June 4, 1997 1997:25 (XVIII)
Tetrachloroethylene February 29, 1980 1981:21 (I)
1,1,1,2-Tetrafluoroethane March 29, 1995 1995:19 (XVI)
Tetrahydrofuran October 31, 1989 1991:8 (XI)
Tetranitromethane April 4, 1989 1989:32 (X)
Thioglycolic acid June 1, 1994 1994:30 (XV)
Thiourea December 1, 1987 1988:32 (IX)
revised June 2, 1999 1999:26 (XX)
Thiram October 31, 1989 1991:8 (XI)
Thiurams, some October 31, 1989 1991:8 (XI)
Tin and inorganic tin compounds October 22 2003 2005:7 (XXV)
Titanium dioxide February 21, 1989 1989:32 (X)
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Toluene February 29, 1980 1981:21 (I)
revised February 6 2002 2002:19 (XXIII)
Toluene-2,4-diamine November 1, 2000 2001:20 (XXII)
Toluene-2,6-diamine November 1, 2000 2001:20 (XXII)
Toluene-2,4-diisocyanate April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
Toluene-2,6-diisocyanate April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
1,1,1-Trifluoroethane February 24, 1999 1999:26 (XX)
Trichlorobenzene September 16, 1993 1993:37 (XIV)
1,1,1-Trichloroethane March 4, 1981 1982:9 (II)
Trichloroethylene December 14, 1979 1981:21 (I)
Trichlorofluoromethane June 2, 1982 1982:24 (III)
1,1,2-Trichloro-1,2,2-trifluoroethane June 2, 1982 1982:24 (III)
Triethanolamine August 25, 1982 1983:36 (IV)
revised October 23 2002 2003:16 (XXIV)
Triethylamine December 5, 1984 1985:32 (VI)
Trimellitic anhydride September 12, 1989 1991:8 (XI)
Trimethylolpropane November 16, 1994 1995:19 (XVI)
Trinitrotoluene April 17, 1991 1992:6 (XII)
Vanadium March 15, 1983 1983:36 (IV)
Vinyl acetate June 6, 1989 1989:32 (X)
Vinyl toluene December 12, 1990 1992:6 (XII)
White spirit December 16, 1986 1987:39 (VIII)
Wood dust June 17, 1981 1982:9 (II)
revised June 25, 2000 2000:22 (XXI)
Xylene February 29, 1980 1981:21 (I)
Zinc April 21, 1982 1982:24 (III)
Zinc chromate May 24, 2000 2000:22 (XXI)
Zinc dimethyl dithiocarbamate September 12, 1989 1991:8 (XI)
Ziram September 12, 1989 1991:8 (XI)
Sent for publication May 2005
